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ABSTRACT 
Matthew Beau Dufek:  
The Effect of the Dynamic Interplay of P-glycoprotein and  
Cytochrome P450 3A on the Portal Bioavailability of Dual Substrates 
(Under the direction of Dhiren R. Thakker, Ph.D.) 
 
 
The intestinal epithelium is a critically important and highly complex barrier that 
comprises several physical as well as biochemical features that limit intestinal absorption of 
intact drug, thereby affecting systemic bioavailability. Cytochrome P450 3A (CYP3A) and 
P-glycoprotein (P-gp) are two important biochemical barriers present in the intestinal 
epithelium that contribute to the barrier properties via different mechanisms, i.e. first-pass 
metabolism and apical efflux, respectively. To date, mutually contradicting conclusions have 
been reached on whether P-gp would enhance or attenuate the intestinal metabolism of dual 
P-gp/CYP3A substrates during oral absorption. These conclusions are mostly based on 
findings from either static in vitro models or pharmacokinetic (PK) modeling. Systematic 
studies on the effect of P-gp on CYP3A-mediated intestinal first-pass metabolism of dual P-
gp/CYP3A substrates in vivo, where the interactions between these two proteins are likely to 
be more complex, are lacking.  Here, the effect of the interplay of P-gp and CYP3A in 
mediating intestinal first-pass metabolism and absorption of the dual P-gp and CYP3A 
substrates, loperamide and amprenavir were investigated in vivo, using intact portal vein 
cannulated mice that were competent or deficient in P-gp expression. Additionally, 
mechanistic studies on the effect of P-gp efflux on intestinal first-pass metabolism of 
loperamide and amprenavir were conducted using fresh intestinal tissues from P-gp deficient 
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and P-gp competent mice and in human intestinal epithelium, where P-gp efflux was 
functional (control) or inhibited with elacridar (GF120918), using an Ussing-type diffusion 
chamber. 
These studies demonstrated that P-gp decreases intestinal Cyp3a-mediated 
metabolism of loperamide at intestinal lumen concentrations that are near the apparent Km for 
oxidative Cyp3a-mediated metabolism. As a result, P-gp shows a surprising effect of 
increasing, rather than decreasing, loperamide absorption into the portal circulation by 
sparing the drug from first-pass metabolism.  Additional studies on the interplay of P-gp and 
Cyp3a in mice using the dual P-gp/Cyp3a substrate amprenavir showed that intestinal first-
pass metabolism of amprenavir in intact P-gp competent and P-gp deficient mice was similar 
regardless of the presence or absence of P-gp. Additionally, these studies showed that the 
reduction in portal bioavailability (FG) observed in P-gp competent and P-gp deficient mice 
following an oral dose of amprenavir was solely due to extensive intestinal first-pass 
metabolism. 
Studies on how P-gp efflux affects loperamide FG and intestinal first-pass metabolism 
in humans was studied in fresh intestinal epithelial tissue from humans, which showed that, 
similar to the findings in mouse, P-gp efflux reduced the rate and extent of metabolism at 
concentrations near the apparent Km for metabolism. Using the ex vivo data from human and 
mice intestinal tissue and in vivo data from mice, semi-physiologically based 
pharmacokinetic (PBPK) modeling was attempted to predict the effect of the interplay of P-
gp and CYP3A during intestinal absorption of loperamide in humans. The modeling 
suggested that in the presence of P-gp the FG of loperamide in humans is expected to increase 
at doses that produce intestinal concentrations that are within the linear range of metabolism 
 v 
by CYP3A. Cumulatively, these studies highlight that the dynamic interaction of P-gp and 
CYP3A during intestinal absorption is highly complex and is expected to be significantly 
different for dual substrates that elicit different efficiencies of intestinal P-gp-mediated AP 
efflux and/or CYP3A-mediated metabolism. 
 vi 
 
 
 
 
 
ACKNOWLEDGEMENTS 
 
Words cannot begin to express my deepest gratitude for my advisor and friend Dr. 
Dhiren R. Thakker.  I will always be indebted for his support, guidance, and most 
importantly his belief in me throughout the constant struggles that one encounters 
through life. 
 I am gratefully indebted to Dr. Daniel E. Keyler for his contribution to both my 
scientific and personal life, without his continued guidance, mentorship, and friendship 
none of this would have ever been possible.   
 I would like to thank all the members of my dissertation committee, Drs. Philip C. 
Smith, Moo J. Cho, Mary F. Paine, Joseph W. Polli, and Matthew D. Troutman for their 
support, patience, and contribution to my graduate training.    
 I would also like to thank past and present the members of the laboratory of 
Dhiren Thakker at the Eshelman School of Pharmacy at the University of North Carolina 
at Chapel Hill.  Specifically, I would like to thank Chester L. Costales, Tianxiang (Kevin) 
Han and Dr. Ruth S. Everett for their friendship and willingness to go the extra-mile 
during the completion of this dissertation.  I would also like to thank faculty and students 
at the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill 
that contributed throughout my graduate training and made my time here so satisfying.  I 
would like to especially thank Mrs. Amber Allen and Ms. Lauren A. Wall who were 
always willing to help or just listen and made everyday a little bit better.  I particularly 
grateful for the opportunity to work and become close friends with Dr. Ruth S. Everett, 
 vii 
you have been pivotal in my development and I thank you for your patience and 
willingness to contribute so greatly to my scientific training. 
I would like to thank my mother Lynette J. Dufek and father Patrick A. Dufek for 
their encouragement when I was a child and their help throughout this extremely long 
journey.  I would like to thank my father in-law Robert R. Fuller and mother in-law Jayne 
Fuller who have been as pivotal in my life as my own parents. 
I am grateful for my brother Peter A. Dufek for pushing me to be better than I 
thought I could be when we were kids.  Though we were not together when you passed 
on from this life, you will always be my brother and in my heart.    
Most importantly, I would like to thank my beloved daughter Sophia Grace 
Dufek, who even in the hardest of times you always brought a smile to my face.  You 
make everyday better and are the motivation behind my every breath and idea.  I love you 
always. 
Lastly and most importantly, I am forever indebted to my wife Bobbi Marie 
Dufek, for her constant love and support over the past 17 years.  None of this would have 
been possible with out you.  You truly are the love of my life and words cannot describe 
the love I hold for you for standing side-by-side with me throughout our journeys and for 
giving me our darling daughter Sophia.  I love you yesterday, today, always. 
 
 
 
 
 
 
 
 
 viii 
 
 
 
 
 
 
 
Dedicated to: 
my darling Sophia Grace Dufek, 
may this help provide you a lifetime of unlimited opportunities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix 
 
 
TABLE OF CONTENTS 
Page 
LIST OF TABLES............................................................................................................ xii 
LIST OF FIGURES .......................................................................................................... xii 
LIST OF ABBREVIATIONS.......................................................................................... xvi 
Chapter 
1. INTRODUCTION .........................................................................................................1 
A. ROLE OF THE INTESTINE IN ORAL ABSORPTION........................................2 
1. The Small Intestine..........................................................................................3 
2. The Intestinal Epithelium ................................................................................3 
B. MECHANISMS OF INTESTINAL ABSORPTION ..............................................5 
C. THE INTESTINAL ATP-BINDING CASSETTE (ABC) EFFLUX  
      TRANSPORTERS...................................................................................................6 
 
1. Intestinal ABCB1/MDR1 P-glycoprotein..........................................................7 
2. Intestinal ABCC2/MRP2 ...................................................................................9 
3. Intestinal ABCG2/BCRP .................................................................................10 
D. INTESTINAL METABOLISM.............................................................................11 
1. Phase I Metabolism in the Intestine: Cytochrome P450 (CYP) ......................12 
2. Phase II Metabolism in the Intestine................................................................13 
E. INTERPLAY OF P-gp EFFLUX AND CYP3A-MEDIATED  
      METABOLISM .....................................................................................................14 
 
1. Relationship of AP Efflux by P-gp and Intestinal Metabolism 
      in Mediating Permeability Across the Enterocyte ..........................................19 
 x 
 
F. METHODS TO STUDY INTESTINAL EFFLUX AND METABOLISM..........20 
1. In Vitro Methods ..............................................................................................21 
2. Ex Vivo: Side-by-Side Diffusion Chambers ....................................................23 
3. In Situ: Isolated Perfused Intestine ..................................................................25 
4. In Vivo Methods...............................................................................................26 
G. RATIONALE AND OVERVIEW OF PROPOSED RESEARCH .......................28 
H. FIGURES...............................................................................................................32 
I. REFERENCES ......................................................................................................39 
2. P-GLYCOPROTEIN (P-gp) REDUCES FIRST-PASS INTESTINAL 
METABOLISM AND ENHANCES PORTAL BIOAVAILABILITY OF 
LOPERAMIDE IN MOUSE........................................................................................51 
 
A. ABSTRACT...........................................................................................................52 
B. INTRODUCTION .................................................................................................54 
C. EXPERIMENTAL METHODS.............................................................................57 
D. RESULTS ..............................................................................................................67 
E. DISCUSSION........................................................................................................73 
F. ACKNOWLEDGEMENTS...................................................................................83 
G. FIGURES...............................................................................................................84 
H. TABLE...................................................................................................................92 
I. REFERENCES ......................................................................................................93 
3. P-gp EFFLUX DOES NOT AFFECT FIRST-PASS METABOLISM OF THE  
DUAL P-gp AND Cyp3a SUBSTRATE AMPRENAVIR DURING  
INTESTINAL ABSORPTION IN MICE....................................................................98 
 
A. ABSTRACT...........................................................................................................99 
B. INTRODUCTION ...............................................................................................101 
 xi 
C. EXPERIMENTAL METHODS...........................................................................104 
D. RESULTS ............................................................................................................112 
E. DISCUSSION......................................................................................................117 
F. ACKNOWLEDGEMENTS.................................................................................122 
G. FIGURES.............................................................................................................123 
H. TABLE.................................................................................................................130 
I. REFERENCES ....................................................................................................131 
4. FROM MICE TO MAN: IS THE ORAL BIOAVAILABILITY OF DUAL  
P-GLYCOPROTEIN (P-gp) AND CYTOCHROME P 450A (CYP3A) 
SUBSTRATES GREATER IN THE PRESENCE OF P-gp EFFLUX  
IN HUMANS? ...........................................................................................................134 
 
A. ABSTRACT.........................................................................................................135 
B. INTRODUCTION ...............................................................................................137 
C. EXPERIMENTAL METHODS...........................................................................140 
D. RESULTS ............................................................................................................148 
E. DISCUSSION......................................................................................................153 
F. ACKNOWLEDGMENTS ...................................................................................157 
G. FIGURES.............................................................................................................159 
H. TABLES ..............................................................................................................165 
I. REFERENCES ....................................................................................................171 
5. CONCLUSIONS .......................................................................................................175 
 A. PROJECT STRATEGY.......................................................................................176 
 
B. KEY FINDINGS..................................................................................................178 
 
C. SIGNIFICANCE..................................................................................................180 
 
D. FUTURE STUDIES ............................................................................................182 
 xii 
 
E. FIGURES.............................................................................................................184 
 
F. REFERENCES ....................................................................................................186 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiii 
LIST OF TABLES 
Table 2.1 The kinetic parameters of loperamide metabolism in intestinal  
 tissue from P-gp competent or deficient mice ...........................................92 
 
Table 3.1 The absorptive permeability and kinetic parameters of metabolism  
 for amprenavir in intestinal tissue from P-gp competent or  
 deficient mice...........................................................................................130 
 
Table 4.1 The physiologic parameters of the ACAT compartmental model  
 used for fasted mouse oral absorption of loperamide simulations...........165 
 
Table 4.2. The physiologic parameters of the ACAT compartmental model  
 used for fasted human oral absorption of loperamide simulations. .........166 
 
Table 4.3. Key biopharmaceutial and pharmacokinetic properties of  
 loperamide................................................................................................167 
 
Table 4.4. The absorptive transport of loperamide across human jejunal  
 epithelium ................................................................................................168 
 
Table 4.5. The predicted dose dependent oral absorption of loperamide in P-gp 
competent or P-gp deficient mice using GastroPlus®. .............................169 
 
Table 4.6. The simulated portal bioavailability of oral loperamide in humans  
 using GastroPlus® ....................................................................................170 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xiv 
LIST OF FIGURES 
Figure 1.1. The organs of GI tract and the accessory organs of digestion that are 
involved in the absorption of nutrients, which can then be utilized by  
 the cells of the human body .......................................................................32 
 
Figure 1.2. The villus unit of the small intestine that is involved in the  
 regulation of absorption of nutrients, drugs, and xenobiotics  
 from the external environment...................................................................33 
 
Figure 1.3. Schematic representation of the physical and biochemical barriers  
 to absorption across the intestinal epithelium............................................34 
 
Figure 1.4. Schematic representation of the Caco-2 Transwell™ Model ....................35 
 
Figure 1.5. Schematic representation of Ussing type side-by-side  
 diffusion chamber ......................................................................................36 
 
Figure 1.6. Schematic representation of isolated intestinal perfusion methods  
 to measure intestinal permeability, metabolism, and absorption...............37 
 
Figure 1.7. Schematic representation of isolated intestinal perfusion methods  
 in humans using a “Loc-I-Gut” perfusion technique to measure  
 intestinal permeability, metabolism, and absorption .................................38 
 
Figure 2.1. The chemical structure of loperamide and its major metabolites  
 (monodesmethyl-loperamide and didesmethyl-loperamide), which  
 are produced by CYP3A-mediated metabolism ........................................84 
 
Figure 2.2. The metabolism of loperamide in P-gp competent or P-gp deficient  
 mouse intestinal tissue ...............................................................................85 
 
Figure 2.3. The oxidative metabolism of the Cyp3a-specific probe substrate, 
testosterone in mouse intestinal tissue .......................................................86 
 
Figure 2.4. The in vivo oral absorption of loperamide into the portal circulation  
 of portal vein cannulated mice...................................................................87 
 
Figure 2.5. The extent of metabolism and absorptive transport of loperamide  
 ex vivo across mouse intestinal tissue ........................................................88 
 
Figure 2.6. The portal bioavailability of loperamide in P-gp competent or  
 deficient mice.............................................................................................89 
 
Figure 2.7. The effect of P-gp and Cyp3a in mediating the portal bioavailability  
 of loperamide, in the presence or absence of oxidative metabolism .........90 
 xv 
 
Figure 2.8. The systemic absorption of loperamide in P-gp competent or P-gp 
deficient mice.............................................................................................91 
 
Figure 3.1. The chemical structure of amprenavir and its main metabolites  
 (M1-M5) formed by CYP-mediated metabolism in humans...................123 
 
Figure 3.2. The metabolism of amprenavir ex vivo in intestinal tissue from P-gp  
 competent or deficient mice.....................................................................124 
 
Figure 3.3. The extent of metabolism of amprenavir ex vivo in intestinal tissue  
 from P-gp competent or P-gp deficient mouse ........................................125 
 
Figure 3.4. The oral absorption of amprenavir measured in portal vein  
 cannulated mice .......................................................................................126 
 
Figure 3.5. The oral absorption of amprenavir into the systemic circulation  
 of P-gp competent or deficient mice........................................................127 
 
Figure 3.6. The dose-dependent affect of the interaction of P-gp and Cyp3a  
 on the portal bioavailability of amprenavir in P-gp competent  
 or deficient mice ......................................................................................128 
 
Figure 3.7. The relative roles of P-gp and Cyp-mediated metabolism in  
 determining the portal bioavailability of amprenavir in vivo  
 in mice......................................................................................................129 
 
Figure 4.1. The schematic diagram of the advanced compartmental absorption  
 and transit (ACAT) model .......................................................................159 
 
Figure 4.2. The ex vivo rate and extent of metabolism of loperamide by CYP3A  
 over 90 min during absorptive transport across control or P-gp  
 inhibited human intestinal epithelium......................................................160 
 
Figure 4.3. The fraction of dose transported as unchanged parent across control  
 or P-gp-inhibited human intestinal epithelium ........................................161 
 
Figure 4.4. The simulated (GastroPlus®) intestinal absorption of oral loperamide  
 in mice......................................................................................................162 
 
Figure 4.5. The relationship between ex vivo and in vivo models of intestinal 
absorption used to study the effect of the interplay of P-gp and  
 CYP3A on the oral bioavailability of dual substrates..............................163 
 
Figure 4.6. Simulations examining the effect of changes in efficiency of  
 intestinal P-gp efflux and dose on mouse portal bioavailability..............164 
 xvi 
 
Figure 5.1. The relationship between ex vivo and in vivo models of intestinal 
absorption used to study the effect of the interplay of P-gp and  
 CYP3A on the oral bioavailability of dual substrates..............................184 
 
Figure 5.2. Competing effects of intestinal P-gp efflux on portal bioavailability of 
dual P-gp and CYP3A substrates.............................................................185 
 xvii 
LIST OF ABBREVIATIONS 
A Area   
AAALAC Association for Assessment and Accreditation of Laboratory 
Animal Care 
 
ABC Adenosine-5'-triphosphate-binding cassette  
 
ABT 1α-aminobenzotriazole 
ACAT Advanced compartmental absorption and transit 
ACE Angiotensin II converting enzyme 
ADAM Advanced dissolution, absorption, metabolism model  
ANOVA Two-way analysis of variance 
AP Apical  
AQ Absorptive quotient  
ATP Adenosine-5'-triphosphate 
AUC Area under the curve 
AUCPortal  Area under the curve of portal concentration 
AUCSystemic Area under the curve of systemic concentration 
BCRP Breast cancer resistance protein 
BCS Biopharmaceutical Classification System 
BMI Body mass index 
BL Basolateral 
Caco-2 Human epithelial colorectal adenocarcinoma  
CD Dose concentration 
CYP  Cytochrome P450 
CYP3A Cytochrome P450 3A 
 xviii 
DMSO Dimethyl sulfoxide 
ER Extraction ratio  
EtOH Ethanol 
FG Portal bioavailability  
FM Fraction of dose metabolized  
FT Fraction of dose transported  
GI Gastrointestinal 
GST Glutathione-S-transferases 
HIV Human immunodeficiency virus 
IACUC Institutional Animal Care and Use Committee  
IP Intraperitoneal  
IRB Institutional Review Board 
IV Intravenous 
J Mass of drug transported over time 
KBR Krebs Bicarbonate Ringer  
Km Concentrations of half the maximum metabolic velocity 
LLC-PK1 Porcine kidney epithelial 
MAbsorbed Mass of parent drug absorbed from intestine 
MApical Mass of total metabolite in apical compartment 
MBasolateral Mass of total metabolite in basolateral compartment 
MCF-7 Michigan Cancer Foundation-7 
MDCKII cells Madin-Darby Canine Kidney II 
MDR Multi drug resistance protein 
 xix 
Mintacellular Mass of total metabolite within cellular compartment 
MPortal Mass of parent drug in the portal circulation 
mRNA Messenger RNA 
MRP Multi drug resistance-associated protein 
MRT Mean residence time 
MSystemic  Mass of the parent drug returned to the portal circulation from the  
  systemic circulation 
 
NaCl  Sodium chloride 
NaOH Sodium hydroxide 
NIH National Institutes of Health  
Papp Apparent permeability  
Papp,AB Apparent permeability from apical to basolateral compartment 
P-gp P-glycoprotein  
ParentBasolateral  Parent drug in basolateral compartment 
PBPK Physiological based pharmacokinetic  
PhIP 2-Amino-1-methyl-6-phenylimidazo-[4,5-b]-pyridine 
PhRMA Pharmaceutical Research Manufacturer of America 
PK Pharmacokinetic  
PPD Passive permeability 
QPortal Portal blood flow 
S  Dose concentration 
SD Standard deviation  
SLC Solute carrier 
SULT Sulfotransferase 
 xx 
t Time  
TPA 12-0-tetradecanoylphorbol 
UGT UDP-glucuronosyltransferase 
UV Ultraviolet 
V Rate of metabolism  
Vmax Maximum velocity of metabolism  
CHAPTER 1 
 
 
 
 
INTRODUCTION 
  2 
1.A. ROLE OF THE INTESTINE IN ORAL ABSORPTION 
 The gastrointestinal (GI) tract of mammals has evolved into an efficient organ 
system that serves the dual function of promoting the ingestion and extraction of nutrients 
that are necessary for survival and providing critical protection to the body from potential 
environmental pathogens and toxins.  Structurally, the GI tract is comprised of a 
preparative and storage region (alimentary canal and stomach), an absorptive region 
(small intestine), a region for water reabsorption (colon), and a waste storage region 
(distal colon and rectum) (Figure 1.1).  The GI tract plays a critical role in determining 
the success or failure of a therapeutic agent and/or pharmaceutical formulation upon oral 
administration, because many physical and biochemical architectural elements of the GI 
tract affect the absorption of these drugs.  Among different routes by which therapeutic 
agents can be administered for the safe and effective treatment of diseases, the oral route 
is preferred for a majority of drugs due to the ease of use, lower cost, and greater patient 
compliance. 
However, before any orally administered drug can gain access to the systemic 
circulation and elicit a therapeutic response, it must first successfully circumvent the 
sequential series of barriers of the GI tract and liver.  Historically, it was believed that the 
bioavailability of orally administered drugs was mediated by the permeability of the drug 
across the intestinal epithelium and its metabolism in the liver.  However, studies have 
shown that intestinal first-pass metabolism (Benet, 1996; Paine et al., 1996) and efflux 
transporters (Augustijns et al., 1993; Schinkel et al., 1995; Giacomini et al., 2010) within 
the intestine play a significant role in determining oral bioavailability. 
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1.A1. THE SMALL INTESTINE  
 A majority of the absorption of an orally administered drug occurs within the 
small intestine (Figure 1.1), which in humans is composed of three distinct regions, the 
duodenum, jejunum, and ileum.  The duodenum, which is the first section of the small 
intestine, is approximately 25-30 cm in length, has a pH of ~6.0–6.5, and is the region 
where a majority of the chemical digestion of food occurs.  The second region of the 
small intestine is the jejunum, which is ~2.5 m in length, has a pH of ~7.0–7.5, and 
functions primarily in the regulation and absorption of nutrients that have been ingested.   
The ileum, which is the final and most distal region of the small intestine, is ~3.0–3.5 m 
in length, has a typical pH of ~7.5, and links the small intestine to the colon by the 
ileocecal valve.  The primary function of the ileum is to absorb any residual nutrients that 
have not been absorbed by the jejunum, as well as some important dietary components, 
such as vitamin B12 (Valman and Roberts, 1974) and bile salts (Tilson et al., 1975).  All 
nutrients or xenobiotics that are absorbed across the mucosa of the small intestine are 
transported through the inferior and superior mesenteric veins, which converge with the 
gastric and cystic veins immediately prior to the liver to form the portal vein.  The portal 
vein in humans is ~8 cm in length and functions in transporting the drained blood of the 
small intestine and colon to the liver, and eventually to the systemic circulation. 
1.A.2. THE INTESTINAL EPITHELIUM 
 
The GI tract can be characterized as a long hollow tube that is surrounded by a 
wall composed of four main tissue layers. These layers include the outermost serosa and 
adventitia connective tissues, the muscularis externa layer that is involved in the 
peristaltic movements of the intestine, the submucosa that consists of dense connective 
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tissues and digestive nerves, and the innermost layer of the intestinal wall that is lined by 
the mucosa.  The mucosa of the small intestine is a highly folded mucosal membrane 
layer containing many small finger-like projections called villi (Figure 1.2).  The villi and 
the microvilli cumulatively contribute to substantially increasing the overall surface area 
of the small intestine so as to maximize the absorption of nutrients from the gut contents 
(Johnson, 1987).  Each villus is comprised of a single layer of enterocytes that are 
spatially separated as immature proliferating crypt cells located in the lower base region 
of the villus and functional absorptive enterocytes that are located at the tips of the villus 
(Figure 1.2) (Gassler et al., 2006).  The intestinal mucosa is comprised of four different 
types of cells that include, (i) the enterocytes that contain the ancillary microvilli 
structures and function as the primary intestinal absorptive cells of the intestine and 
accounts for approximately 90% of the total epithelial cells within the intestine (Cheng 
and Leblond, 1974), (ii) the mucous producing exocrine goblet cells,  (iii) the 
enteroendocrine cells that migrate from the crypt base to the villus and are involved in the 
secretion of digestive enzymes and hormonal peptides, and  (iv) the paneth cells that 
migrate towards the crypt base and are responsible for the secretion of antimicrobial 
peptides (Cheng and Leblond, 1974; Gassler et al., 2006).  These intestinal epithelial cells 
create a continuous monolayer through the association of neighboring cells whose 
membranes are joined together by tight junctions, thus forming a virtually impermeable 
barrier to fluid or xenobiotics (Figure 1.3).  Several studies have shown that the immature 
crypt cells are significantly more permeable than mature epithelial cells and as the 
intestinal epithelial cells mature, the tight junctions between the enterocytes become less 
permeable (Figure 1.2). As a result, highly permeable lipophilic drugs are absorbed 
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primarily at the villi tips while poorly permeable hydrophilic drugs have to reach the 
lower regions of the villi in order to diffuse across the epithelial monolayer (Strocchi and 
Levitt, 1993; Gassler et al., 2006). 
1.B. MECHANISMS OF INTESTINAL ABSORPTION  
 There are two different routes by which nutrients or xenobiotics are absorbed 
across the intestinal epithelium, namely paracellular or transcellular.  Paracellular 
transport, which occurs through the gaps between adjoining intestinal epithelial cells, is 
restricted by the presence of multi-protein complexes known as tight junctions.  
Transport through the tight junctions is typically inefficient and is only possible for small 
molecular weight and small diameter hydrophilic molecules (Figure 1.3).  Transcellular 
transport, which is the passage of a drug from the intestinal lumen across the cell 
membranes and through the cytosol into the venous blood supply, can occur by passive 
diffusion or carrier mediated transport (Figure 1.3).  The passive diffusion of a drug 
across the intestinal epithelium (Figure 1.3) is largely dependent on the presence of a 
concentration gradient across the cell monolayer and the physicochemical properties of 
the drug.  In addition to passive transcellular diffusion, the absorption of many nutrients 
and xenobiotics is mediated by facilitated diffusion or active transport involving specific 
carrier mediated transporters that are present within the mucosa.  A majority of the 
transporters present in the intestine belong to either the solute carrier (SLC) or adenosine-
5'-triphosphate (ATP)-binding cassette (ABC) superfamilies of transporters (Figure 1.3).  
Members of the SLC transporter family use a variety of transporter mechanisms, such as 
uniporter, antiporter, and symporter transport for facilitate the transport nutrients or drugs 
across the membranes of the enterocytes (Geyer et al., 2006).  In general, SLC 
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transporters do not require an energy source other than the presence of a chemical 
gradient that is formed by the translocation of ions across the membrane of the intestinal 
epithelium.  On the other hand, the transporters of the ABC family utilize ATP in order to 
extrude intracellular drug against its concentration gradient back into the lumen, thereby 
limiting uptake (Juliano and Ling, 1976) and absorption (Augustijns et al., 1993; 
Schinkel et al., 1995).  Since a major focus of the current research is to study the role of 
efflux transporters in drug disposition, some of the important facets of these transporters 
are discussed below in more detail. 
1.C. THE INTESTINAL ATP-BINDING CASSETTE (ABC) EFFLUX 
        TRANSPORTERS 
The human genome encodes 49 transporters that belong to the ABC family of 
transport proteins (Vasiliou et al., 2009).  These transporters are named for their 
conserved, specific ABC domain, which is a 200–250 amino acid globular protein unit 
that can bind and hydrolyze ATP.  The structural architecture of all ABC transporters 
includes of four central structural domains that include two membrane bound domains 
that contain six transmembrane segments each, and two cytosolic nucleotide-binding 
domains, which contain the ABC signature motifs (Higgins, 1992).  The nucleotide-
binding domains are the sites of ATP hydrolysis and are highly conserved across all ABC 
transporters (Higgins, 1992). The transmembrane domains of ABC transporters, which 
form the transport pathway, exhibit a greater diversity and vary in the total number of 
transmembrane helices per domain, which may explain why ABC transporters are 
involved in the physiological transport of essential nutrients, such as lipids, bile acids, 
peptides, and hormones, as well as xenobiotics and drugs (Ueda et al., 1992; Burton et 
al., 1993; Dean et al., 2001).  It has been shown that there are several ABC drug 
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transporters that are functionally expressed and exhibit variable expression over the entire 
length of the intestine (Thorn et al., 2005; Englund et al., 2006; Berggren et al., 2007), 
including ABCB1 [multidrug resistance protein 1, (MDR1)], ABCC1-6 [multidrug 
resistance-associated proteins 1-6, (MRP1-6)], and ABCG2 [breast cancer resistance 
protein, (BCRP)] (Dean et al., 2001; Berggren et al., 2007; Oostendorp et al., 2009).  
These transporters are considered to be important in protecting the body from potentially 
harmful compounds by limiting or preventing intestinal absorption (Borst et al., 1993; 
Schinkel and Jonker, 2003; Giacomini et al., 2010). An increasing number of studies 
have attributed the activity of ABC transporters to the low bioavailability that is observed 
for many chemically diverse compounds (Lown et al., 1997; van Asperen et al., 1997; 
Polli et al., 1999; FDA, 2006; Giacomini et al., 2010).   
1.C.1. INTESTINAL ABCB1/MDR1 P-GLYCOPROTEIN  
Since the 1976 discovery of the ABCB1 [MDR1] transporter (commonly referred 
to as P-glycoprotein (P-gp)) in tumor cells that displayed multidrug resistance to 
anticancer drugs (Juliano and Ling, 1976), the role of drug transporters in influencing 
oral bioavailability and therapeutic efficacy has become apparent (FDA, 2006; Zhang et 
al., 2009; Giacomini et al., 2010).  P-gp is expressed in several tissues, such as the liver, 
kidney, adrenal gland, lung, eye, epithelial cells of the blood brain barrier, and intestine 
(Thiebaut et al., 1987; Cordon-Cardo et al., 1989). It has been shown that P-gp is 
expressed on the apical (AP) membrane of the enterocytes and its expression increases 
gradually from low levels in the stomach and duodenum to higher levels in the ileum and 
colon.  Additionally, the colon and distal regions of the ileum have similar messenger 
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RNA (mRNA) levels, which are approximately 6-fold greater than that observed in the 
duodenum (Thiebaut et al., 1987; Thorn et al., 2005).   
Studies performed by Sparreboom et al. (1997) using P-gp deficient mice were 
the first to demonstrate that the poor absorption of orally administered paclitaxel was due 
to the presence of P-gp in the intestine (Sparreboom et al., 1997).  These results 
supported previous in vitro experiments showing that the inhibition of P-gp-mediated 
efflux could improve oral bioavailability (Augustijns et al., 1993; Wacher et al., 2001).  It 
has been shown that P-gp exhibits a broad substrate specificity that includes a 
substantially large number of drugs used across a wide range of therapeutic drug classes 
(Gottesman and Pastan, 1993; Pawagi et al., 1994). In general, the compounds that are 
effluxed by P-gp are structurally and pharmacologically unrelated neutral or positively 
charged hydrophobic compounds. There have been several pharmacophore models 
proposed for the substrate specificity of P-gp, which have mostly included the presence 
of planar aromatic rings, lipophilic functional groups, or hydrogen bond acceptors 
(Pawagi et al., 1994).  
The role of P-gp in influencing the bioavailability of therapeutic agents continues 
to be an area of active research.  The exact mechanism by which P-gp reduces the 
intracellular accumulation of drugs is not currently known, but the two models of the 
mechanism of drug extrusion by P-gp include the “hydrophobic vacuum cleaner” and the 
“P-gp flipase model”.  The hydrophobic vacuum cleaner mechanism, which proposes that 
a drug molecule is detected and immediately expelled as it enters the plasma membrane, 
is based on several lines of evidence including, (i) drug efflux kinetics, which 
demonstrate a simultaneous increase in the efflux of a drug and decrease in the influx of 
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the drug into the cytosol (Skovsgaard, 1978; Stein et al., 1994),  (ii) fluorescence studies 
with rhodamine 123 (Kessel, 1989) and daunomycin (Busche et al., 1989) that show 
dissimilar fluorescence spectra in drug resistant (P-gp competent) and drug sensitive (P-
gp deficient) cells, suggesting that rhodamine 123 may not have reached the cytoplasm in 
cells that expressed P-gp, and (iii) the removal of doxorubicin by P-gp directly from the 
plasma membrane (Raviv et al., 1990).  However, the P-gp flipase mechanism of P-gp 
efflux proposes that P-gp effectively detects drug that is present within the inner leaflet of 
the cell membrane bilayer and then “flips” the drug back into the extracellular medium, 
or from the inner leaflet to the outer leaflet of the membrane.  This reduces the 
intracellular drug concentration and increases the concentration of the extracellular 
medium (Higgins and Gottesman, 1992; Higgins, 1994a; Higgins, 1994b).  Additionally, 
the flipase mechanism can account for much of the evidence that has been used to justify 
the hydrophobic vacuum cleaner model of P-gp. 
1.C.2. INTESTINAL ABCC2/MRP2 
 Like P-gp, MRP2 is expressed on the AP membrane of the epithelial cells of the 
small intestine and several other tissues including the liver, heart, lung, and blood brain 
barrier (Miller et al., 2000; Dietrich et al., 2003).  Many compounds that are transported 
by MRP2 are also substrates for efflux by P-gp, although this overlap is not complete for 
all substrates.  MRP2 is involved in transporting many drugs and endogenous compounds 
such as organic anions, glutathione, glucuronide, sulfate conjugates, as well as basic 
drugs (Evers et al., 2000).  Though the functional importance of MRP2 within the 
intestine is not clearly understood, recent studies have demonstrated that Mrp2 is 
responsible for reducing the systemic exposure of the food-derived carcinogen 2-amino-
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1-methyl-6-phenylimidazo-[4,5-b]-pyridine (PhIP) in mice by decreasing its uptake from 
the intestine and increasing its biliary and intestinal excretion (Evers et al., 2000; Dietrich 
et al., 2001; Dietrich et al., 2003).  These studies established that some dietary 
components of humans are substrates for MRP2, and that MRP2 may serve a protective 
function within the intestine and liver.  Additionally, several studies have shown that the 
induction or inhibition of MRP2 affects the oral bioavailability of many clinically 
relevant drugs, including chemotherapeutic drugs (Kauffmann et al., 1997; Borst et al., 
2000; Naruhashi et al., 2001), antibiotics (Gerk and Vore, 2002), and several angiotensin 
II converting enzyme (ACE) inhibitors that are used to treat congestive heart failure 
(Nishino et al., 2000). 
1.C.3. INTESTINAL ABCG2/BCRP 
 BCRP is an ABC half-transporter that was first discovered in Michigan Cancer 
Foundation-7 (MCF-7) breast cancer cells that were resistant to doxorubicin (Doyle et al., 
1998).  BCRP has a broad tissue distribution, but is primarily found in the liver, small 
intestine, colon, and blood brain barrier (Maliepaard et al., 2001a).   Though the role of 
BCRP within the body has not been elucidated, several studies have shown that BCRP 
mediates the oral bioavailability and distribution of several clinically relevant 
chemotherapeutic agents such as mitoxantrone (Maliepaard et al., 2001b), topotecan, 
docetaxel, and imatinib (Breedveld et al., 2006), therefore further supporting the 
hypothesis that BCRP may function in a similar manner to P-gp and MRP2 in protecting 
the body from toxins.  BCRP is expressed at the AP membrane of the small intestine, 
with a particularly high expression within the tissue of the jejunum (Taipalensuu et al., 
2001).  
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1.D. INTESTINAL METABOLISM 
The elimination of drugs from the body can be mediated by chemical 
modification through, (i) phase I metabolizing enzymes, such as the cytochrome P450 
(CYP) system, (ii) conjugation of the drug with a glucuronic acid, glutathione, or sulfate 
group through phase II metabolism, or (iii) a combination of both (i) and (ii).   These 
modifications, in most cases, result in the parent drug becoming more water soluble and 
suitable for excretion by transporters in the liver, kidney, or intestine.  Until recently, it 
was widely believed that the liver was the only major organ responsible for the 
metabolism of most therapeutic compounds, and that metabolism within the intestine 
played a relatively minor role in determining the overall oral bioavailability.  However, 
studies have shown that cytochrome P450 3A (CYP3A), which is considered to be the 
major phase I metabolizing enzyme in humans, is involved in the oxidative metabolic 
clearance of >50% of marketed drugs (FDA, 1997; Wilkinson, 2005) and is highly 
expressed at the villus tips of the small intestine (Figure 1.2). Although CYP3A 
constitutes only ~30% of the total hepatic CYP content in humans (Shimada et al., 1994), 
it accounts for approximately 82% of the total CYP content in the human small intestine 
(Paine et al., 1997; Paine et al., 2006), which highlights its importance in mediating 
intestinal absorption.  Additionally, several studies have demonstrated that the low 
bioavailability of orally administered cyclosporine was due to extensive metabolic 
extraction by the intestine, and that metabolic extraction within the liver was significantly 
lower than that observed in the gut (Hebert et al., 1992; Gomez et al., 1995; Benet, 1996).  
Taken together, these observations validate the small intestine as one of the major sites of 
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pre-systemic drug metabolism and an important determinant of oral bioavailability as 
well as a potential site for drug-drug and diet-drug interactions. 
1.D.1. PHASE I METABOLISM IN THE INTESTINE: CYTOCHROME  
             P450 (CYP) 
Several metabolic enzymes, such as the hydrolases, alcohol and aldehyde 
dehydrogenases, as well as xanthine and amine oxidases, which are present within the 
intestine are involved in drug/xenobiotic metabolism via phase I reactions.  However, the 
most predominant mechanisms involved in the biotransformation of therapeutic 
compounds are catalyzed by the CYP enzymes.  There are several CYP metabolizing 
enzymes in the human small intestine, which include CYP3A (82% of the total intestinal 
CYP), CYP2C9 (14%), CYP2C19 (2%), CYP2J2 (1.4%), and CYP2D6 (0.7%) (Paine et 
al., 2006).   CYP3A constitutes approximately 82% of the total CYP content within the 
intestine, and is by far the most prevalent intestinal metabolizing enzyme (Paine et al., 
2006).  The expression of CYP3A is highest in the proximal duodenum and gradually 
decreases over the length of the intestine (Paine et al., 1997). It has been shown that the 
CYP metabolizing enzymes are most highly expressed at the villus tips of the small 
intestine (Figure 1.2) (Shimada et al., 1994).  This provides an extremely large surface 
area over which the CYP3A enzymes are able to interact with substrates during intestinal 
absorption, therefore providing favorable conditions for extensive metabolism by CYP3A 
in the intestine.  Many clinically relevant CYP3A substrates, such as cyclosporine (Benet, 
1996; Hebert, 1997), midazolam (Paine et al., 1996), saquinavir (Schmitt et al., 2009), 
tacrolimus (Hebert, 1997), and verapamil (Tracy et al., 1999), undergo extensive 
metabolism within the small intestine.  
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It has been shown that genetic differences in the genes responsible for the 
expression of the metabolizing enzymes can cause significant inter-individual variability 
in the expression and activity of many CYP metabolizing enzymes (Lown et al., 1997).  
Additionally, there have been several studies that show that the presence of genetic 
polymorphisms in the CYP3A genes can cause substantial changes in the metabolic route 
of elimination, resulting in the need for adjustments in doses and/or dosing schedules so 
as to achieve a safe and effective use of the therapeutic agent. Equally important is the 
alteration in metabolic routes of elimination, such as those mediated by CYP enzymes.  
This can be caused by the inhibition or induction of CYP metabolizing enzymes by 
concomitant drug administration (Watkins et al., 1987) or diet (Gupta et al., 1990; Li et 
al., 1994). In humans, the induction or inhibition of CYP metabolizing enzymes mediated 
by the co-administration of drugs can result in decreases or increases in the blood and/or 
tissue concentrations of a drug or metabolite or cause the accumulation of potentially 
toxic substances.  Additionally, for drugs that exhibit a narrow therapeutic window, the 
presence of high variability, genetic polymorphisms, or the induction/inhibition of CYP 
enzymes can substantially alter a drug’s safety and efficacy profiles.   
1.D.2. PHASE II METABOLISM IN THE INTESTINE 
 The mucosa that lines the small intestine also contains several phase II 
metabolizing enzymes that contribute to the pre-systemic metabolism of numerous drugs.  
The specific phase II metabolizing enzymes that have been identified within the intestine 
include n-acetyltransferases, glutathione s-transferase, methyltransferases, 
sulfotransfersases, and UDP glucuronosyltransferases (McCarver and Hines, 2002).  
Most phase II metabolic reactions involve the addition of a hydrophilic functional group 
  14 
to the xenobiotic, which results in an increase in the molecular weight and water 
solubility of the compound.  However, most phase II conjugates are too hydrophilic to 
passively diffuse across the cell and require transporters, such as the ABC  or SLC 
transporters, to facilitate their elimination from the body.  Therefore, it has been proposed 
that phase II metabolizing enzymes and efflux transporters work cooperatively to reduce 
the absorption of phenols and polyphenols and metabolite conjugates (Zamek-
Gliszczynski et al., 2006).  
1.E. INTERPLAY OF P-GP EFFLUX AND CYP3A-MEDIATED METABOLISM 
 Both P-gp and CYP3A are expressed at the enterocytic villi tips of the small 
intestine.  P-gp is located at the AP membrane facing the intestinal lumen and 
microsomal CYP3A is expressed on the intracellular membranes of the endoplasmic 
reticulum.  Due in part to co-localization, similarities in protective function, and 
extensive and overlapping substrate specificities (Wacher et al., 1995; Gan et al., 1996), 
there exists an opportunity for the interaction between CYP3A and P-gp during the 
intestinal absorption of shared substrates (dual substrates) of these two proteins.  In recent 
years, several published accounts have proposed hypotheses of synergy between 
metabolizing enzymes and transport proteins whereby the rate or extent of metabolite 
formation is affected by active drug transport.  The earliest studies to examine the effect 
of P-gp on CYP3A-mediated intestinal metabolism were conducted with cyclosporine 
and indinavir.  These studies showed that the drug undergoes greater metabolism during 
absorptive transport against the direction of P-gp-mediated efflux (AP to BL) than that 
observed during secretory transport (BL to AP) across human epithelial colorectal 
adenocarcinoma (Caco-2) cells (Gan et al., 1996; Hochman et al., 2000).  Additional 
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studies on the metabolism of K02 (Zhang et al., 1998) and digoxin (Salphati and Benet, 
1999) showed that metabolism was reduced when P-gp efflux was inhibited by 
ketoconazole.  Cumulatively, these studies led to the conclusion that P-gp efflux would 
enhance intestinal metabolism of dual substrates, and that following the oral 
administration of dual P-gp/CYP3A substrates, P-gp increased the intestinal mean 
residence time (MRT) of the drug within the intestinal epithelia, thereby providing 
increased opportunities for metabolism and resulting in decreased oral bioavailability.  
However, since these studies only investigated substrates or inhibitors that inhibit both P-
gp and CYP3A, the decreased metabolism observed could not be definitively attributed to 
P-gp inhibition. 
 Additional studies that supported the potential for the in vivo interplay of 
metabolizing enzymes and transport proteins were demonstrated by gender differences in 
the in vivo clearance of CYP3A substrates, where women exhibited a higher clearance 
than men.  However, this increase in clearance did not correlate with the expression of 
CYP3A4; instead it was shown to be due to the expression of P-gp (Cummins et al., 
2002a; Cummins et al., 2002b).  Additional studies by Cummins et al., using Caco-2 cells 
that were transfected with CYP3A4, showed that P-gp increased CYP3A4-mediated 
metabolism of the dual P-gp and CYP3A4 substrates K77 (Cummins et al., 2002a) and 
sirolimus (Cummins et al., 2004) during their absorptive transport across the Caco-2 cell 
monolayers.  It was suggested that P-gp-mediated efflux decreased the efficiency of drug 
transport across the cells in the absorptive direction, which could result in increased 
exposure of the dual substrates to the metabolizing enzymes (Cummins et al., 2002a; 
Benet et al., 2004; Cummins et al., 2004).  Another study on the metabolism and 
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intestinal absorption of the dual P-gp and CYP3A substrate, K77, using an in situ single-
pass rat intestinal perfusion model demonstrated that the inhibition of intestinal P-gp 
efflux with the P-gp inhibitor elacridar (GF120918) resulted in a reduction in the 
extraction ratio (ER) of K77, with no effect on the CYP3A only substrate, midazolam.  
Based on these results, the authors concluded that P-gp efflux increased the intestinal 
metabolism of K77 by CYP3A (Cummins et al., 2003).   These studies proposed that P-
gp AP efflux could increase CYP3A-mediated intestinal metabolism of a dual substrate 
during absorption by, (i) controlling access of the drug to the metabolizing enzymes and 
(ii) effectively prolonging the exposure of the drug to the metabolizing enzymes through 
repeated cycles of absorption and efflux.  According to this view, P-gp, working 
synergistically with CYP3A, would attenuate the bioavailability of drugs that are shared 
substrates of both proteins.  However, these conclusions have been primarily based on the 
observation that the inhibition of P-gp results in a decrease in the ER as defined by 
(Fisher et al., 1999) (Equation 1) or as modified by (Benet et al., 2004) (Equation 2) for a 
limited number of compounds.  
  
€ 
ER =  M metabolite∑M metabolite + M Parent Basolateral∑
  Equation 1 
 
  Equation 2 
 
Knight et al. (2006) demonstrated that the use of ER, as proposed by Cummins and Benet 
(Cummins et al., 2002a; Cummins et al., 2003; Benet et al., 2004; Cummins et al., 2004), 
does not accurately estimate the extent of metabolism in the presence or absence of P-gp.  
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It was shown that the ER would decrease by definition due to the inhibition of P-gp.  This 
is because both equations 1 and 2 include the mass of intact parent that is present in the 
basolateral (BL) compartment (Equation 1) or in the BL and cellular compartments 
(Equation 2).  Therefore, the denominator would increase due to the inhibition of P-gp 
efflux, causing an increase in the flux and intracellular concentrations of the parent drug 
(Knight et al., 2006).  Additionally, the inclusion of the mass of unmetabolized parent in 
the denominator of Equation 2 could result in the overestimation of the amount of drug 
metabolized, since the equation assumes that the intracellular drug would not be 
metabolized and be transported to the BL compartment. However, intracellular parent 
drug is not exclusively destined to be absorbed from within the cell.  Moreover, it is 
possible for the intracellular drug to be transported to either the AP or BL compartments 
or be metabolized, which would lead to an overestimation of the extent of drug 
metabolized within the intestine.  This highlights the fact that an alteration in the ER may 
not accurately describe changes in the rate or extent of metabolism since the effect of P-
gp on absorptive transport is incorporated in the ER equation.   
 Using theoretical pharmacokinetic (PK) modeling, Tam et al. (2004) were unable 
to predict the findings that P-gp enhances intestinal metabolism under nonsaturating 
conditions (Tam et al., 2003).  Instead it was proposed that P-gp efflux would reduce the 
intracellular concentrations of the parent drug, which would result in a reduction in the 
rate of CYP3A-mediated metabolism and effectively increase the apparent Km for 
CYP3A-mediated metabolism (Tam et al., 2003).  These models also demonstrated that 
under linear conditions, intestinal P-gp efflux would increase the MRT of dual substrates 
within the intestine.  Furthermore, the reduced intracellular concentrations mediated by 
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P-gp efflux would have a greater effect on metabolism than the increase in MRT, 
resulting in a reduction in the rate of metabolite formation and/or the total metabolite 
formed (Tam et al., 2003).  Additionally, it was shown that under saturating metabolic 
conditions, the rate of metabolism could increase in the presence of P-gp efflux, but this 
effect would be limited by the rate of absorption and dose (Tam et al., 2003).   
Recent studies by Knight (2007) demonstrated that the rate of metabolism of the 
dual P-gp/CYP3A (Cyp3a) substrate loperamide was reduced in the presence of P-gp 
efflux in both in Caco-2 cells in which CYP3A expression was induced by treatment with 
1α,25-dihydroxyvitamin D3 (Schmiedlin-Ren et al., 1997), and in fresh intestinal tissue 
from mice that were genetically deficient or competent in P-gp expression.  It was also 
shown that P-gp efflux reduced the rate of metabolism of dual P-gp/CYP3A substrate 
loperamide under linear conditions of CYP3A-mediated metabolism (Knight, 2007). 
These studies further emphasize the importance of defining system linearity and 
exploring the role of efflux on metabolism in terms of both the enzyme rate and extent of 
metabolism.  
To date, most studies involving the interactions between CYP3A and P-gp have 
utilized in vitro models, such as Caco-2 cell monolayers (Gan et al., 1996; Hochman et 
al., 2000; Cummins et al., 2001; Johnson et al., 2001; Cummins et al., 2002a; Li et al., 
2002; Cummins et al., 2003; Benet et al., 2004; Cummins et al., 2004), in situ models of 
intestinal tissue (Cummins et al., 2003), and theoretical PK model analyses (Tam et al., 
2003; Badhan et al., 2009).  However, no in vivo systematic studies on the effect of P-gp 
on CYP3A-mediated intestinal first-pass metabolism have been conducted where the 
differences between static versus dynamic conditions within the intestine would be 
  19 
expected to complicate the role of the interaction of P-gp and CYP3A in mediating oral 
bioavailablity of dual substrates. 
1.E.1. RELATIONSHIP OF AP EFFLUX BY P-GP AND INTESINTAL 
             METABOLISM IN MEDIATING PERMEABILITY ACROSS THE 
             ENTEROCYTE  
The passive permeability of a drug across an individual enterocyte occurs in three 
steps, which are determined by the structural properties of the cell and the drug.  These 
processes include, (i) passive diffusion of the drug across the lipid bilayer of the AP 
membrane of the enterocyte, (ii) diffusion and distribution of the drug within the cell, or 
(iii) partitioning of the drug across the BL membrane into the mesenteric circulation. For 
drugs that are substrates of P-gp or CYP3A, the overall passive permeability across the 
enterocyte is mediated by P-gp efflux at the AP membrane, which reduces permeability 
into the cytosol, or metabolic elimination of intracellular drug by CYP3A, respectively. 
For dual P-gp/CYP3A substrates, the passive permeability of a drug across the enterocyte 
is mediated both by P-gp efflux and CYP3A-mediated metabolism.  The cumulative 
effect of these processes in mediating permeability across the cells can be determined 
using the equation   
  
€ 
JTotal = JPassive − JEfflux − JMetabolism   Equation 3 
where JTotal is the total flux of the mass of a drug across the cell that is mediated by the 
individual contributions of passive permeability (JPassive), P-gp efflux (JEfflux), and 
CYP3A-mediated metabolism (JMetabolism). 
 Metabolism within the intestine is often described by Michaelis-Menten kinetics: 
                                     Equation 4 
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where V is the velocity of the metabolic reaction, S is the substrate concentration, and Km 
is the Michaelis constant which describes the affinity of the enzyme for the substrate and 
is defined as the concentration at which the rate of metabolism is 50% of the maximum of 
the metabolic reaction (Vmax).  The metabolic elimination of a drug, as described by 
Michaelis-Menten kinetics, is dose dependent in nature.  At substrate concentrations near 
the Km, the reaction velocity is linear with respect to concentration.  As substrate 
concentrations approach levels that result in enzymatic saturation, additional increases in 
the substrate concentration do not result in a proportionate increase in metabolic 
elimination.  Once the metabolic process is saturated, the clearance remains constant (i.e., 
zero-order rather than first-order), which can lead to an increase in the fraction of dose 
absorbed and exposure of the drug within the body.       
1.F. METHODS TO STUDY INTESTINAL EFFLUX AND METABOLISM 
 There are a variety of in vitro tools available for investigating the individual 
contribution of P-gp efflux or CYP-mediated metabolism in influencing the membrane 
permeability of therapeutic compounds.  Some of the in vitro experimental models 
available to study the metabolic profile of a compound include incubations with liver or 
intestinal microsomes or S9 fractions from various species, hepatocytes, or cell lines 
transfected with specific metabolizing enzymes.  These models allow for the detection of 
metabolism and quantification of intrinsic clearance rates.  Additionally, the involvement 
of specific CYP isoforms can be examined using recombinant human CYPs, which are 
packaged in supersomes.  This method allows for the investigation of the contribution of 
a single metabolic enzyme to the overall clearance of therapeutic agents (Gasser et al., 
1999).  
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 The effect of P-gp efflux on intestinal permeability is most commonly studied in 
vitro using cells lines such as Caco-2 (Hidalgo et al., 1989; Artursson, 1990; Artursson 
and Magnusson, 1990), MDR1-Madin-Darby Canine Kidney (MDCKII) (Pastan et al., 
1988), or porcine kidney epithelial (LLC-PK1) (van Helvoort et al., 1996) cells 
transfected with the P-gp encoding human MDR1 gene.  These cells are cultured on 
transwell™ membrane inserts where they form confluent, polarized monolayers and 
express functional P-gp at varying levels on the AP plasma membrane (Figure 1.4).  
Membrane permeability and efflux studies that are performed using these cells offer a 
high degree of reproducibility and ability for high throughput, and are widely accepted as 
the gold standard for determination of the involvement of P-gp in the absorption, 
distribution, or elimination of developmental compounds (Polli et al., 2001; Giacomini et 
al., 2010; Proctor, 2010).  However, the investigation of the functional interaction of P-gp 
and CYP3A presents several unique issues that must be addressed in models that contain 
both efflux transporters and metabolizing enzymes, such as P-gp and CYP3A 
respectively, so as to determine how transporter mediated efflux alters intestinal 
metabolism. 
1.F.1. IN VITRO METHODS  
Very few in vitro models facilitate studies for which the objective is to understand 
the interplay between CYP3A4 metabolism and P-gp efflux.  Most cell lines that are 
typically utilized for studying drug permeability, such as Caco-2 cells, have none or low 
oxidative metabolic capacity (Prueksaritanont et al., 1996).  Additionally, many of the 
cell-based assays that are used to assess the metabolic profile of a compound are devoid 
of the functional expression of transporters.  However, it has been shown that some Caco-
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2 cell lines exhibit low oxidative metabolism for cyclosporine (Gan et al., 1996), and the 
expression levels of CYP3A4 in this cell line can vary substantially from one laboratory 
to another, thus reducing their utility in investigating the interplay of efflux transporters 
and metabolizing enzymes.  Crepsi et al. (1996), developed CYP3A4 transfected Caco-2 
cell lines to allow for the simultaneous investigation of drug transport and metabolism in 
an isolated in vitro system.  They demonstrated that the metabolic conversion of 
testosterone to 6β-hydroxytestosterone was approximately 100-fold greater in the 
CYP3A4 transfected Caco-2 cells than that observed in control cells. Additionally, it was 
shown that there was no difference in the passive permeability of paracellular and 
transcellular probe substrates between the control and transfected Caco-2 cells, 
demonstrating that the transfection of the Caco-2 cells with CYP3A4 cDNA did not alter 
the integrity of the cell monolayer (Crespi et al., 1996).  Further studies showed that the 
addition of sodium butyrate and 12-O-tetradecanoylphorbol (TPA) to the culture media 
of the CYP3A4 transfected Caco-2 cells resulted in significantly higher expression of 
CYP3A4 (Crespi et al., 1996).  In another study, Caco-2 and LLC-PK1 cells that 
expressed P-gp were transfected with CYP3A4 using an adenovirus that contained 
CYP3A4 and CYP NADPH reductase genes.  These CYP3A4 transfected cells exhibited 
greater metabolism of midazolam and testosterone (specific CYP3A4 substrates), as well 
as highly polarized efflux ratios of digoxin and vinblastine (specific P-gp substrates) 
(Brimer et al., 2000) and provided a cell-based system where the effect of efflux and 
metabolism could be studied concurrently.  Subsequent studies demonstrated that 
CYP3A4 transfected Caco-2 cells had increased CYP3A4 expression and showed 
similarities in function, growth, and monolayer integrity to untransfected Caco-2 cells.  
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However, the increase in CYP3A4 expression in these cells did not result in a linear 
increase in CYP3A4 metabolic activity, demonstrating instability in the expression 
CYP3A4 (Hu et al., 1999).  These studies highlighted the need for further optimization of 
the culture conditions and routine monitoring of controls in order to account for 
variability in transporter expression over time and from laboratory to laboratory.  Further 
modifications in the culture conditions of the Caco-2 cells demonstrated that incubation 
with culture media containing fetal bovine serum and 1α,25-dihydroxyvitamin-D3 
resulted in a significant dose dependent increase in the expression of functional CYP3A 
(Schmiedlin-Ren et al., 1997).  Additionally, these studies showed that 1α,25-
dihydroxyvitamin-D3-treated Caco-2 cells exhibited increased metabolic conversion of 
the CYP3A4 specific probe substrate, midazolam, and the rate of metabolic clearance of 
midazolam, but it was shown that these levels were lower than that observed in the 
human intestinal mucosa (Paine et al., 2002), thus providing a more stable cell-based 
model for the simultaneous investigation of metabolism and drug transport. 
1.F.2. EX VIVO: SIDE-BY-SIDE DIFFUSION CHAMBERS  
 The Ussing side-by-side diffusion chamber provides a valuable method for the 
study of the transport of electrolytes, nutrients, and drugs across the intestinal epithelium.  
This method was originally developed by Hans H. Ussing over 50 years ago to study 
NaCl transport in frog skin (Kalman and Ussing, 1955).  Recently, the Ussing chamber 
has been employed for the investigation of drug permeability and metabolism across 
intestinal tissue from humans (Rogers et al., 1987; van de Kerkhof et al., 2006) and 
several preclinical species, such as pig (Smith et al., 1988; Lampen et al., 1998), rabbit 
(Smith et al., 1988), rat (Ungell et al., 1992), and mouse (Knight, 2007; Inagaki-
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Tachibana et al., 2008; Clarke, 2009).  In these studies, the intestinal mucosa or whole 
intestinal tissue is mounted between two buffer compartments, with the intestinal tissue 
acting as the barrier between the AP and BL compartments (Figure 1.5), and the buffer is 
continuously oxygenated so as to maintain tissue viability for up to 4 hours (Inagaki-
Tachibana et al., 2008).   
Unpublished results from our laboratory and studies by Knight (2007) examined 
the permeability of several probe substrates of P-gp (i.e., digoxin, saquinavir, and taxol) 
and the paracellular probe substrate mannitol across jejunal intestinal tissue from humans 
and P-gp deficient or P-gp competent mice.  These studies showed that the absorptive 
passive permeability of digoxin was significantly reduced across intestinal tissue from P-
gp competent mice compared to that observed across intestinal tissue from P-gp deficient 
mice, and the apparent absorptive permeability rates were similar to those observed in 
Caco-2 cells (Troutman and Thakker, 2003a; Troutman and Thakker, 2003b).  Moreover, 
the permeability of mannitol across human and mouse jejunum was similar to previously 
observed values in rodent (Stephens et al., 2002) and human (Cobden et al., 1980; Adachi 
et al., 2003) intestine.  However, the permeability of mannitol across mouse jejunum 
tissue was approximately 10-fold greater compared to the permeability observed in 
normal (Proctor et al., 2008) and CYP3A-induced Caco-2 cell monolayers (Knight, 
2007), which highlights possible differences in intestinal permeability between species. 
Additional studies by Knight (2007) demonstrated that the CYP3A probe substrate, 
testosterone, undergoes extensive metabolic conversion to 6β-hydroxytestosterone during 
absorptive transport across mouse intestinal tissue, and that there was no difference in 
Cyp3a expression or metabolic transformation of testosterone in intestinal tissue from P-
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gp competent and P-gp deficient mice (Knight, 2007).  These results support the use of 
intestinal tissue from preclinical species as a novel approach to studying the interaction 
between P-gp and CYP3A.  Although more labor intensive, these and several other 
studies (van de Kerkhof et al., 2007; Clarke, 2009) demonstrated that the Ussing type 
diffusion chamber provides a beneficial and physiologically relevant ex vivo model to 
investigate the interplay of P-gp and CYP3A4 due to the endogenous expression of these 
proteins within the intestinal tissue.  
1.F.3. IN SITU: ISOLATED PERFUSED INTESTINE 
In situ intestinal perfusion studies in humans or laboratory animals offer relevant 
experimental models to investigate the effect of transport and metabolism on the 
absorption of investigational drugs in different regions of the intestine while maintaining 
normal tissue physiology, blood flow, and the endogenous expression and co-localization 
of intestinal transporters and metabolizing enzymes.  Isolated single pass intestinal 
perfusion studies are most commonly performed in rodents, such as mice and rats, due to 
similarities in their intestinal physiology to the human intestine, as well as the ease of 
performing the procedure (Ehrhardt and Kim, 2008).   For this method, the intestinal 
segment that is selected for study is first surgically isolated, and the isolated intestinal 
lumen is then perfused with the drug in a physiologic buffer (Figure 1.6).  The conditions 
under which the study is performed can be closely monitored in terms of drug 
concentration, pH, osmolarity, flow rate, and the specific intestinal region to be studied.  
In situ intestinal perfusion studies are the nearest experimental model to an intact human 
or animal.  These studies allow for the measurement of permeability, metabolism, or 
absorption of the drug, which can be determined from the disappearance of drug or 
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appearance of metabolite in the dose solution (Fisher and Parsons, 1949), or by sampling 
the venous blood supply from the isolated intestinal segment by cannulation of the 
mesenteric vein associated with the isolated intestinal segment (Hirayama et al., 1989; 
Cummins et al., 2003).  However, it is not possible to perform isolated single pass 
intestinal perfusion studies in humans due to the invasive nature of the procedure.  The 
Loc-I-Gut® technique was developed by Knutson et al. (1989) for studying the intestinal 
absorption and secretion of drugs in humans (Knutson et al., 1989; Lennernas et al., 
1992).  This technique involves the introduction of a long multichannel tube through the 
mouth of an anesthetized patient into the small intestine.  A 10 cm segment of the 
intestine is then isolated by the inflation of two balloons that are attached to the tube, 
(Figure 1.7).  Similar to isolated perfused intestine studies performed in laboratory 
animals, the test drug solution is administered through the tube, and the permeability 
and/or absorption of the drug is quantified from the disappearance of drug from the dose 
solution (Knutson et al., 1989).  However, when designing or performing isolated 
perfused intestinal studies in humans or laboratory animals to investigate the interplay of 
transport and metabolism within the intestine, it is important to consider regional 
differences in the passive permeability of drugs across the intestine, as well as differences 
in the expression of drug transporters and metabolizing enzymes between species and 
within the various regions of the intestine itself. 
1.F.4. IN VIVO METHODS 
The majority of methods that have been developed to study the effect of drug 
transport and metabolism in the intestine in vivo in intact humans or animals provide an 
indirect measure of drug absorption where the contribution of the liver or intestine to 
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overall metabolism is difficult to discriminate.  Because of ethical and technical 
limitations, intestinal absorption and first-pass metabolism in humans is most often 
determined indirectly by the comparison of the area under the curve (AUC) following the 
intravenous (IV) and oral administration of the drug.  However, there are several 
assumptions that are typically made using this approach, such as complete intestinal 
absorption and systemic clearance of IV administered drug occurring exclusively in the 
liver.  Typically these assumptions, which should be carefully considered when 
estimating intestinal absorption and metabolism, are not tested or may be invalid and 
could lead to misleading conclusions when using these methods (Lin et al., 1999).   
One direct and sophisticated method available to investigate intestinal absorption 
and metabolism is the intraduodenal administration of a drug during the anhepatic phase 
of a liver transplantation procedure in humans (Kolars et al., 1991; Paine et al., 1996) or 
in animals (Yamaguchi et al., 1989; Tanaka et al., 2000).  Following administration of the 
drug, blood can be sampled directly from the portal vein, therefore providing a direct 
measurement of intestinal absorption without the involvement of hepatic metabolism.   
Another reliable and relatively easier technique that allows for the direct measurement of 
intestinal absorption is the portal cannulation of laboratory animals, such as dogs 
(Mouzas and Smith, 1969), rabbits (Barr and Riegelman, 1970), and rats (Pelzmann and 
Havemeyer, 1971).  In portal cannulation studies, an indwelling catheter is surgically 
inserted into the portal vein of anesthetized animals.  The drug is then administered by 
oral gavage and blood samples are collected via the cannula over an extended period of 
time. The additional sampling of blood from the systemic circulation through the 
catheterization of the jugular vein allows for the direct measurement of the amount of 
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drug that is absorbed from the intestine into the portal blood using the portal and systemic 
AUCs (Hoffman et al., 1995).  The use of an intact portal cannulation model in rats or 
mice provides a direct and relatively inexpensive quantitative method for the in vivo 
evaluation of drug permeability, oral absorption, and intestinal first-pass metabolism. The 
portal cannulation model also provides a novel and direct approach to investigate the 
dynamic interaction of P-gp and CYP3A during oral absorption in an intact animal under 
non-static physiologic conditions. 
1.G. RATIONALE AND OVERVIEW OF PROPOSED RESEARCH 
 The intestinal epithelium is an important and highly complex barrier that is 
composed of several physical as well as biochemical barriers that limit intestinal drug 
absorption, therefore affecting systemic bioavailability. CYP3A and P-gp mediate 
intestinal absorption by oxidative metabolism or AP efflux, respectively.  However, the 
exact nature of these interactions during the absorption of shared substrates, and their 
affect on oral bioavailability in preclinical species or in humans, is not clearly 
understood.   
The central hypotheses and specific aims of the dissertation project were designed 
to address this important gap in our understanding of the interaction between P-gp and 
CYP3A within the intestinal epithelium, and the effect of this interaction on in vivo 
intestinal first-pass metabolism and oral bioavailability of compounds that are dual 
substrates of P-gp and CYP3A.  The interaction of P-gp and Cyp3a was investigated ex 
vivo using mouse intestinal tissue from P-gp competent and P-gp deficient mice, and in 
vivo using a portal vein cannulated mouse model, which allowed for self-consistent 
comparison of results from similar studies performed ex vivo and in vivo in mice.  In 
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silico modeling of this ex vivo – in vivo relationship of the effect of the interplay of P-gp 
and CYP3A during oral absorption provided a better understanding of the intestinal 
absorption of dual P-gp/CYP3A substrates in humans. 
The following hypotheses were tested by the studies described in this 
dissertation: 
Following administration of dual P-gp/CYP3A substrates that generate intestinal 
concentrations that are near the Km of CYP3A-mediated metabolism: 
1. P-gp efflux decreases intestinal first-pass metabolism of dual substrates during 
absorptive transport. 
a. The reduction in metabolism is concentration dependent. 
b. The reduction in metabolism is directly related to the efficiency of 
efflux by P-gp as defined by the absorptive quotient (AQ, Chapter 2). 
2. For dual P-gp/CYP3A substrates that elicit a high efficiency for efflux by P-
gp.  
a. The effect of P-gp efflux in reducing overall intestinal metabolism by 
CYP3A will outweigh the effect of P-gp efflux alone in attenuating 
intestinal absorption. 
b. The decrease in intestinal first-pass metabolism will result in P-gp 
efflux enhancing portal bioavailability (FG),  
The Specific Aims designed to test these hypotheses are as follows: 
Specific Aim 1: Quantify the permeability and metabolic transformation of dual 
Cyp3a/P-gp substrates (e.g., amprenavir and loperamide) during absorptive transport 
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across matched intestinal epithelium from P-gp deficient and P-gp competent mice in an 
Ussing-type diffusion apparatus. 
a Determine the efficiency of P-gp efflux in attenuating the absorptive passive 
permeability of amprenavir and loperamide across mouse intestinal tissue.  
b Evaluate the effect of P-gp on the apparent Km for oxidative metabolism of 
loperamide and amprenavir in fresh mouse intestinal tissue. 
c Determine the effect of P-gp efflux on the rate and extent of Cyp3a-mediated 
metabolism during absorptive transport of amprenavir and loperamide across 
fresh mouse intestinal tissue. 
 
Specific Aim 2:  Determine the effect of P-gp efflux on intestinal first-pass metabolism 
and FG of intact drug after oral administration of dual P-gp and Cyp3a substrates 
evaluated in Specific Aim 1 using portal and jugular vein cannulated P-gp deficient and 
P-gp competent mice.  
a Evaluate the effect of the interaction between P-gp and Cyp3a within the 
intestinal epithelium, and its effect on intestinal first-pass metabolism/oral 
bioavailability of the dual Cyp3a/P-gp substrates amprenavir or loperamide in 
mice. 
b Evaluate how oral dose/intestinal concentration of the dual substrate alters the 
interplay of P-gp and Cyp3a during intestinal absorption of amprenavir and 
loperamide in mice. 
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c Determine how intestinal P-gp efflux or Cyp3a metabolism independently 
alters the intestinal absorption of amprenavir or loperamide in mice. 
 
Specific Aim 3: Examine the permeability and metabolic transformation of the dual 
CYP3A/P-gp substrate loperamide during absorptive transport across fresh human 
intestinal epithelium in the presence or absence of the P-gp inhibitor GF120918 to 
understand how P-gp efflux affects loperamide FG in humans. 
a. Determine the effect of P-gp efflux on the rate and extent of CYP3A-
mediated metabolism during absorptive transport of loperamide across 
fresh human intestinal tissue. 
b. Examine the relationships of findings on the interplay between P-gp efflux 
and intestinal metabolism of loperamide in fresh intestinal epithelial tissue 
from humans (+/- P-gp inhibitor GF120918) to those obtained in intestinal 
tissue from P-gp competent and deficient mice (Specific Aim 1).   
c. Develop an in silico model of the interplay of P-gp and CYP3A during 
intestinal absorption that is based on findings from ex vivo studies using 
intestinal tissue from human and mouse (Specific Aim 1), and from in vivo 
studies in mice (Specific Aim 2) to predict the effect of the interplay of P-
gp and CYP3A on the intestinal absorption of loperamide in humans. 
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1.H. FIGURES 
 
Figure 1.1: The organs of GI tract and the accessory organs of digestion that are 
involved in the absorption of nutrients, which can then be utilized by the cells of the 
human body.  Reproduced with permission from David Darling Ph.D. 
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Figure 1.2: The villus unit of the small intestine that is involved in the regulation of 
absorption of nutrients, drugs, and xenobiotics from the external environment.  The 
intestinal epithelium continually renews from the proliferation of crypt cells located at the 
base of the villi.  As proliferative cells begin to differentiate they migrate towards the tip 
of the villus where they differentiate into mature enterocytes and form a tight monolayer 
that has low permeability and exhibits increased expression of metabolizing enzymes, 
such as the CYP450’s.  
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Figure 1.3: Schematic representation of the physical and biochemical barriers to 
absorption across the intestinal epithelium.  The routes of absorption across the 
intestinal epithelium through passive transcellular or paracellular diffusion or by 
membrane proteins that facilitate carrier mediated drug transport or apical efflux (i.e.,  
ABC transporters).  The metabolic enzymes (i.e., CYPs) present in the intestinal 
enterocytes function to prevent absorption of drug/xenobiotics (green dots) across the 
intestine by metabolizing drug (black dot), therefore reducing oral bioavailability.  
Redrawn and adapted from presentation by Joseph Polli Ph.D.   
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Figure 1.4: Schematic representation of the Caco-2 Transwell™ Model.  Transwell™ 
experimental system with Caco-2 cells grown on porous membrane supports, providing 
access to both the apical and basolateral compartments for dosing and/or sampling.   
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Figure 1.5: Schematic representation of Ussing type side-by-side diffusion chamber. 
Fresh mouse or human jejunum is mounted between two chambers, which are filled with 
Krebs bicarbonate buffer and oxygenated to maintain viability.  Reproduced with 
permission from Beverly Knight Ph.D (Knight, 2007). 
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Figure 1.6: Schematic representation of isolated intestinal perfusion methods to 
measure intestinal permeability, metabolism, and absorption.  An isolated single pass 
intestinal perfusion technique in a rat where the intestinal segment is surgically isolated 
and then perfused with drug in a physiologic buffer.   
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Figure 1.7: Schematic representation of isolated intestinal perfusion methods in 
humans using a “Loc-I-Gut” perfusion technique to measure intestinal 
permeability, metabolism, and absorption.  The Loc-I-Gut perfusion technique is 
performed by the insertion of a small tube down the esophagus and into the small 
intestine of an anesthetized patient and absorption of drug occurs from a 10 cm segment 
of intestine that has been isolated between two inflated balloons. 
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METABOLISM AND ENHANCES PORTAL BIOAVAILABILITY OF 
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2.A. ABSTRACT 
The systematic study of the effect of P-glycoprotein (P-gp) on cytochrome P450 
3A (CYP3A)-mediated intestinal first-pass metabolism of dual P-gp/CYP3A substrates in 
vivo, where the interactions between these two proteins are likely to be more complex, 
are lacking. In this study, a systematic approach was employed where matched ex vivo – 
in vivo mouse models of intestinal absorption to systematically study the effect of the 
efflux transporter P-gp on altering intestinal Cyp3a-mediated metabolism of the dual P-
gp and Cyp3a substrate loperamide.  The dynamic interaction of P-gp and Cyp3a in an 
intact mouse was investigated in the presence or absence of P-gp using an acute 
indwelling catheter that was inserted into the portal and jugular veins, so that the overall 
dose-dependent effect of P-gp efflux on intestinal first-pass metabolism and FG of the 
dual Cyp3a and P-gp substrate loperamide could be investigated following oral 
administration of loperamide.  These studies showed that at low doses of loperamide, 
which produced intestinal concentrations that were near the apparent Km for oxidative 
metabolism, the FG of loperamide in P-gp competent mice was several times greater than 
that observed in P-gp deficient mice.  The increase in the portal bioavailability (FG) of 
loperamide was caused by P-gp efflux effectively protecting loperamide from intestinal 
first-pass metabolism by Cyp3a, presumably by reducing loperamide intracellular 
concentration.  However, at high doses of loperamide, P-gp had no effect on loperamide 
intestinal absorption.   
Furthermore, the in vivo effects of P-gp on first-pass metabolism and oral 
absorption of loperamide were elucidated by transport and metabolism studies in fresh 
intestinal tissue from P-gp deficient and P-gp competent mice using an Ussing-type 
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diffusion apparatus. It was shown that rate and extent of Cyp3a-mediated metabolism 
during absorptive transport of loperamide in mouse intestinal tissue was significantly 
reduced in the presence of P-gp efflux at concentrations that were near the apparent Km 
for Cyp3a-mediated metabolism. However, at concentrations that were several fold 
greater than the apparent Km for metabolism, Cyp3a appeared to be saturated, which 
resulted in no difference in the rate or extent of loperamide metabolism in intestinal tissue 
that was either P-gp competent or P-gp deficient.  Cumulatively, these novel findings 
provide a new understanding on how the interplay between P-gp and CYP3A is altered 
based on the dose of P-gp/CYP3A dual substrates, which in turn influences the FG. 
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2.B. INTRODUCTION 
The intestinal epithelium is an important and highly complex barrier that 
comprises several physical as well as biochemical features that limit intestinal absorption 
of drug, thereby affecting systemic bioavailability.  Consequently, the intestine 
constitutes a critical determinant of the therapeutic efficacy of orally administered drugs 
(Benet, 1996; Paine et al., 1996).  Cytochrome P450 3A (CYP3A) and P-glycoprotein (P-
gp) are two important biochemical barriers in the intestinal epithelium that contribute to 
the barrier properties via different mechanisms, i.e. first-pass metabolism and apical (AP) 
efflux, respectively.  They influence the systemic bioavailability and therapeutic efficacy 
of many drugs over a widely diverse class of xenobiotic agents (Wacher et al., 1995), 
such as the anti-HIV drug saquinavir (Fitzsimmons and Collins, 1997; Sinko et al., 2004) 
or the immuno-suppressive agent, cyclosporine (Gomez et al., 1995; Benet, 1996; Gan et 
al., 1996).  The role of CYP3A in drug interactions is well established (FDA, 1997; Liu et 
al., 2007; Zhou, 2008) (FDA Drug Development and Drug Interaction Website, 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugIn
teractionsLabeling/ucm091806.htm).  More recently, transporters, including P-gp, have 
emerged as important players in drug interactions (Giacomini et al., 2010; Proctor WR, 
2010).  Of the various drug transporters, P-gp is the most studied.  Additionally, in the 
recent United States Food and Drug Administration guidance to address transporter-
mediated drug-drug interactions, P-gp is featured prominently as a key efflux transporter 
that could mediate such interactions and affect the safe and effective use of therapeutic 
agents (FDA, 2006; Huang et al., 2007; Zhang et al., 2009).  P-gp and CYP3A both 
accept substrates with wide diversity in chemical structure; accordingly, the two proteins 
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share many substrates.  In the intestinal epithelium, P-gp presents the first barrier to P-
gp/CYP3A dual substrates before these compounds can reach the intracellular 
membranes of the endoplasmic reticulum where they are metabolized by CYP3A.  
Therefore, it is generally accepted that P-gp and CYP3A would interact with respect to 
affecting the cellular disposition of their shared substrates. However, whether P-gp 
enhances or attenuates Cyp3a-mediated metabolism of shared substrates during intestinal 
absorption in preclinical species or humans is an area of debate.   
Several in vitro studies have been conducted to elucidate the effect of the 
interplay between CYP3A and P-gp on the intestinal absorption of drugs that are 
substrates for both proteins. Some of these studies have been conducted using in vitro cell 
based models of intestinal absorption, such as human epithelial colorectal 
adenocarcinoma (Caco-2) cells that exhibit low oxidative metabolism of the CYP3A 
substrate, cyclosporine (Gan et al., 1996), or Caco-2 cells that were transfected with 
CYP3A4 (Cummins et al., 2004).  These studies showed that P-gp increased CYP3A4-
mediated metabolism of dual P-gp and CYP3A4 substrates during their absorptive (AP to 
basolateral (BL)) transport across the cell monolayers.  Studies on the metabolism and 
intestinal absorption of the dual P-gp and Cyp3a substrate, K77, using an in situ single-
pass rat intestinal perfusion model, demonstrated that the inhibition of intestinal P-gp 
efflux with the P-gp inhibitor elacridar (GF120918) resulted in the reduction of the 
extraction ratio (ER) of K77, but had no effect on the Cyp3a-only substrate, midazolam 
(Cummins et al., 2003).  Based on these results the authors concluded that P-gp efflux 
increased intestinal metabolism of K77 by Cyp3a (Cummins et al., 2003).  These studies 
propose that P-gp AP efflux can increase CYP3A-mediated intestinal metabolism of a 
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dual substrate during absorption by controlling access of the drug to the metabolizing 
enzymes and effectively prolonging the exposure of the drug to the metabolizing 
enzymes through repeated “cycles” of absorption and efflux.  According to this view, P-
gp, working synergistically with CYP3A, would attenuate the bioavailability of drugs 
that are shared substrates for both proteins (Gan et al., 1996; Cummins et al., 2002; 
Cummins et al., 2003; Benet et al., 2004).  However, Tam et al. (2000), based on 
theoretical considerations, did not support this notion, and suggested that P-gp would 
decrease the rate of CYP3A-mediated metabolism under non-saturating conditions by 
reducing the intracellular concentration of the substrate, thus effectively increasing the 
apparent Km of the substrate for CYP3A (Tam et al., 2003). 
To date, mutually contradicting conclusions have been reached on whether P-gp 
would enhance or attenuate the metabolism of dual P-gp/CYP3A substrates during oral 
absorption.  These conclusions are entirely based on either in vitro models, such as Caco-
2 cell monolayers (Gan et al., 1996; Hochman et al., 2000; Cummins et al., 2001; 
Johnson et al., 2001; Cummins et al., 2002; Li et al., 2002; Cummins et al., 2003; Benet 
et al., 2004; Cummins et al., 2004), single pass rat intestinal perfusion model (Cummins 
et al., 2003), or pharmacokinetic (PK) modeling (Tam et al., 2003; Badhan et al., 2009).  
The present study, for the first time, evaluates the effect of P-gp on (i) intestinal first-pass 
metabolism and (ii) oral bioavailability in the portal circulation (FG) of the dual P-
gp/CYP3A substrate, loperamide, in an in vivo mouse model that utilizes portal vein 
cannulation of P-gp deficient and P-gp competent mice.  Furthermore, the in vivo effects 
of P-gp on first-pass metabolism and oral absorption of loperamide were elucidated using 
transport and metabolism studies in the intestinal tissue from P-gp deficient and P-gp 
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competent mice using an Ussing-type diffusion apparatus.  These studies yielded an 
unexpected result, which showed that P-gp increased the FG of loperamide in the low 
dose group.  A combination of in vivo and ex vivo studies revealed that the effect of P-gp 
on sparing loperamide from extensive first-pass metabolism far outweighed its effect on 
attenuating absorption of the drug via the efflux mechanism, with the net effect of 
increased loperamide bioavailability across the intestinal barrier.    
2.C. EXPERIMENTAL METHODS 
Materials 
Loperamide, terfenadine, testosterone, 6β-hydroxytestosterone, troleandomycin, 
sodium hydroxide, sodium bicarbonate, and Krebs Bicarbonate Ringer (KBR) were 
purchased from Sigma Aldrich (St. Louis, MO, USA).  The metabolites of loperamide 
(monodemethyl- and didemethyl-loperamide) were generously provided by Janssen 
Pharmaceutica  (Beerse, Belgium).  1-Aminobenzotriazole (ABT) was purchased from 
Santa Cruz Biochemicals (Santa Cruz, CA, USA).  Acetonitrile, 95% ethanol (EtOH), 
methanol, ethyl acetate, dimethyl sulfoxide (DMSO) were purchased from Fisher 
Scientific (Pittsburgh, PA, USA).  Ketamine HCl and 0.9% NaCl saline were purchased 
from Veterinary Medical Supply (Zebulon, NC, USA), and xylazine HCl was purchased 
from Webster Veterinary (Sterling, MA, USA).  All other reagents were of analytical 
grade or higher and triple deionized water was used in all experimental procedures. 
Animals 
Male CF-1 (P-gp competent) and Mdr1a1-/- (P-gp deficient) mice were purchased 
from Charles River Laboratories (Wilmington, MA, USA).  The animals were housed 
according to approved Association for Assessment and Accreditation of Laboratory 
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Animal Care (AAALAC) and the University of North Carolina at Chapel Hill 
Institutional Animal Care and Use Committee (IACUC) requirements and protocols.  The 
animal housing facility was under the care, supervision, and animal husbandry of the 
University of North Carolina at Chapel Hill’s Division of Laboratory Animal Medicine, 
in compliance with The Animal Welfare Act public laws 89-544 and 91-579.  All animals 
were maintained under a normal 12-hour day/night schedule with lights on at 8:00 am. 
Diffusion Chamber Studies 
P-gp competent and P-gp deficient mice were fasted overnight and then 
anesthetized with an intraperitoneal (IP) injection of ketamine (140 mg/kg) and xylazine 
(15 mg/kg).  A 10 cm segment of jejunum was gently dissected and immediately flushed 
with 10 ml ice-cold KBR with 50% complete EDTA-free protease inhibitor (Roche, 
Basel, Switzerland).  The harvested intestinal segment was separated into four 2 cm 
segments, mounted between two halves of a diffusion chamber insert and held in place by 
eight small pins as quickly as possible.  The inserts were then mounted between two side-
by-side diffusion chambers (Physiologic Instruments, San Diego, CA, USA). KBR (3 ml) 
at 37°C was added to each chamber and bubbled with oxygen/carbon dioxide (95:5) gas 
to maintain tissue viability (Johnson et al., 2002). The intestinal tissues were 
preincubated (AP and BL) for 30 min at 37°C in 3 ml KBR buffer solution or for Cyp3a 
inhibition studies, with KBR buffer containing 100 µM of the Cyp3a inhibitor 
troleandomycin or 1mM of the Cyp inhibitor ABT.   
After the equilibration period, the transepithelial electrical resistance was 
measured to test the epithelial integrity of the intestinal tissue.  The KBR buffer from the 
BL chamber was removed and replaced with fresh buffer (3 ml), while the buffer in the 
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AP chamber was replaced with 3 ml of an appropriate concentrations of loperamide (20, 
50 or 100 µM) in KBR buffer containing 0.1% EtOH or testosterone (0.1, 0.25, 0.5, and 
1.0 mM) in KBR buffer containing 0.1% EtOH.  The intestinal tissues were incubated for 
90 min at 37°C after which KBR buffer from the AP and BL chambers was collected.  
The intestinal tissues were washed ten times in ice-cold KBR buffer, homogenized for 30 
sec with a sonic dismembrator in 200 µl of 50:50 KBR and 2N NaOH, and vortexed with 
0.5 ml ethyl acetate for 1 min. The homogenates were then centrifuged at 9,000 g at 4°C 
for 10 min, and the supernatants collected.  The homogenized tissues were then washed 
with 0.5 ml ethyl acetate, vortexed, centrifuged, and the supernatants collected two 
additional times. The supernatants were combined and then evaporated under nitrogen 
gas for 10 min, and reconstituted in the KBR.  All samples were stored at -20°C until 
analysis using liquid chromatography-mass spectrometry (LC/MS/MS). 
In Vivo Studies 
Portal Vein Cannulation of Mouse 
P-gp competent and P-gp deficient mice were fasted overnight and anesthetized 
with an IP injection of ketamine (140 mg/kg) and xylazine (15 mg/kg).  The depth of 
anesthesia was monitored throughout the surgical procedure and experiment by the toe 
pinch reflex and if appropriate, a 35 mg/kg dose of ketamine was administered 
intramuscularly in the hind limb to maintain the anesthetic plane.  A 2 cm abdominal 
midline incision was made and the intestine was pushed to the side exposing the portal 
vein.  A saline filled silastic catheter  (0.025" OD x 0.012" ID) (Braintree Scientific, 
Braintree, MA), with a 28 ga. needle tip (Becton, Dickinson Biosciences, Franklin Lakes, 
NJ USA) attached to the end, was inserted into the portal vein and secured to the 
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surrounding tissue with a micro-serrefines vascular clamp (FST, Foster City, CA). The 
animal’s body temperature was monitored throughout the experiment by placement of a 
rectal thermometer (Fisher Scientific, Pittsburgh, PA, USA) and maintained at 37°C on 
surgical board (VWR, Radnor, PA), which was maintained at 37°C with a heating pad  
(Jarden Corporation, New York, NY, USA).  Doses of 0.23, 0.47, and 0.95 mg/kg of 
loperamide, which produce approximate intestinal concentration of 50, 100, or 200 µM, 
respectively were administered to the portal vein cannulated P-gp competent (n=6) or P-
gp deficient mice (n=6) by oral gavage in 300 µl of 0.9% NaCl with 1% EtOH.  For Cyp 
inhibition studies, 50 mg/kg ABT was dosed three hours prior to initiation of the study by 
oral gavage in 100 µl of 0.9% NaCl to P-gp competent (n=6) or P-gp deficient mice 
(n=6).  Then an additional 50 mg/kg ABT was co-administered with a 0.23 mg/kg dose of 
loperamide in 300 µl of 0.9% NaCl with 1% EtOH at the start of the study.  Portal blood 
samples (20 µl) were withdrawn through the portal cannula over four hours (at 10, 30, 60, 
120, 180, and 240 min).  Each blood sample was replaced with an equal volume of 10 U 
heparinized 0.9 % NaCl saline.   The blood samples were placed in heparinized 
microcentrifuge tubes (Fisher Scientific, Pittsburgh, PA, USA), and stored on ice until the 
completion of the experiment.  Following centrifugation at 9,000 g at 4°C for 10 min, 
plasma was collected, and the samples were stored at -80°C. 
Jugular Cannulation of Mouse 
P-gp competent and P-gp deficient mice were fasted overnight and then 
anesthetized, as described above, and implanted with an acute indwelling jugular 
catheter.  A 1 cm incision was made in the neck and the jugular vein gently exposed by 
blunt dissection.  A silastic jugular catheter  (0.05" OD x 0.01" ID)  (Braintree Scientific, 
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Braintree, MA) was inserted into the right jugular vein and advanced to the junction of 
the vena cava and the right atrium and sutured to tissue surrounding the vein. The 
catheter was then tunneled subcutaneously to the back where the cannula was 
exteriorized between the scapulae.  The animal’s body temperature was monitored 
throughout the entirety of the surgical procedure and experiment, as described above.  
Doses of 0.23, 0.47, and 0.95 mg/kg of loperamide, were administered by oral gavage in 
300 µl of 0.9% NaCl saline with 1% EtOH to jugular vein cannulated P-gp competent 
(n=6) or P-gp deficient mice (n=6).  Cyp inhibition in mice was completed as described 
above.  Systemic blood samples (20 µl) were withdrawn through the jugular cannula over 
four hours (at 10, 30, 60, 120, 180, and 240 min) and prepared as described previously 
and then stored at -80°C.  
Loperamide Blood to Plasma Ratio 
Fresh blood was collected from P-gp competent mice in heparinized centrifuge tubes 
(Fisher Scientific, Pittsburgh, PA, USA) and immediately mixed to prevent clotting.  
Whole blood (1 ml) was then spiked with loperamide to obtain a final concentration of 10 
nM.  The blood was then gently shaken at 37°C for 30 min.  After shaking, an aliquot of 
100 µl whole blood was collected in quadruplicates.  Plasma samples were obtained by 
centrifuging 100 µl aliquots of whole blood at 9000 g at 4°C for 10 min. Whole blood 
samples and plasma samples were processed by precipitation with 250 µl of ice-cold 
acetonitrile containing a 10 ng/ml terfenadine internal standard. 
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Analytical Procedure 
Liquid Chromatography-Mass Spectrometry (LC-MS/MS)  
The preparation of each portal and systemic plasma sample (10 µl) for analysis 
was performed by precipitation with the addition of 50 µl of ice-cold acetonitrile, 
containing terfenadine (10 ng/ml) as the internal standard.  For diffusion chamber studies, 
50 µl of each experimental buffer sample was mixed with 50 µl of ice-cold acetonitrile, 
containing a 10 ng/ml terfenadine internal standard.  All samples were then vortexed for 
1 min and centrifuged at 9000 g at 4°C for 10 minutes.  Loperamide and its two 
metabolites, monodemethyl-loperamide and didemethyl-loperamide, were quantified in 
samples obtained from the receiver and donor compartments of the diffusion apparatus, 
in the intestinal tissue, and in each portal and jugular plasma sample using LC-MS/MS. 
The LC/MS/MS system consisted of LC10-ADVP quaternary pumps (Shimadzu, Kyoto, 
Japan) that were fitted with a CTC-PAL autosampler (LEAP Technologies, Carrboro, 
NC) and a Sciex API-4000 triple-quadropole mass spectrometer (Applied Biosystems, 
Foster City, CA).  The mobile phases consisted of 0.1% formic acid in water (A) and 
0.1% formic acid in methanol (B).  The chromatographic separation of analytes was 
performed with a linear gradient of 5-95% A in B at a flow rate of 0.8 ml/min over four 
min, and a sample injection volume of 5 µl.  The analytical column was an Aquasil C18, 
50x2.1m, with a 5 µm particle size (Thermo-Scientific, Waltham, MA, USA). The 
samples were ionized using TuroboIonSpray ion source and the positive ions were 
monitored at the following transitions: 477/266 for loperamide, 463/252 for 
monodemethyl-loperamide, and 449/238 for didemethyl-loperamide, and 472/436 for 
terfenadine.  Calibration standard curves that ranged from 0.1-100 ng/ml were linear (R2 
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> 0.99) and were analyzed at the beginning and end of the run for each experimental 
group for sample quantification.  The data were acquired and processed using Analyst 
1.4.1 (Applied Biosystems, Foster City, CA, USA). 
High-Performance Liquid Chromatography (HPLC) 
Testosterone diffusion chamber study samples were prepared by the mixing of 40 
µl of each experimental buffer sample with 60 µl of methanol, containing corticosterone 
(25 ng/ml) internal standard.  All samples were vortexed for 1 min, centrifuged at 9000 g 
at 4°C for 10 minutes, and then transferred to glass micro-inserts (National Scientific, 
Rockwood, TN, USA) placed in autosampler vials (National Scientific, Rockwood, TN, 
USA).  Testosterone and its Cyp3a specific metabolite, 6β-hydroxytestosterone was 
quantified in triplicate as previously described (Knight, 2007), using a HP1100 HPLC 
(Agilent Technologies, Santa Clara, CA) with UV detection at 242 nm for testosterone 
and 260 for corticosterone.  The mobile phases consisted of water (A) and methanol (B). 
The samples were injected in triplicate with an injection volume of 50 µl and 
chromatographic separation of analytes was performed with a linear gradient of 40-75% 
A in B at a flow rate of 1.0 ml/min over 10 min.  The analytical column was a Zorbax 
Eclipse XDB-C8, 4.6 X 150 mm, with 5 µm particle size (Agilent Technologies, Santa 
Clara, CA). The standard curves of testosterone ranged from 0.2-200 ng/ml were linear 
(R2 > 0.99) throughout the range, and were analyzed at the beginning and end of the run 
for sample quantification. 
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Data Analyses 
For the metabolic studies, a Michaelis-Menten model (Equation 1) was fit to the 
data. 
                     
  Equation 1 
V represents the rate of metabolism, Vmax is the maximum rate of metabolism, Km is the 
concentration at which half of the maximum velocity is achieved, and S is the loperamide 
dosing concentration.  The model was fit using GraphPad Prism® 4.0 (GraphPad 
Software Inc., La Jolla, CA, USA) with a R2  of > 0.90 to confirm a goodness of fit.  The 
apparent permeability (Papp) of loperamide across the mouse intestinal tissue was 
calculated according to Equation 2, 
          
  Equation 2 
where J  represents the mass of drug transported, integrated over time (dQ/dt), A is the 
area of the intestinal tissue, and CD is the initial concentration of drug in the donor 
compartment, with studies conducted under sink conditions (Artursson and Karlsson, 
1991). 
The efficiency of P-gp in attenuating the passive permeability during intestinal 
absorption can be quantitatively expressed as the absorptive quotient (AQ) (Equation 3).  
      
            Equation 3 
This parameter can be determined experimentally by measuring (i) apparent permeability 
(AP to BL) in the presence of P-gp mediated efflux (Papp,AB) and (ii) passive permeability 
in the absence of P-gp (PPD) (P-gp inhibited with GF120918), and by calculating the 
decrease in permeability caused by P-gp in relation to the PPD (Troutman and Thakker, 
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2003a; Troutman and Thakker, 2003b).  Thus, for a compound with an AQ of 0.9, P-gp 
efflux attenuates PPD during absorptive transport by 90%. 
The fraction of dose transported (FT) across mouse intestinal tissue segments 
from P-gp competent and P-gp deficient mice in the absorptive direction was quantified, 
according to Equation 5,  
  
  Equation 4 
where ParentBasolateral is the mass of unmetabolized parent drug present in the receiver 
compartment of the diffusion chamber 90 min after the administration of the drug dose to 
the donor compartment. Dose is the mass of loperamide present in the dose solution in 
the donor compartment of the diffusion chamber at the initiation of the experiment. 
Using equation 5, the fraction of dose metabolized (FM) was quantified from the 
amount of total metabolite present in the receiver and donor compartments, and in mouse 
intestinal tissue. 
                     Equation 5 
M is the total mass of the major Cyp3a metabolites of loperamide, monodemethyl-
loperamide and didemethyl-loperamide (Figure 2.1), which were present in the donor 
(MApical), receiver   (MBasolateral) compartments of the diffusion chamber and the mouse 
intestinal tissue (MIntracellular) at 90 min following the administration of the dose (mass) to 
the donor compartment.  
The portal bioavailability (FG) was quantified as previously described by Hoffman 
et. al (1995) as briefly described below.   
                                            Equation 6 
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MPortal is the mass of parent drug calculated from measured concentrations in the portal 
blood over time, MAbsorbed is the total mass of the parent drug absorbed across the 
intestine over time, and MSystemic is the mass of the parent drug returned to the portal vein 
from the systemic circulation over time.   
The total drug in the portal vein that was absorbed directly from the intestine 
(Equation 7) or from the systemic circulation (Equation 8) was quantified from the portal 
blood flow (QPortal) in mouse (Davies and Morris, 1993), the area under the portal blood 
concentration-time curve to time (t) (AUCPortal (0-t hr.)), and the mean area under the 
systemic blood concentration-time curve to t (AUCSystemic (0-t hr.)) following the oral 
administration of the dose, where the blood concentration of loperamide in the portal and 
systemic was calculated by conversion of portal and systemic plasma concentration 
(Uchimura et al., 2010) using the blood to plasma ratio of loperamide..  
                    Equation 7 
and 
                     Equation 8 
 
Expressing MAbsorbed (Equation 6) relative to the mass of the dose allows for a direct 
quantification of the fraction of dose absorbed into the portal circulation (FG), as 
expressed in Equation 9. 
                 
€ 
FG = MAbsorbedDose              
Equation 9 
Statistical Analysis 
The overall difference in measured values (e.g. metabolic rate, Km, Papp, FT, FM, 
FG) between the mouse strains or treatments was determined using a two-way analysis of 
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variance (ANOVA) followed by a Bonferroni post-test, unless specifically noted, using 
GraphPad Prism® statistical software 4.0 for Mac (GraphPad Software Inc., La Jolla, CA, 
USA).  All values are expressed as the mean ± standard deviation (SD).  The criterion for 
a significant difference in values was considered as p < 0.05. 
2.D. RESULTS 
Metabolism of Loperamide during Absorptive Transport Across Intestinal Tissue 
from P-gp Competent or P-gp Deficient Mice.  The rate of loperamide metabolite 
(Figure 2.2) formation during absorptive transport, i.e. AP to BL compartment, across 
intestinal tissue from P-gp competent and P-gp deficient mice is shown as a function of 
the initial concentration in the donor compartment (Figure 2.2).  The rate of metabolism 
was lower in the presence of P-gp than in its absence throughout the concentration range, 
causing a leftward shift of the metabolic rate versus concentration profile for the 
intestinal tissue from P-gp deficient mice relative to that from P-gp competent mice.  The 
difference in the metabolic rate due to P-gp was greatest at concentrations near the 
apparent Km for Cyp3a-mediated metabolism (Figure 2.2).  At high concentrations, as 
loperamide metabolism appeared to approach saturation, this difference gradually 
decreased (Figure 2.2).  P-gp competent and P-gp deficient mice showed no difference in 
Cyp3a expression (data not shown) or metabolic activity toward testosterone (Figure 
2.3A), a Cyp3a probe substrate (Kenworthy et al., 1999) that is not subject to AP efflux 
by P-gp.  The Michaelis-Menten model of enzyme kinetics (Equation 1) was fit to the 
data represented in the loperamide metabolic rate versus concentration plots for intestinal 
tissue from P-gp competent and P-gp deficient mice.  The analysis showed that the 
apparent Km for Cyp3a-mediated metabolism was approximately 5-fold less (p < 0.001) 
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in P-gp deficient versus P-gp competent intestinal tissue (4.5 ± 2.4 µM versus 22 ± 4.8, 
respectively µM) (Table 2.1).  There was no difference in the calculated Vmax for 
oxidative metabolism of loperamide by Cyp3a in the intestinal tissues of P-gp competent 
or P-gp deficient mice (Table 2.1).   
The Effect of the Interplay between P-gp and Cyp3a In Vivo on Intestinal 
Absorption of Loperamide into the Portal Circulation of Mouse.  The effect of P-gp 
on loperamide metabolism during its absorptive transport across the intestinal tissue 
suggests that P-gp could affect the oral absorption of this drug by two opposing effects; 
i.e. attenuate absorption by AP efflux and enhance absorption of the intact loperamide by 
reducing first-pass metabolism.  The oral absorption of loperamide was studied over four 
hours (which is expected to encompass the transit time of loperamide through the mouse 
small intestine) (Hsu, 1982; Suckow et al., 2001) in portal vein cannulated mice that were 
competent or deficient in P-gp expression.  The rationale was that if P-gp is affecting the 
absorption of intact loperamide by a combination of effect on the first-pass metabolism 
and permeability, this should be evaluated in the portal circulation before loperamide is 
further metabolized in the liver or excreted in bile.  Following the oral administration of 
loperamide to both groups of mice, blood samples were withdrawn from the implanted 
cannulas and loperamide oral absorption profiles were generated by plotting the portal 
plasma concentration versus time (Figure 2.4A).  
 Contrary to what is generally expected, following administration of a low dose of 
loperamide (0.23 mg/kg), the intestinal absorption of loperamide into the portal 
circulation of P-gp competent mice (AUC0-240 min = 270 ± 77 ng*min/ml) was 
significantly higher (p < 0.01) than that observed in P-gp deficient mice (AUC0-240 min = 
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90 ± 14 ng*min/ml)  (Figure 2.4).  For the 0.47 mg/kg dose the portal vein plasma 
concentrations of loperamide were slightly attenuated in P-gp competent mice (AUC0-240 
min = 270 ± 140 ng*min/ml) compared to P-gp deficient mice (AUC0-240 min = 420 ± 54 
ng*min/ml) (Figure 2.4).  However, at the 0.94 mg/kg dose, there was no difference in 
the absorption of loperamide into the portal circulation of P-gp competent (AUC0-240 min = 
4900 ± 3000 ng*min/ml) and P-gp deficient mice (AUC0-240 min = 5700 ± 2900 
ng*min/ml) (Figure 2.4B). 
Effect of P-gp on the Absorptive Transport and Extent of Metabolism of 
Loperamide in Intestinal Tissue from P-gp Competent and P-gp Deficient Mice.  
The absorptive transport of loperamide was investigated in intestinal tissue from P-gp 
competent and P-gp deficient mice to elucidate the unexpected increase in loperamide 
portal concentrations that were apparently caused by intestinal P-gp.  At 50 µM and 100 
µM concentration, the FT, which is the fraction of dose transported as unmetabolized 
loperamide (defined in Equation 4) in the absorptive direction (AP to the BL), was 
significantly greater (p < 0.01) for the intestinal tissues from P-gp competent mice (0.59 
± 0.19 and 0.41 ± 0.11 %, respectively) than for the intestinal tissue from P-gp deficient 
mice (0.23 ± 0.082 and 0.17 ± 0.096 %, respectively) (Figure 2.5A).  The passive 
permeability (Equation 2) of loperamide (20 µM) across the mouse intestinal tissue in 
which the Cyp activity was completely inhibited (Figure 2.3B) by the Cyp inhibitor 
troleandomycin (100 µM), was approximately 9-fold lower across P-gp competent 
intestinal tissue (5.5 ± 1.1 nm/sec) than that across intestinal tissue from P-gp deficient 
mice (0.61 ± 0.047 nm/sec) (p < 0.001) (Table 2.1).  This attenuation in passive 
permeability by P-gp is consistent with previous studies that have shown that loperamide 
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absorptive transport is significantly reduced by P-gp efflux in Caco-2 (Knight, 2007) and 
Madin Darby canine kidney II cells (MDCKII)  (Acharya et al., 2006) cells, which 
express P-gp but have no Cyp activity.  
 The FM, which is the fraction of loperamide dose metabolized during absorptive 
transport (Equation 5), was examined at concentrations that were either near the apparent 
Km (20 µM and 50 µM) or above the apparent Km (100 µM) for Cyp3a-mediated 
metabolism.  At concentrations of 20 µM and 50 µM, the FM was significantly lower (p 
< 0.05) for the intestinal tissue from P-gp competent mice (0.067 ± 0.057 and 0.055 ± 
0.012 %, respectively) than for the intestinal tissue from P-gp deficient mice (0.14 ± 0.02 
and 0.096 ± 0.006 %, respectively) (Figure 2.5B).  However, P-gp had no effect on the 
FM at a 100 µM concentration of loperamide (0.060 ± 0.017 % versus 0.074 ± 0.033 %, 
Figure 2.5B) .  These results are consistent with the notion that P-gp can reduce the 
metabolism of loperamide by lowering the intracellular concentration of the drug under 
linear conditions for metabolism (i.e., near or below the apparent Km), but P-gp would 
not have any effect on metabolism at doses of loperamide that generate sufficiently high 
intracellular concentrations to saturate the metabolic process. The FM in P-gp competent 
intestinal tissue was equivalent at all three concentrations of loperamide (20 µM, 50 µM, 
100 µM).  However, the FM in P-gp deficient intestinal tissue decreased across the three 
concentrations of loperamide, which demonstrates that saturation of Cyp3a-mediated 
metabolism of loperamide begins to occur at ~50 µM in the absence of P-gp efflux 
(Figure 2.5B).  This result is consistent with the previous conclusion that greater 
intracellular concentrations of loperamide are achieved in the absence of P-gp than in its 
presence for the same concentrations of loperamide.   
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P-gp Decreases Cyp3a-mediated Intestinal First-pass Metabolism and Increases 
Portal Bioavailability of Loperamide in Mouse.  The above results from the 
loperamide transport and metabolism studies in the intestinal tissue suggest that the 
higher portal loperamide concentrations in P-gp competent versus P-gp deficient mice are 
likely due to sparing of loperamide from intestinal first-pass metabolism by P-gp during 
oral absorption of the drug.  Hence, the bioavailability of loperamide in the portal 
circulation (FG) over four hours was estimated (Hoffman et al., 1995) (Equation 9)  after 
correction of the portal (Figure 2.4) and systemic (Figure 2.8) plasma concentration to 
whole blood concentrations of loperamide using the blood (10 ± 2.4 nM) to plasma (14 ± 
1.5 nM) ratio of loperamide (0.71 ± 0.06).  As anticipated from the results in Figure 2.4, 
at a dose of 0.23 mg/kg of loperamide (intestinal concentration of ~50 µM), the FG of 
loperamide was 6-fold greater (p < 0.001) in P-gp competent mice (2.6 ± 0.70 %) than in 
P-gp deficient mice (0.40 ± 0.09 %)  (Figure 2.6).  The increase in loperamide FG in P-gp 
competent mice (1.7 ± 1.0 %) compared to P-gp deficient mice (1.1 ± 0.22 %) was 
somewhat lower at a higher dose of 0.47 mg/kg (Figure 2.6).  Unlike at the lower doses, 
the absorption of loperamide into the portal circulation following the 0.95 mg/kg dose 
was equivalent in P-gp competent (16 ± 11 %) and P-gp deficient mice (17 ± 12 %).  
Interestingly, in P-gp deficient mice there was a 3-fold increase (p < 0.01) in FG when the 
dose was doubled from 0.23 mg/kg and 0.47 mg/kg, and a 10-fold increase in FG as the 
dose increased from 0.47 mg/kg to 0.95 mg/kg (Figure 2.6).  The results suggest that 
first-pass intestinal metabolism was likely saturated somewhere between 0.47 and 0.95 
mg/kg doses, with the first sign of saturable metabolism apparent between 0.23 mg/kg 
and 0.47 mg/kg.  The FG at 0.23 mg/kg and 0.47 mg/kg was approximately equal in the 
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P-gp competent mice (Figure 2.6), indicating that the saturation of intestinal metabolism 
of loperamide occurs at higher doses in the presence of P-gp efflux (Figure 2.6). 
Deconvoluting the Barrier Effects of P-gp-mediated Apical Efflux and Intestinal 
First-pass Metabolism in Loperamide Oral Absorption.  The extremely low FG in P-
gp deficient mice at 0.23mg/kg and 0.46 mg/kg doses suggests that intestinal first-pass 
metabolism is a significant barrier to oral absorption of loperamide.  Similarly, the role of 
P-gp, without an overlapping effect of the first-pass intestinal metabolism in the oral 
absorption of loperamide, was investigated by determining the FG of a 0.23 mg/kg dose 
of loperamide in mice that were treated with the mechanism-based Cyp inhibitor, ABT 
(100 mg/kg).  It has been reported that at this dose ABT completely abolished Cyp 
metabolic activity in mice (Balani et al., 2004).  The complete inhibition of Cyp 
metabolic activity in P-gp competent and deficient mouse intestine was confirmed with 
studies that showed that the metabolic conversion of the Cyp3a probe substrate, 
testosterone, during absorptive transport across mouse intestinal tissue was completely 
inhibited (no detectable metabolites) by treatment with 1mM ABT, while robust 
metabolism of testosterone was observed under normal conditions (untreated) (P-gp 
competent = 37 ± 8.4 pmol/min/cm2 and P-gp deficient = 36 ± 4.0 pmol/min/cm2) (Figure 
2.3B).   Additionally, mice that were treated with a 100 mg/kg  dose of ABT orally (2 x 
50 mg/kg oral dose in 100 µl = ~130 mM ABT), as adapted from studies by Balani et al. 
(2004) (Balani et al., 2004) and described in the methods section, had a greater than 40-
fold increase in the oral absorption of testosterone (following a 0.4 mg/kg dose) into the 
portal circulation compared to P-gp competent mice (AUC0-120 min = 2.6 ± 0.35 
µg*min/ml)  treated with saline (AUC0-120 min = 0.06 ± 0.03 µg*min/ml)  ).  When FG was 
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compared in P-gp competent (3.6 ± 3.8 %) and P-gp deficient (28 ± 20 %) mice in which 
Cyp3a was inhibited, it was clear that P-gp-mediated efflux attenuated the intestinal 
absorption of loperamide significantly but to a lesser extent (~8-fold) (p < 0.001) than 
first-pass metabolism did (~70-fold) (p < 0.001).    Interestingly, in P-gp competent mice, 
the effect of Cyp3a-mediated first-pass metabolism on loperamide FG was dampened 
(Figure 2.7).    
The In Vivo Effect of the Interplay between P-gp and Cyp3a on Oral Absorption of 
Loperamide in Mouse.  At a dose of 0.23 mg/kg, loperamide systemic plasma 
concentrations were similar in P-gp competent and P-gp deficient mice (Figure 2.8).  For 
compounds whose absorptive transport is efficiently attenuated by P-gp, as is the case for 
loperamide, the systemic concentrations in P-gp competent mice are expected to be lower 
than those in P-gp deficient mice.  Therefore, similar systemic plasma concentrations of 
loperamide in the two groups of mice suggest that P-gp’s effect on sparing loperamide 
from intestinal first-pass metabolism must compensate for the attenuation of absorption 
caused by this efflux transporter.  The systemic exposure of loperamide following a 0.47 
mg/kg oral dose of loperamide was approximately 10-fold greater (p < 0.001) in P-gp 
deficient mice versus P-gp competent mice (Figure 2.8).  At this higher dose, partial or 
complete saturation of metabolism in the intestine would reduce or eliminate P-gp’s 
ability to spare loperamide from first-pass metabolism.  Therefore, the effect of P-gp to 
inhibit absorption due to efflux into the intestinal lumen would likely dominate.  
2.E. DISCUSSION 
Given the overlap of substrate activity of many compounds for CYP3A and P-gp, 
there has been extensive investigation of the effect of the interplay of P-gp and CYP3A 
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on first-pass metabolism and oral bioavailability.  In recent years, several reports have 
been published in which a synergistic interplay between P-gp and CYP3A within the 
intestine has been invoked (Gan et al., 1993; Cummins et al., 2002a; Cummins et al., 
2002b; Cummins et al., 2003; Benet et al., 2004; Cummins et al., 2004).  According to 
this hypothesis, following oral administration of a dual P-gp/CYP3A substrate, P-gp 
efflux would increase the mean residence time (MRT) of the substrate within the 
intestine. This would result in increased metabolism of the compound by CYP3A; thus, 
P-gp and CYP3A would cooperate in decreasing bioavailability of the dual substrate.  
However, others have proposed that the interaction between P-gp and CYP3A is more 
complex and may depend on the dose/concentration of the dual substrate (Tam et al., 
2003; Knight, 2007).  Tam et al., (2003) suggested that for linear conditions of 
metabolism, P-gp efflux would substantially decrease metabolism by reducing 
intracellular drug concentration, and that the effect on the rate of metabolism would be 
greater than the effect on MRT (Tam et al., 2003).  At high doses when metabolism is 
saturated, the effect of P-gp efflux on increasing MRT would result in a net increase in 
the extent of intestinal metabolism (Tam et al., 2003; Pang et al., 2009).  However, these 
conclusions are primarily based on theoretical PK modeling and in vitro data, and there is 
still considerable debate on the exact nature of these interactions and what is the effect of 
these interactions on oral bioavailability of P-gp/CYP3A dual substrates.  
The studies presented here, for the first time, systematically evaluated the effect 
of P-gp, on (i) first-pass metabolism and (ii) oral bioavailability of a P-gp and Cyp3a dual 
substrate using a portal vein cannulated in vivo mouse model of intestinal absorption and 
a matched ex vivo model of mouse intestinal transport and metabolism. The in vivo model 
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is critical in understanding the true interactions between P-gp and Cyp3a because these 
interactions are expected to be complex due to differences in the expression of the two 
proteins along the length of the intestinal tract (Paine et al., 1997; Tamura et al., 2002; 
Tamura et al., 2003; Iida et al., 2005), intestinal transit, and alterations in drug 
concentration as it travels down the intestinal tract.  Such complexity simply could not be 
duplicated in an ex vivo or in vitro model of intestinal absorption.  
The effect of P-gp on intestinal absorption and first-pass metabolism was assessed 
by conducting parallel studies in P-gp deficient (Mdr1a1-/-) mice and P-gp competent 
mice.  It was shown that intestinal Cyp3a activity in these two groups of mice was 
equivalent as determined by quantification of Cyp3a-mediated first-pass metabolism of 
the Cyp3a probe substrate testosterone, which is not a substrate for efflux by P-gp (Chan 
et al., 2004), to 6β-hydroxytestosterone (Figure 2.3A).  This provided evidence that  
Cyp3a activity in both these groups of animals was equivalent.  It was recognized at the 
onset of these studies that to elucidate the effect of P-gp on intestinal first-pass 
metabolism of a compound, systemic sampling of the absorbed compound would not be 
useful because first-pass metabolism, and possibly first-pass biliary excretion, in the liver 
would also be reflected in any analysis of the samples obtained from the systemic 
circulation.  Therefore, an acute indwelling catheter was inserted into the portal and 
jugular veins of mice so that the overall effect of P-gp efflux on intestinal first-pass 
metabolism and FG could be determined following orally administered doses of the dual 
Cyp3a/P-gp substrates.   Further, intestinal tissues from P-gp competent and P-gp 
deficient mice were mounted between two chambers of an Ussing-type diffusion chamber 
to examine intestinal transport as well as metabolism that would occur during absorptive 
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transport of P-gp and Cyp3a dual substrates.  This approach allowed determination of the 
kinetic parameters for transport and metabolism, and in turn enabled proper design of the 
in vivo experiments (e.g. dose that would achieve intestinal concentration near Km for 
metabolism).  Further, the results obtained in the in vivo studies could be mechanistically 
evaluated in an ex vivo mouse model. 
 Loperamide, a µ-opioid receptor agonist that is used in the effective treatment of 
diarrhea, was selected to study the interplay of P-gp and Cyp3a during intestinal 
absorption.   Loperamide, which has low aqueous solubility (0.028 mg/ml) and a high 
passive permeability (Mahar Doan et al., 2002; Varma et al., 2005), is described by the 
Biopharmaceutics Classification System (BCS) (Amidon et al., 1995) as a Class II 
compound.  Loperamide has a very low oral bioavailability (Heykants et al., 1974; 
Miyazaki et al., 1979) that is attributed to both very efficient P-gp mediated efflux 
(Schinkel et al., 1996; Acharya et al., 2006) and extensive Cyp3a-mediated first-pass 
metabolism (Kim et al., 2004) in the gastrointestinal (GI) tract.  Thus, loperamide 
provided a relevant example of a compound that is subject to very high intestinal first-
pass metabolism and very efficient P-gp-mediated efflux.  In fact a quantitative measure 
of efficiency of P-gp (AQ, Equation 3) revealed that P-gp attenuated passive permeability 
of loperamide by nearly 60% in Caco-2 cells (AQ = 0.60 ± 0.09) (Knight, 2007), and 
nearly 90% in mouse intestinal tissue (AQ = 0.88 ± 0.10).  It must be pointed out that to 
determine the efficiency of P-gp in attenuating passive permeability of loperamide (Table 
2.1) in the mouse intestinal tissue, Cyp3a activity was completely inhibited by treatment 
of the tissue with the known Cyp3a inhibitor troleandomycin (100 µM) (Figure 2.3B).  
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For these studies, the oral absorption of loperamide in portal cannulated mice was 
studied over four hours, which is several times longer than the standard 30-60 minute 
small intestinal transit time that is observed in mice (Hsu, 1982; Suckow et al., 2001).  
However for these studies, it was necessary to maintain cannulated mice under anesthesia 
throughout each study using a mixture of ketamine and xylazine.  Studies by Hsu (1982), 
demonstrated that the administration of xylazine can result in up to a 2-fold delay in 
small intestinal transit time (Hsu, 1982); therefore the minimum induction dose of 
xylazine necessary to safely and humanely perform each surgical procedure was 
administered. Additionally, anesthetic maintenance doses of anesthesia consisted of 
ketamine only, which has been shown to have a little or no effect on small intestinal 
transit (Freye and Knufermann, 1994; Freye et al., 1998).  The maximum delay in small 
intestinal transit from the administration of anesthesia is typically around two hours, and 
it is therefore expected that the four-hour study period would encompass the entire transit 
time of loperamide through the mouse small intestine.   
 The in vivo studies produced a surprising result that the portal plasma 
concentrations of loperamide (0.23 mg/kg, 50 µM) were several fold higher in P-gp 
competent than in P-gp deficient mice (Figure 2.4).  Accordingly, FG of loperamide was 
as much as 6-fold higher in P-gp competent mice compared to that in P-gp deficient mice 
(Figure 2.6).  Thus, in the presence of P-gp, the intestinal absorption of intact loperamide 
across the intestinal epithelium into the portal circulation increased compared to when P-
gp was absent, despite P-gp’s high efficiency for attenuating absorptive transport of 
loperamide.  Because, the absorption of an intact compound across intestinal epithelium 
is a function of both its intestinal permeability and its intestinal first-pass metabolism, it 
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follows that the presence of P-gp must have caused an increase in loperamide FG by 
sparing its intestinal first-pass metabolism.  This conclusion is in contrast to the proposal 
by Benet et al. that P-gp efflux would enhance intestinal first-pass metabolism by 
increasing the exposure of parent drug to metabolizing enzymes as it travels down the 
length of the intestine (Cummins et al., 2002; Cummins et al., 2003; Benet et al., 2004; 
Cummins et al., 2004).  It is important to note that the conclusion derived from the in vivo 
study is consistent with the results obtained in the ex vivo study which showed that the 
metabolism of loperamide (rate and extent) was significantly lower during its absorptive 
transport across intestinal tissue from P-gp competent versus P-gp deficient mice (Figures 
2.1 and 2.4B).   
At higher doses (0.47 mg/kg, ~100 µM; 0.94 mg/kg, ~200 µM ), the portal plasma 
concentrations of loperamide in P-gp competent and P-gp deficient mice were nearly 
equal (Figure 2.4) and so were the FG of loperamide  (Figure 2.6).  This result suggested 
that P-gp spared the first-pass intestinal metabolism of loperamide, but that this effect 
was not as large at 0.94 mg/kg and 0.47 mg/kg doses as at the 0.23 mg/kg dose.  This is 
presumed to be due to saturation of the Cyp3a-mediated metabolism of loperamide and to 
a lesser degree P-gp at the two higher doses, as would be predicted from the ex vivo study 
on the rate (Figure 2.1) and extent (Figure 2.5B) of loperamide metabolism as a function 
of concentration.  A comparison of the loperamide concentration-time profiles in the 
portal circulation generated at 0.23 mg/kg, 0.47 mg/kg, and 0.94 mg/kg doses reveal that 
the concentration time profiles in P-gp competent mice were nearly identical (Figure 2.4).  
This suggests that doubling the dose from 0.23 to 0.47 mg/kg in P-gp competent mice 
doubles the first-pass metabolism rate, and as a result, the net intact loperamide that 
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reaches the portal circulation remains unchanged.  In contrast, the portal concentrations 
increased ~4-fold in P-gp deficient mice when the dose is doubled from 0.23 to 0.47 
mg/kg (Figure 2.4).  This showed that intestinal first-pass metabolism may have partially 
saturated between these two doses, thus causing disproportionate increase in portal 
concentrations as the dose doubled.  Additionally, the portal and systemic plasma 
concentrations of loperamide at the 0.23 mg/kg dose in P-gp deficient mice were similar.  
In P-gp deficient mice, the intracellular concentrations of loperamide in the intestinal 
tissue would be expected to be higher, thus saturating the intestinal first-pass metabolism 
at a lower dose/concentration.  Therefore, this similarity in portal and systemic 
concentrations is likely due to the fact that in the absence of P-gp, loperamide undergoes 
extensive intestinal first-pass metabolism, thus resulting in the intestine being the most 
significant contributor to the oral bioavailability of loperamide.  This conclusion is 
consistent with the results from the ex vivo study in which the percent of loperamide dose 
metabolized by intestinal tissue from P-gp deficient and P-gp competent mice was 
measured at different concentrations of loperamide during its absorptive transport (Figure 
2.5B).  The results showed evidence of saturation of metabolism (i.e., decrease in the 
percent of dose metabolized with an increase in dose) at a lower dose of loperamide in 
the intestinal tissue from P-gp deficient mice compared to the intestinal tissue from P-gp 
competent mice   Interestingly, at the highest dose of 0.94 mg/kg, the portal plasma 
concentrations increased ~15-fold in comparison to 0.47 mg/kg dose in both P-gp 
deficient and P-gp competent mice (Figure 2.4); which is most likely a reflection of 
saturation of intestinal first-pass metabolism in both P-gp competent and deficient mice at 
the higher dose than saturation of P-gp in the P-gp competent group.   
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The chemical inhibition of Cyp-metabolic activity achieved by treating P-gp 
competent and P-gp deficient mice with the mechanism-based Cyp inhibitor, ABT, 
provided insights into the role of P-gp in attenuating loperamide absorption solely due to 
apical efflux, without the overlapping effect of P-gp on first-pass metabolism of the dual 
substrate.  In the absence of Cyp activity, the FG (0.23 mg/kg oral dose) of loperamide 
was reduced by > 8-fold in P-gp competent mice compared to P-gp deficient mice (Figure 
2.7, bars on the right side), consistent with the fact that absorptive transport of 
loperamide is attenuated by P-gp efflux (AQ = 0.9).  Thus, the reversal of this behavior, 
i.e., much greater FG of loperamide in P-gp competent mice compared to P-gp deficient 
mice, when Cyp activity is intact (Figure 2.7, bars on the left side) must be due to sparing 
of first-pass metabolism by P-gp.  The significant role of Cyp-mediated metabolism in 
attenuating the FG is evidenced by the result that in P-gp deficient mice, the FG of 
loperamide increased by 70-fold greater when Cyp was inhibited (Figure 2.7, comparison 
of the solid bars).  These results demonstrate the individual contribution of P-gp and 
Cyp3a in limiting intestinal absorption of loperamide in lowering the oral bioavailability 
of loperamide (Heykants et al., 1974; Miyazaki et al., 1979).  Finally, the comparison of 
the loperamide FG in P-gp competent mice in which Cyp activity was functional or 
inhibited by ABT showed that they were equivalent to each other.  This result appears to 
suggest that the metabolism of loperamide by Cyp3a does not affect loperamide FG in 
animals with functional P-gp.  This apparent absence of the effect by Cyp-mediated first-
pass metabolism of loperamide on it FG can be explained in one of several ways: (i) P-gp 
attenuates the intestinal first-pass metabolism of loperamide by reducing the intracellular 
concentration, thus minimizing the effect of metabolism on FG.  (ii) P-gp-mediated efflux 
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of loperamide does not allow it (at least in part) to enter the cytosol, and thus the 
compound traverses the cell through the lipid bilayer of the cell membrane, never coming 
in contact with the metabolizing enzymes that are present in the endoplasmic reticulum 
inside the cell.  (iii) Presumably, P-gp present in the intracellular membranes (i.e., 
endoplasmic reticulum) is keeping the drug (at least in part) from coming in contact with 
the membrane bound Cyp enzymes in the endoplasmic reticulum.  Regardless of which of 
these (or yet another) mechanisms are operative, the fact remains that P-gp spares the 
drug from Cyp-mediated first-pass metabolism, and thus indirectly contributes to 
increasing its oral bioavailability.  As a consequence, one cannot assume in this case that 
inhibition of P-gp by co-administered drug would necessarily increase absorption of 
intact loperamide and increase its exposure.   
In addition to the effect of the interplay of P-gp and Cyp3a within the intestine on 
the FG of loperamide, the effect of this interaction on oral absorption of loperamide into 
the systemic circulation was studied using jugular vein cannulated mice that were 
competent or deficient of P-gp expression.  This was important to investigate as it was 
recognized that the consequence of the interactions of P-gp and Cyp3A in the intestine 
could be further modulated when the drug passes through the liver where it could be 
further metabolized by hepatic Cyp3A and/or excreted into the bile via P-gp mediated 
efflux.   At 0.23 mg/kg dose, the systemic exposure of loperamide was similar in P-gp 
competent and P-gp deficient mice (Figure 2.8); suggesting that P-gp had no overall 
effect on loperamide systemic bioavailability.  Since, FG is greater in the P-gp competent 
mice compared to P-gp deficient mice (Figures 2.5 and 2.6), this result suggests that a 
greater amount of the absorbed drug is cleared hepatically in the P-gp competent animals 
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compared to P-gp deficient animals.  The systemic exposure (0.47 mg/kg oral dose) to 
loperamide was significantly greater in P-gp deficient mice versus P-gp competent mice 
(Figure 2.8).  This dose-dependence effect of P-gp on the oral absorption of intact 
loperamide into systemic circulation is consistent with the dose-dependent interplay 
between P-gp and intestinal metabolism (Figures 2.3, 2.4 and 2.5).   
 Finally, the matched study of loperamide transport and metabolism across P-gp 
competent or deficient mouse intestinal tissue provided the percent of dose metabolized 
as an alternative to ER, as previously defined (Cummins et al., 2002; Cummins et al., 
2003; Benet et al., 2004), for quantitative assessment of intestinal metabolism during 
absorptive transport, so that the results could be easily compared to the actual FG 
observed in vivo from portal vein cannulated mice.  Knight et al. (2006) demonstrated 
that the use of ER, as proposed by Cummins and Benet (Cummins et al., 2002; Cummins 
et al., 2003; Benet et al., 2004; Cummins et al., 2004), does not accurately estimate the 
extent of metabolism in the presence or absence of P-gp, which is due to the fact that P-
gp directly influences the amount of parent drug that appears in the receiver 
compartment.  Therefore, by definition, P-gp activity affects the ER, irrespective of its 
effect on metabolism (Knight et al., 2006).  The ER, calculated according to Cummins et 
al. (Cummins et al., 2003), was comparable in both P-gp competent and P-gp deficient 
mouse intestinal tissue (0.92 ± 0.08 and 0.91 ± 0.06, respectively) at a 20 µM 
concentration of loperamide, which indicates that P-gp efflux of loperamide does not 
influence its Cyp3a-mediated metabolism. However, the same data, recalculated using 
the ER equation described by Benet et al. (Benet et al., 2004) and Cummins et al. 
(Cummins et al., 2002; Cummins et al., 2004), which includes the intracellular parent 
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concentration, showed that the ER was significantly reduced (p < 0.001) in P-gp deficient 
mouse intestinal tissue compared to intestinal tissue from P-gp competent mice (0.07 ± 
0.06 versus 0.24 ± 0.10).  This increase in the ER in the presence of P-gp would lead to 
the conclusion that P-gp efflux enhances loperamide metabolism by Cyp3a. These 
conclusions are in contrast to the findings presented here, which demonstrate that P-gp 
enhances intestinal bioavailability by sparing intestinal first-pass metabolism. These 
contradictory results on how P-gp affects Cyp3a-mediated metabolism, calculated from 
the same data, provide convincing evidence that the use of ER is erroneous, and can lead 
to inaccurate conclusions on how P-gp efflux affects metabolism. 
In conclusion, these are the first studies that clearly demonstrate that P-gp 
decreases Cyp3a-mediated intestinal first-pass metabolism of the dual P-gp/Cyp3a 
substrate loperamide during its oral absorption, and thus increases its FG.  The results also 
show that this effect of sparing first-pass metabolism of loperamide is dose-dependent, 
with the effect diminishing at doses that are likely to saturate the intestinal metabolism.   
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2.G. FIGURES 
 
Figure 2.1. The chemical structure of loperamide and its major metabolites 
(monodesmethyl-loperamide and didesmethyl-loperamide) which are produced by 
CYP3A-mediated metabolism. 
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Figure 2.2. The metabolism of loperamide in P-gp competent or P-gp deficient 
mouse intestinal tissue.  The ex vivo rate of metabolism during absorptive transport of 
loperamide across P-gp competent (solid circle) or P-gp deficient (open circle) mouse 
intestinal tissues that were mounted in side-by-side diffusion chambers.  Solid and dotted 
lines represent the fit of the Michaelis-Menten model of enzyme kinetics to the data from 
P-gp competent (solid line) (Vmax = 31 ± 2.1 pmol/min/cm2, Km = 22 ± 4.8 µM) and P-gp 
deficient (dotted line) (Vmax = 30 ± 3.2 pmol/min/cm2, Km = 4.5 ± 2.4 µM) mouse 
intestinal tissue (Knight, 2007).  Values are expressed as the mean ± SD of n=3 mice with 
four intestinal tissues per mouse.  
Statistical significance of difference groups was determined by two-way ANOVA with 
Bonferroni multiple comparison test. * = p < 0.05 or ** = p < 0.01 for the comparison 
between intestinal tissue from P-gp competent or P-gp deficient mice.  
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Figure 2.3. The oxidative metabolism of the Cyp3a-specific probe substrate, 
testosterone in mouse intestinal tissue.  (A) The rate of metabolism of testosterone, 
which is a Cyp3a-specific probe substrate and a P-gp non-substrate, measured over 90 
min during absorptive transport across intestinal tissue from P-gp competent (solid circle) 
mice, which was mounted in an Ussing-type diffusion chamber.  (B) The rate of 
metabolism of testosterone (250 µM), in P-gp competent or P-gp deficient mouse 
intestinal tissue that was untreated (P-gp competent) or co-incubated with the Cyp3a 
inhibitor troleandomycin (0.1 mM) or the Cyp inhibitor ABT (1 mM).  Values are 
expressed as the mean ± SD of n=3 mice with four intestinal tissues from each mouse.  
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Figure 2.5. The extent of metabolism and absorptive transport of loperamide ex vivo 
across mouse intestinal tissue.  (A) The percent of intact loperamide transported across 
P-gp competent (open bars) or P-gp deficient (closed bars) mouse intestinal tissue into 
the receiver compartment of an Ussing-type diffusion chamber. (B) The percent of 
loperamide dose metabolized over 90 min, during absorptive transport across P-gp 
competent (open bars) or P-gp deficient (closed bars) mouse intestinal tissue.  Values are 
expressed as the mean + SD of n=3 mice with four intestinal tissues from each mouse. 
A and B: Statistical significance determined by two-way ANOVA with Bonferroni 
multiple comparison test where,  * = p < 0.05 or ** = p < 0.01 for the comparison of P-gp 
competent and P-gp deficient mice.  B) # = p < 0.05 represents the comparison of the 20 
and 50 µM loperamide concentrations in P-gp deficient mouse intestinal tissue.    
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Figure 2.6.  The portal bioavailability of loperamide in P-gp competent or deficient 
mice.  The FG of loperamide was quantitatively derived by conversion of portal and 
systemic loperamide plasma concentration to whole blood concentrations using the mean 
ratio, 71% (range:  66% – 81%), of the whole blood to plasma concentration of 
loperamide measured at 10 nM in mouse.  The FG of loperamide in P-gp competent (open 
bars) or P-gp deficient (closed bars) mice at doses of loperamide that produce intestinal 
concentrations relative to the apparent Km (22 µM) for Cyp3a-mediated metabolism.  The 
FG for P-gp competent and P-gp deficient mice respectively was 2.6 ± 0.70 and 0.40 ± 
0.09 % for the 0.23 mg/kg dose; 1.7 ± 1.0 and 1.1 ± 0.22 % for the 0.47 mg/kg dose; and 
16 ± 11 and 17 ± 12 % for the 0.94 mg/kg dose.  Values are expressed as the mean + SD 
of n=6 mice. 
FG = portal bioavailablity.  *** = p < 0.001 for the 0.23 mg/kg loperamide dose for the 
comparison of P-gp competent and P-gp deficient mice, or ## = p < 0.01 represents the 
comparison of the 0.23 mg/kg to the 0.47 mg/kg dose of P-gp deficient mice determined 
by a two-way ANOVA with Bonferroni post hoc test. 
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Figure 2.7.  The effect of P-gp and Cyp3a in mediating the portal bioavailability of 
loperamide, in the presence or absence of oxidative metabolism.  The role of P-gp and 
intestinal first-pass metabolism by Cyp3a in mediating the oral FG of loperamide (0.23 
mg/kg) in P-gp competent (open bars) or P-gp deficient (closed bars) mice in the presence 
(+Cyp) or absence (-Cyp) of Cyp-mediated metabolism.  Cyp inhibited mice were treated 
with the Cyp inhibitor ABT.  Values are expressed as the mean ± SD of n=6 mice. 
FG = portal bioavailablity.  * = p < 0.05 for –Cyp group or *** = p < 0.001 for +Cyp 
group represents the comparison of P-gp competent and P-gp deficient mice, ### = p < 
0.001 represents the comparison ±Cyp of P-gp deficient mice.  
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Figure 2.8. The systemic absorption of loperamide in P-gp competent or P-gp 
deficient mice.  (A) The oral absorption of loperamide (0.23mg/kg and 0.47 mg/kg) 
measured in systemic plasma of P-gp competent (solid circle) or P-gp deficient (open 
circle) mice that had jugular vein cannula implanted, which was observed over 240 min.  
(B) The respective AUC0-240 min of the systemic loperamide plasma concentration profiles 
from P-gp competent (black bar) and P-gp deficient (gray bar) mice.  Values are 
expressed as the mean + SD of n=6 mice. 
Statistical significance was determined using a two-tailed t-test, with ** = p < 0.001 for 
the comparison of P-gp competent and P-gp deficient mice. 
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2.H. TABLE 
 
Table 2.1. The kinetic parameters of loperamide metabolism in intestinal tissue 
from P-gp competent or deficient mice.  
 
Vmax Km 
Papp (-Cyp) 
(20 µM) 
P-gp Competent  31 ± 2.1       22 ± 4.8 *** 0.61 ± 0.047 *** 
P-gp Deficient  30 ± 3.2  4.5 ± 2.4       5.5 ± 1.1 
 
The ex vivo metabolic Vmax and Km of loperamide metabolism and its apparent 
permeability in the presence or absence of Cyp3a-mediated metabolism across intestinal 
tissue from P-gp competent or P-gp deficient mice (Knight et al., 2006). The absorptive 
transport of loperamide across P-gp competent or P-gp deficient mouse intestinal tissue in 
the presence (Papp (-Cyp)) or absence (Papp (+Cyp)) of the Cyp3a inhibitor troleandomycin. 
Treatment of mouse intestinal tissue from P-gp competent or P-gp deficient mice with 
100 µM troleandomycin completely abolished oxidative metabolism of testosterone 
(Figure 2.3).  Values are expressed as the mean ±SD of n=3 mice with four intestinal 
tissues from each mouse. 
Vmax = pmol metabolite/min/cm2, Km = µM, and Papp = nm/sec.  *** = p < 0.001 
significance between P-gp competent and P-gp deficient mice, as determined using a 
two-tailed Wilcoxon t-test. 
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P-gp EFFLUX DOES NOT AFFECT FIRST-PASS METABOLISM OF THE 
DUAL P-gp AND Cyp3a SUBSTRATE AMPRENAVIR DURING  
INTESTINAL ABSORPTION IN MICE. 
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3.A. ABSTRACT 
Recent studies showed that P-glycoprotein (P-gp) decreases intestinal cytochrome 
P450 3A (CYP3A)-mediated metabolism of loperamide at intestinal lumen 
concentrations that are near the apparent Km for oxidative CYP3A-mediated metabolism.  
As a result, P-gp shows a surprising effect of increasing, rather than decreasing, 
loperamide absorption into the portal circulation by sparing the drug from first-pass 
metabolism.  Here, the effect of the interplay of P-gp and Cyp3A in mediating intestinal 
first-pass metabolism and absorption of another P-gp/Cyp3a dual substrate amprenavir, 
which is less efficiently effluxed by P-gp than loperamide, was investigated in vivo, using 
intact portal vein cannulated mice that were competent or deficient in P-gp expression.  
Following the oral administration of amprenavir, the bioavailability in the portal 
circulation (FG) of amprenavir in P-gp competent mice was reduced by less than 2-fold 
compared to that in P-gp deficient mice.  Mechanistic studies on the effect of P-gp efflux 
on Cyp3a-mediated metabolism of amprenavir were conducted using fresh intestinal 
tissue from P-gp deficient and P-gp competent mice (mounted in an Ussing-type 
diffusion chamber).  These studies revealed that P-gp efflux did reduce oxidative 
metabolism of amprenavir by Cyp3a, but this reduction was small and showed that 
amprenavir is subject to extensive intestinal first-pass metabolism, regardless of whether 
P-gp efflux is present or not.  Further, these studies showed that the extent of intestinal 
first-pass metabolism of amprenavir in intact P-gp competent and P-gp deficient mice 
was similar, and that the reduced FG of amprenavir is the result of substantial intestinal 
first-pass metabolism by Cyp3a.  Cumulatively, these studies highlight that the dynamic 
interaction of P-gp and CYP3A during intestinal absorption is expected to be very 
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different for dual substrates that elicit different efficiencies for intestinal P-gp-mediated 
apical (AP) efflux and/or CYP3A-mediated metabolism.  
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3.B. INTRODUCTION 
 The bioavailability of all orally administered drugs is influenced by the physical 
barrier properties of the intestine and biochemical barriers that are present within the 
enterocytes that line the intestine, such as cytochrome P450s (CYP) and P-glycoprotein 
(P-gp).  Cytochrome P450 3A (CYP3A) and P-gp, which are both highly expressed 
within the intestine, contribute to the intestinal barrier properties via different 
mechanisms; i.e., oxidative first-pass metabolism and apical (AP) efflux, respectively.  It 
has been shown that systemic bioavailability and therapeutic efficacy of many drugs are 
altered by P-gp efflux (Benet, 1996; Lown et al., 1997; Wilkinson, 2005; Giacomini et 
al., 2010; Proctor WR, 2010) or intestinal first-pass metabolism (FDA, 1997; Liu et al., 
2007; Zhou, 2008).  P-gp and CYP3A both have very broad substrate specificities; 
therefore, there are many compounds that undergo efflux by P-gp and CYP3A-mediated 
metabolism within the intestinal epithelium.  There have been several conflicting reports 
on the interaction between the P-gp and the CYP3A for dual P-gp/CYP3A substrates.  
According to one hypothesis, P-gp increases oxidative metabolism by CYP3A within the 
intestinal epithelium by increasing the exposure of drug to metabolizing enzymes within 
the intestine, thus working synergistically with CYP3A to decrease the oral 
bioavailability of dual substrates (Cummins et al., 2002; Benet et al., 2004; Cummins et 
al., 2004).  However, Pang et al. (Tam et al., 2003) and Thakker et al. (Knight et al., 
2006; Knight, 2007) propose that P-gp decreases the rate of metabolism by reducing the 
intracellular concentration of parent compound.  Studies by Knight (2007), using 
intestinal tissue from P-gp competent or P-gp deficient mice and human epithelial 
colorectal adenocarcinoma (Caco-2) cell monolayers (+/- P-gp inhibitor elacridar 
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(GF120918)) in which CYP3A4 was induced by treatment with 1α,25-dihydroxyvitamin 
D3 showed that the rate of metabolism of loperamide and terfenadine decreased during 
absorptive transport in the presence of P-gp efflux compared to when P-gp was absent 
(Knight, 2007).  In Chapter 2, studies are described that showed that P-gp spared 
intestinal first-pass oxidative metabolism of loperamide (0.23 mg/kg dose), therefore 
resulting in an increase in the portal bioavailability (FG) of loperamide by as much as 6-
fold after oral administration of the drug to P-gp competent mice.  These studies also 
showed that the effect of P-gp on loperamide intestinal first-pass metabolism and FG was 
dependent on the dose of the drug, and that the protective effect of P-gp diminished at 
higher doses.  It was reported in Chapter 2 that P-gp is highly efficient toward loperamide 
in causing its apical efflux in the mouse intestinal tissue, resulting in ~90% reduction in 
absorptive permeability of this compound (absorption quotient (AQ) (AQ = 0.9)) 
(Troutman and Thakker, 2003b).  These observations raised the question if the 
effectiveness of P-gp in sparing intestinal first-pass metabolism and increasing FG is 
dependent on the efficiency of the efflux pump in attenuating absorptive transport.  To 
address this question, studies were undertaken to assess the intestinal P-gp and Cyp3a 
interactions in mice upon oral administration of the dual substrate amprenavir, a 
compound that is considered to be a poorer substrate than loperamide for P-gp (Chapter 2 
and Polli et al., 1999). 
Amprenavir, a protease inhibitor, is an antiretroviral drug that is used for the 
treatment of human immunodeficiency virus (HIV), which functions by slowing or 
preventing HIV viral replication within the body.  Amprenavir is a high dose (1200 
mg/day) drug that has low aqueous solubility (0.4 mg/ml) and exhibits high passive 
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permeability across Caco-2 cell monolayers (Polli et al., 1999), which classifies 
amprenavir as a Class II therapeutic agent according to the Biopharmaceutical 
Classification System (BCS) (Amidon et al., 1995).  It has been documented that the oral 
bioavailability of most HIV protease inhibitors are influenced by oxidative metabolism 
mediated by CYP3A present in the intestine and liver (Kumar et al., 1996; Decker et al., 
1998; Treluyer et al., 2003; Schmitt et al., 2009).  Although the absolute oral 
bioavailability of amprenavir has not been determined, the low and highly variable oral 
absorption of amprenavir is thought to be the result of the combined effect of P-gp efflux 
and oxidative metabolism in the intestine and liver (Polli et al., 1999; Noble and Goa, 
2000).  Several studies have shown that amprenavir undergoes extensive first-pass 
metabolism by CYP3A4, and to a lesser extent by CYP2D6 and CYP2C9 in humans 
(Kumar et al., 1996; Decker et al., 1998; Treluyer et al., 2003).  Interestingly, amprenavir 
is typically co-administered with ritonavir, a potent and selective inhibitor of CYP3A, to 
reduce the effect of first-pass metabolism by CYP3A and improve systemic exposure to 
the drug.  Previous animal studies by Polli et al. (1999), using P-gp competent and P-gp 
deficient mice, showed that P-gp efflux reduced the oral absorption and distribution of 
amprenavir to the CNS and peripheral tissues (Polli et al., 1999).  Additionally, these 
studies demonstrated that the rate of amprenavir absorptive transport across Caco-2 cell 
monolayers with fully functional P-gp was ~50% lower than that observed across cells in 
which P-gp was inhibited (Polli et al., 1999).  Thus, amprenavir elicits a moderate 
efficiency for efflux by P-gp with the absorptive quotient (AQ) value, as defined by 
Troutman and Thakker (2003b), in the middle range (i.e., ~0.5 on a 0 to 1 scale).  
Therefore, amprenavir was chosen as a test compound to investigate the effect of the 
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interplay between intestinal P-gp and CYP3A on first-pass metabolism and FG of a dual 
substrate whose intestinal absorption is attenuated by P-gp with moderate efficiency. For 
these studies, the same model systems were employed that were used for a similar 
investigation on loperamide were employed.  The combined and individual effects of P-
gp and Cyp3a on intestinal first-pass metabolism and FG were assessed using portal vein 
cannulated P-gp competent and P-gp deficient mice in which intestinal Cyp3a was active 
or chemically inhibited.  In addition, Ussing-type diffusion chamber metabolism and 
transport studies were conducted using the intestinal tissue from these mice.   
The combined results from in vivo and ex vivo studies revealed that amprenavir, 
like loperamide, is subject to extensive intestinal first-pass metabolism; however, in 
contrast to the findings with loperamide in Chapter 2, P-gp has little influence on 
intestinal first-pass metabolism or FG of amprenavir.    
3.C. EXPERIMENTAL METHODS 
Materials 
Amprenavir mesylate and [3H]-amprenavir mesylate were generously provided by 
GlaxoSmithKline (Research Triangle Park, NC, USA).  Troleandomycin, sodium 
hydroxide, sodium bicarbonate, and Krebs Bicarbonate Ringer (KBR) were purchased 
from Sigma Aldrich (St. Louis, MO, USA).  1-Aminobenzotriazole (ABT) was purchased 
from Santa Cruz Biochemicals (Santa Cruz, CA, USA).  Acetonitrile, 95% ethanol 
(EtOH), methanol, ethyl acetate, and dimethyl sulfoxide (DMSO) were purchased from 
Fisher Scientific (Pittsburgh, PA, USA).  Tetramethyl ammonium perchlorate and 
trifluoroacetic acid were purchased from VWR (Radnor, PA, USA).  Ketamine HCl and 
0.9% NaCl saline were purchased from Veterinary Medical Supply (Zebulon, NC, USA), 
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and xylazine HCl was purchased from Webster Veterinary (Sterling, MA, USA).  All 
other reagents were of analytical grade or higher and triple deionized water was used in 
all experimental procedures. 
Animals 
Male CF-1 (P-gp competent) and Mdr1a1-/- (P-gp deficient) mice (Charles River 
Laboratories, Wilmington, MA, USA) were maintained (12 hr day/night schedule) under 
the care of the Division of Laboratory Animal Medicine of the University of North 
Carolina at Chapel Hill and in accordance with approved protocols from the Association 
for Assessment and Accreditation of Laboratory Animal Care (AAALAC) of the 
University of North Carolina at Chapel Hill Institutional Animal Care and Use 
Committee (IACUC).   All experiments were carried out in compliance with The Animal 
Welfare Act public laws 89-544 and 91-579.   
Studies with Mouse Intestinal Tissue 
The harvest and preparation of intestinal tissue from P-gp competent and P-gp 
deficient mice was performed as previously described in Chapter 2 (Experimental 
Methods Section).  The intestinal tissue was mounted in the diffusion chamber, and after 
a 30 min equilibration period with KBR buffer in the basolateral (BL) and AP chambers, 
the buffer in the BL chamber was replaced with 3 ml of fresh KBR buffer, and the buffer 
in the AP chamber was replaced with  [3H]-amprenavir (24 Ci/mmol), 0.5 µCi/ml , (5, 10, 
20, 50, 100, and 200 µM) in KBR buffer containing 0.5% EtOH (n=4 intestinal tissues 
for each concentration).  After incubation for 90 min at 37°C, KBR buffer from the AP 
and BL chambers was collected, and the intestinal tissues were processed to extract the 
[3H]-metabolites of amprenavir and intact [3H]-amprenavir (Figure 3.1).  The intestinal 
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tissues were washed ten times in ice-cold KBR buffer, homogenized in 200 µl of 50:50 
KBR and 2N NaOH with a sonic dismembrator for 30 sec, and vortexed with 0.5 ml ethyl 
acetate for 1 min. The homogenates were centrifuged at 9,000 g for 10 min at 4°C, and 
the supernatants collected; washing with ethyl acetate was repeated two additional times.  
The supernatants were combined and then evaporated under nitrogen gas for 10 min, and 
reconstituted in 0.5 ml of mobile phase.  All samples were stored at -20°C.    
Blood to Plasma Ratio of Amprenavir 
Blood was collected from P-gp competent mice in heparinized centrifuge tubes 
(Fisher Scientific, Pittsburgh, PA, USA) and immediately mixed to prevent clotting.  
[3H]-amprenavir, 0.1 nCi/ml was added to whole blood (1 ml) to achieve 10 nM 
concentration of amprenavir and gently shaken at 37°C for 30 min.  After shaking, blood 
samples were aliquoted into 2 groups (i) whole blood samples or (ii) plasma samples.  
Whole blood samples (n=4) were directly aliquoted into glass scintillation vials.  Plasma 
samples (n=4) were collected by centrifuging the blood samples at 9,000 g for 10 min 
4°C.  The plasma was removed and placed in glass scintillation vials. All samples were 
solubilized with 10 ml Cytoscint Scintillation Cocktail (Fisher Scientific, Pittsburgh, PA, 
USA) and measured using liquid scintillation counting (1600 TR Liquid Scintillation 
Analyzer, Packard Instrument Company, Downers Grove, IL, USA).  
In Vivo Studies 
Portal and Jugular Vein Cannulation of Mouse 
Cannulation of the portal and jugular veins of P-gp competent and P-gp deficient 
mice was performed as previously described in Chapter 2, (Experimental Methods 
Section).  Following cannulation of the mice, amprenavir at 0.42 and 2.1 mg/kg doses 
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was administered to the cannulated P-gp competent (n=6) or P-gp deficient mice (n=6) by 
oral gavage in 300 µl of 0.9% NaCl saline with 2% EtOH.  The 300 µl oral bolus of 
amprenavir, which is the maximum volume that can be orally administered to mice, was 
selected to produce approximate intestinal concentrations of 100 and 500 µM for the 0.42 
and 2.1 mg/kg doses of amprenavir, respectively.  For Cyp inhibition studies, 50 mg/kg 
ABT was dosed three hours prior to initiation of the study by oral gavage in 100 µl of 
0.9% NaCl saline to P-gp competent (n=6) or P-gp deficient (n=6) mice.  Then, an 
additional 50 mg/kg ABT was co-administered with a 0.42 mg/kg dose of amprenavir in 
300 µl of 0.9% NaCl saline with 2% EtOH by oral gavage at the start of the study.  Portal 
blood samples (20 µl) were withdrawn through the cannula at 15, 30, 60, 120, 180, and 
240 min and each sample was replaced with an equal volume of 10 U heparinized 0.9% 
NaCl saline.  The blood samples were placed in heparinized microcentrifuge tubes 
(Fisher Scientific, Pittsburgh, PA, USA), and stored on ice until the completion of the 
experiment.  Following centrifugation at 9,000 g at 4°C for 10 min, plasma was collected, 
and the samples were stored at -80°C.  
Analytical Procedures 
Amprenavir Metabolism in the Intestinal Tissue - High Performance Liquid 
Chromatography (HPLC)-Radiochemical Detection  
[3H]-Amprenavir and its main tritiated metabolites, M1, M2, M3, M4, and M5 
(M1-M5) (Figure 3.1) (Treluyer et al., 2003) were quantified in the receiver and donor 
compartments, and in the epithelial tissue.  After transport/metabolism for the indicated 
time, 1 ml sample was removed from the donor and the receiver compartment and 
extracted with 2 ml ethyl acetate.  Following agitation for 10 min, samples were 
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centrifuged at 4,500 g at 4°C for 10 minutes.  The organic phase was removed and placed 
in a microcentrifuge tube.  The aqueous phase was washed with 1 ml ethyl acetate twice, 
and the organic phases were combined. The pooled organic phase was evaporated at 
ambient temperature under nitrogen gas for 20 min, and reconstituted in 100 µl of mobile 
phase. Samples were transferred to glass micro-inserts (National Scientific, Rockwood, 
TN, USA), and placed in autosampler vials (National Scientific, Rockwood, TN, USA).    
 Samples were quantified on a HP1050 HPLC system (Santa Clara, CA, USA) 
consisting of a radial auto-sampler and a quaternary solvent delivery pump that was 
coupled to a variable wavelength UV detector (Agilent, Santa Clara, CA, USA) and a 
Perkin Elmer 500TR Series Radiomatic-Flow Analyzer (Perkin Elmer, Waltham, MA, 
USA).  Samples were injected (70 µl) at ambient temperature onto a Zorbax Eclipse XDB 
C8 column, 150x4.6 mm, with a 5 µM particle size stationary phase (Agilent, Santa 
Clara, CA, USA). The mobile phase consisted of 10 mM tetramethyl ammonium 
perchlorate and 0.1% trifluoroacetic acid-acetonitrile (65:35 v/v) (Treluyer et al., 2003).  
The isocratic elution was performed at 1 ml/min and the eluent was mixed inline in the 
radiomatic flow scintillation detector cell with Perkin Elmer Flo-Scint III scintillation 
fluid (Perkin Elmer, Waltham, MA, USA) at 2 ml/min. The HPLC system was controlled 
using Agilent Chemstation software (Santa Clara, CA, USA) and radiometric signal for 
[3H]-amprenavir and its main [3H]-metabolites (M1-M5) (Figure 3.1) was acquired using 
Flow-One Radiodetection software (Perkin Elmer, Waltham, MA, USA).   
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Oral Absorption and First-pass Metabolism of Amprenavir - Liquid Chromatography 
Mass Spectroscopy (LC-MS/MS)  
 Following the completion of each experiment, 50 µl of ice-cold acetonitrile, 
containing ritonavir (40 ng/ml) as the internal standard, was added to 10 µl of each portal 
and systemic plasma sample.  Samples were vortexed for 1 min and centrifuged at 9,000 
g at 4°C for 10 minutes.  Amprenavir was quantified using LC-MS/MS, which consisted 
of LC10-ADVP quaternary pumps (Shimadzu, Kyoto, Japan) that were fitted with a 
CTC-PAL auto-sampler (LEAP Technologies, Carrboro, NC) and a Sciex API-4000 
triple-quadropole mass spectrometer (Applied Biosystems, Foster City, CA).  An Aquasil 
C18, 50x2.1 mm, with a 5 µm particle size (Thermo-Scientific, Waltham, MA, USA) 
column was eluted at 0.75 ml/min with the mobile phases A (35 mM formic acid and 15 
mM ammonium formate in water) and B (80:20 mixture of acetonitrile and water).  The 
sample was injected in a 3 µl volume, and chromatographic separation started with 100% 
mobile phase A  (0.6 min), followed by a linear gradient from 0 to 95% mobile phase B 
(0.6-4 min), a wash at 95% B for 1 min, and a re-equilibration at 100% mobile phase A 
for 1 min.  The samples were ionized using an APCI source and the positive ions were 
monitored at the 477/266 transitions for amprenavir and 472/436 for ritonavir.  
Calibration standard curves that ranged from 0.1-500 ng/ml were linear throughout the 
range, and were analyzed at the beginning and end of the run for sample quantification.   
The data were acquired and processed using Analyst 1.4.1 (Applied Biosystems, Foster 
City, CA, USA). 
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Data Analyses 
For the metabolic studies, a Michaelis-Menten model (Equation 1) was fit to the 
data using GraphPad Prism® 4.0 (GraphPad Software Inc., La Jolla, CA, USA) and R2 > 
0.9 was used to confirm a good model fit to the data. 
            
€ 
V = V max  ×  [S]Km +  [S]         Equation 1 
V is the rate of metabolism, Vmax is the maximum rate, Km is the concentration at which 
half maximal velocity is achieved, and S is the concentration in the donor compartment. 
The apparent permeability (Papp) across the mouse intestinal tissue for transport studies 
conducted under sink condition was calculated according to Equation 2, 
 
     
         Equation 2 
where Papp represents the permeability across the intestinal tissue (apparent permeability), 
J (dQ/dt) represents the mass of drug transported, over time, A is the area of the intestinal 
tissue membrane, and CD is the initial concentration of drug in the donor compartment 
(Artursson and Karlsson, 1991). 
The efficiency of P-gp in attenuating the rate of transport during intestinal 
absorption is defined as absorptive quotient (AQ) (Equation 3).  
       Equation 3 
This parameter can be obtained by measuring (i) apparent permeability (AP to BL) across 
P-gp competent intestinal tissue (Papp,AB) and (ii) passive permeability (PPD) across 
intestinal tissue from P-gp deficient mice, and by calculating the decrease in permeability 
caused by P-gp as a fraction of PPD (Troutman and Thakker, 2003a; Troutman and 
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Thakker, 2003b).  Thus, for a compound with an AQ of 0.7, P-gp efflux attenuates PPD 
during absorptive transport by 70%. 
The fraction of dose metabolized (FM) was quantified from the amount of total 
metabolite present in the receiver and donor compartments, and in mouse intestinal tissue 
using Equation 4. 
    Equation 4 
M is the total mass of the amprenavir metabolites (M1-M5) (Figure 3.1) in the donor 
(MApical) and receiver (MBasolateral) compartments of the diffusion chamber and in the 
mouse intestinal tissue (MIntracellular) after indicated incubation time (90 min) following the 
initiation of the experiment by adding the dose (mass of amprenavir) to the donor 
compartment. The FG was quantified as previously described by Hoffman et al. (Hoffman 
et al., 1995) and briefly described below.   
          Equation 5 
MPortal is the mass of parent drug measured in the portal blood, MAbsorbed is the sum of the 
contribution of the intestine over time, and MSystemic is the mass of the parent drug 
returned to the portal vein from the systemic circulation.   
The total drug present in the portal vein that was absorbed directly from the 
intestine (Equation 6) or from the systemic circulation (Equation 7), is quantified from 
the portal blood flow (QPortal) in mouse (Davies and Morris, 1993), the area under the 
portal blood concentration-time curve to time (t) (AUCPortal (0-t hr.)), and the mean area 
under the systemic blood concentration-time curve to t (AUCSystemic (0-t hr.)) following the 
oral administration of the dose.  The blood concentration of drug in the portal and 
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systemic was calculated by conversion of portal and systemic plasma concentration 
(Uchimura et al., 2010) using the blood to plasma ratio of amprenavir. 
  Equation 6 
and 
         Equation 7 
Expressing Equation 5 relative to the mass of the orally administered dose allows direct 
quantification of the fraction of dose absorbed from the gut (FG), as expressed in 
Equation 8. 
            
  Equation 8 
Statistical Analysis 
Two-way analysis of variance (ANOVA) followed by a Bonferroni multiple 
comparisons post-test was used to assess the difference between the mouse strains or 
treatments using, GraphPad Prism® statistical software 4.0 for Mac (GraphPad Software 
Inc., La Jolla, CA, USA).  All values are expressed as the mean ± standard deviation 
(SD).  The criterion for a significant difference in values was considered as p < 0.05. 
3.D. RESULTS 
Effect of P-gp Efflux on the Passive Permeability of Amprenavir in the Absorptive 
Direction Across Intestinal Tissue from P-gp competent and P-gp Deficient Mice.  
The efficiency of amprenavir (10 µM) AP efflux across the intestinal tissue from P-gp 
competent mice was determined by estimating the AQ, which quantifies the extent by 
which P-gp reduces the passive permeability in the absorptive direction (Equation 3).  
The amprenavir AQ was determined in the presence of the Cyp3a inhibitor 
troleandomycin (100 µM), so that amprenavir can traverse the intestinal tissue intact and 
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true permeability values of the compound can be obtained.  The passive permeability of 
amprenavir, i.e., the permeability across intestinal tissue from P-gp deficient mice treated 
with 100 µM troleandomycin, was 13.8 ± 6.6 nm/sec.  The Papp of amprenavir across 
intestinal tissue from P-gp competent mice (4.3 ± 1.9 nm/sec) represented ~70% 
reduction of its passive permeability (AQ = 0.69 ± 0.14) (p < 0.001) due to P-gp efflux 
(Table 3.1). 
Metabolism of Amprenavir During Absorptive Transport Across Intestinal Tissue 
from P-gp Competent and P-gp Deficient Mice.  Figure 3.2 depicts the rates of 
amprenavir metabolism during its absorptive (AP to BL) transport across intestinal tissue 
from P-gp competent and P-gp deficient mice plotted against the initial donor 
compartment concentrations.  P-gp reduced the rates of amprenavir metabolism at most 
of the concentrations by a small but significant extent (p < 0.001), as evidenced by the 
slight leftward shift of the rate of metabolism for the intestinal tissue without P-gp versus 
with P-gp.  The greatest difference in metabolism (~14%) occurred at 50 µM (p < 0.001) 
and 100 µM  (p < 0.01) amprenavir concentrations.  The leftward shift of the metabolic 
rate versus concentration profile translated into a higher (p < 0.001) apparent Km for 
Cyp3a-mediated amprenavir metabolism in the intestinal tissue from P-gp competent 
mice (103 ± 20.1 µM) compared to P-gp deficient mice (75.8 ± 13.0 µM) (Table 3.1).  
Additionally, there was no difference in the Vmax for metabolism in intestinal tissue from 
P-gp competent or deficient mice (446 ± 51 and 442 ± 52 pmol/min/cm2, respectively) 
(Table 3.1).    
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Effect of P-gp Efflux on the Extent of Amprenavir Metabolism During Absorptive 
Transport Across the Mouse Intestinal Tissue.  The fraction of amprenavir dose 
metabolized during absorptive transport across the intestinal tissue (FM, Equation 4) was 
determined at concentrations that were in the linear range of metabolism (i.e., below or 
near the apparent Km), and at a concentration that would lead to at least partial saturation 
of the metabolism (200 µM).  At 50 µM amprenavir, the FM was reduced by 
approximately 2-fold (p < 0.05) in P-gp competent mice (2.8 ± 0.95 %) in comparison 
with intestinal tissue from P-gp deficient mice (4.9 ± 0.28 %) (Figure 3.3).  The FM 
values obtained with the two tissues were equivalent when the amprenavir concentration 
was increased to 100 µM (2.8 ± 0.17 % versus 3.3 ± 0.25 %) or 200 µM (2.0 ± 0.19 % 
versus 2.2 ± 0.23 %) (Figure 3.3).  For the P-gp deficient intestinal tissue, there was a 
statistically significant reduction in FM as the amprenavir concentration increased from 
50 µM and 100 µM (p < 0.05) and from 100 µM to 200 µM (p < 0.001) (Figure 3.3).  In 
contrast, in intestinal tissue from P-gp competent mice no difference in the FM between 
the 50 µM and 100 µM concentrations of amprenavir was observed.  However, a 
significant reduction (p < 0.001) was observed between the 100 µM and 200 µM in the P-
gp competent intestinal tissue (Figure 3.3).   
Interaction Between P-gp Efflux and Cyp3a-mediated Metabolism of Amprenavir 
During Intestinal Absorption of Amprenavir in Intact Cannulated Mice.  The plasma 
concentration versus time profiles for amprenavir in the portal (Figure 3.4) and systemic 
(Figure 3.5) circulation were generated using the serial plasma samples that were 
withdrawn from the implanted portal and jugular vein cannula, respectively, over four 
hours.  A 0.42 mg/kg dose of amprenavir, administered via oral gavage in 0.3 ml volume, 
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which would generate an intestinal concentration of ~100 µM, produced very similar 
plasma concentration time profile in the portal circulation of P-gp competent and P-gp 
deficient mice (Figure 3.4A).  The intestinal absorption of amprenavir into the portal 
circulation of P-gp deficient mice (AUC0-240 min = 3700 ± 2100 ng*min/ml) over four 
hours was only slightly greater (p > 0.05) than that observed in P-gp competent mice 
(AUC0-240 min = 2800 ± 500 ng*min/ml) (Figure 3.4A and 3.4C).  At a higher dose of 2.1 
mg/kg, which would produce an intestinal amprenavir concentration of ~500 µM and is 
expected to saturate intestinal Cyp3a (Figure 3.2), the intestinal absorption of amprenavir 
into the portal circulation was equivalent between P-gp competent (AUC0-240 min = 29000 
± 30000 ng*min/ml) and P-gp deficient (AUC0-240 min = 25000 ± 18000 ng*min/ml) mice 
(Figure 3.4B and 3.4D).  Comparisons of the AUC0-240 min between the two doses showed 
a ~10-fold increase in the intestinal absorption of amprenavir into the portal circulation in 
both strains of mice. 
The absorption of amprenavir into the systemic circulation was equivalent in P-gp 
competent and P-gp deficient mice following either a 0.42 mg/kg dose (AUC0-240 min = 
1100 ± 680 ng*min/ml and 890 ± 300 ng*min/ml, respectively) or a 2.1 mg/kg dose 
(AUC0-240 min = 1900 ± 540 ng*min/ml and 2400 ± 1000 ng*min/ml, respectively) of 
amprenavir (Figure 3.5).  Additionally, there was a ~3-fold and ~10-fold decrease in the 
AUCs of amprenavir between the portal (Figure 3.4) and systemic (Figure 3.5) 
circulation for the 0.42 and 2.1 mg/kg dose, respectively, which is indicative of hepatic 
clearance that is presumably by oxidative metabolism and/or P-gp-mediated biliary 
excretion in the liver.  There was a less than proportional 2- to 3-fold increase in the 
systemic concentrations between the 0.42 and 2.1 mg/kg doses in P-gp competent and P-
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gp deficient mice (Figure 3.5), which may be related to issues with solubility rather than 
differences in the absorption rate or first-pass metabolism at this dose. 
The Effect of P-gp Efflux in Altering Cyp3a-mediated Metabolism and Portal 
Bioavailability of Amprenavir in Mouse.  The role of P-gp efflux in altering Cyp3a-
mediated metabolism during intestinal absorption, and therefore causing subsequent 
changes in the FG of amprenavir (Equation 8), was investigated over four hours (which is 
expected to encompass the entire transit time of amprenavir through the mouse small 
intestine, as discussed in Chapter 2) (Hsu, 1982; Suckow et al., 2001).  At a 0.42 mg/kg 
oral dose of amprenavir, the FG was reduced by ~2-fold (p < 0.05) in P-gp competent 
mice (1.5 ± 0.48 %) compared to that in P-gp deficient mice (2.9 ± 0.87 %) (Figure 3.6).  
The FG of amprenavir following a 2.1 mg/kg dose was slightly reduced in P-gp competent 
mice (3.4 ± 1.8 %) compared to P-gp deficient mice (4.5 ± 1.6 %) (Figure 3.6).  Further 
examination of the amprenavir FG in P-gp competent mice between the doses revealed 
that there was an increase (~2-fold, p < 0.01) in the FG between the 0.42 mg/kg and 2.1 
mg/kg oral doses of amprenavir (Figure 3.6). Although more variable, there was no 
difference observed in the FG of amprenavir between these two doses in P-gp deficient 
mice (Figure 3.6).   
The Role of P-gp and Cyp3a in Mediating the Portal Bioavailability of Amprenavir 
in Mouse.   The role of P-gp in modulating the FG of amprenavir (0.42 mg/kg oral dose) 
was investigated in the absence of first-pass metabolism by inactivating Cyp3a with ABT 
as previously described in Chapter 2.  In the absence of Cyp3a activity, the FG of 
amprenavir was 2-fold greater (p < 0.05) in mice that lacked P-gp (28 ± 3.7 %) than in 
mice that had functional P-gp (13 ± 7.3 %) (Figure 3.7).  These results suggest that P-gp 
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has a modest effect in attenuating the intestinal absorption of amprenavir.  In contrast, the 
FG of amprenavir in P-gp deficient mice was reduced by approximately 10-fold (p < 
0.001) in mice that had functional Cyp metabolic activity compared to mice in which Cyp 
activity was inhibited by ABT (Figure 3.7), providing unequivocal evidence that 
intestinal first-pass metabolism plays a much bigger role than P-gp efflux in attenuating 
the oral bioavailability of amprenavir.  Notably, the FG of amprenavir was attenuated by 
>8-fold by Cyp-mediated metabolism even in P-gp competent mice (p < 0.001) (Figure 
3.7).  Taken together, these results suggest that when both P-gp efflux and Cyp-mediated 
first-pass metabolism are functional, first-pass metabolism of amprenavir by Cyp 
enzymes in the intestine, and not P-gp efflux, play a dominant role in attenuating the FG 
of this drug. 
3.E. DISCUSSION 
P-gp and CYP3A both contribute to the prevention of the intestinal absorption of 
therapeutic agents and xenobiotics that may cause harm to the body.  Due to their co-
localization, similarities in functioning as a protective barrier within the intestine, and the 
extensive and overlapping substrate specificities between CYP3A and P-gp, there is a 
substantial potential for the interaction of P-gp and CYP3A within the intestine to 
influence oral bioavailability of drugs that are substrates for both proteins.  The mouse 
provides a physiologically relevant model to study the effect of efflux by P-gp on 
intestinal metabolism, due to the endogenous expression of relevant transporters and 
metabolizing enzymes.  The availability of the P-gp deficient mouse, which lacks 
functional expression of P-gp, enables for the evaluation of the interaction of P-gp and 
Cyp3a in a model without the requirement for the use of P-gp chemical inhibitors.  
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Therefore, the effect of P-gp efflux on Cyp3a-mediated intestinal first-pass metabolism 
and FG of compounds that are substrates for both P-gp and Cyp3a can be directly 
determined from the comparison of results obtained in P-gp competent mice to those in 
P-gp deficient mice.  The use of matched ex vivo and in vivo models of intestinal 
absorption in the same species provided an advantage in that the results can be directly 
related to each other.  Therefore, studies were designed to determine how the interactions 
of these two proteins alter overall intestinal first-pass metabolism and oral absorption of 
intact drug in vivo as demonstrated in studies with loperamide described in Chapter 2.  
These studies showed that at sub-saturating conditions of Cyp3a, the FG of the dual 
Cyp3a and P-gp substrate, loperamide, was greater in P-gp competent mice than in P-gp 
deficient mice.   This improvement in the intestinal absorption of loperamide in the 
presence of P-gp was due to P-gp sparing loperamide from intestinal first-pass 
metabolism.  These are the first findings that, contrary to the accepted role of P-gp in 
attenuating the intestinal absorption of P-gp substrates, efflux of a compound by P-gp can 
result in improvement of intestinal absorption compared to when P-gp is absent.  The 
question arises whether other P-gp/CYP3A dual substrates would be affected in a similar 
way during their intestinal absorption.  One would expect that the interaction of P-gp and 
CYP3A during intestinal absorption would be different for other dual substrates that have 
physiochemical and biochemical properties that are different to that of loperamide; for 
example, higher passive permeability or varying efficiencies for efflux by P-gp and/or 
metabolism.  To address this question, a second dual P-gp and Cyp3a substrate, 
amprenavir, was investigated using experimental models and designs that were very 
similar to that used for the investigation of loperamide (Chapter 1).   
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 The efficiency of P-gp in attenuating absorptive transport across mouse intestinal 
tissue was examined by quantifying the extent to which P-gp efflux attenuates the passive 
permeability of amprenavir.  The P-gp efficiency toward amprenavir was quantitatively 
assessed by comparing absorptive apparent permeability of the drug across intestinal 
tissue from P-gp competent and P-gp deficient mice in which Cyp3a was chemically 
inactivated to avoid metabolic degradation of amprenavir during these measurements.   
The P-gp efficiency, expressed as AQ (Chapter 2, Troutman and Thakker, 2003b) toward 
amprenavir was estimated to be 0.69, which indicates that P-gp attenuated the absorptive 
transport of amprenavir across intestinal tissue by ~70%.  This estimate of AQ for 
amprenavir was higher than that estimated previously (~0.50) in the Caco-2 cell model 
(Polli et al., 1999); however, the data established that absorptive transport of amprenavir 
is attenuated by P-gp with much lower efficiency than that of loperamide (AQ = 0.89).   
 Ex vivo mouse intestinal tissue studies showed that unlike in the case of loperamide, the 
rate (Figure 3.2) and extent (Figure 3.3) of amprenavir oxidative metabolism is only 
modestly reduced by P-gp over a wide range of concentrations during absorptive 
transport across mouse intestinal tissue (Figure 3.2).  The maximum effect of P-gp efflux 
on the rate of amprenavir metabolism was observed at concentrations that were near the 
apparent Km (103 µM) for oxidative metabolism, and yielded a ~14% reduction in the 
rate of metabolism.  As concentrations increased, the effect of P-gp in reducing 
metabolism of amprenavir was attenuated, and the effect was nearly absent at 
concentrations that would produce saturation of Cyp3a.  However, a closer examination 
of the data at the higher doses studied (100 and 200 µM) show that Cyp3a may have been 
saturated prior to the 100 µM concentration of amprenavir.  Therefore, the estimate of the 
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Km (103 µM) for Cyp3a-mediated metabolism may have been overestimated using the 
concentrations studied.  A much lower effect of P-gp on the intestinal oxidative 
metabolism (rate and extent) of amprenavir compared to loperamide during absorptive 
transport may be due to higher rates of amprenavir metabolism (Figures 2.1 and 3.2) or 
lower amprenavir AQ (0.69 for amprenavir versus 0.88 for loperamide) in the mouse 
intestinal tissue, or both.    
The target dose (0.42 mg/kg) of amprenavir for in vivo studies using portal vein 
cannulated mice was selected to achieve intestinal concentrations of ~100 µM, which is 
the approximate value of Km for amprenavir metabolism by intestinal enzymes based on 
the studies in mouse intestinal tissue, as represented in Figure 3.2 and Figure 3.3.  A dose 
of 2.1 mg/kg was selected to achieve intestinal concentration of amprenavir (~500 µM) at 
5-fold the apparent Km value, so that intestinal metabolism would be nearly saturated.    
 The in vivo studies in portal vein cannulated mice showed that the portal 
concentrations of amprenavir were comparable in the P-gp competent and P-gp deficient 
mice after a sub-saturating (0.42 mg/kg) or saturating (2.1 mg/kg) oral dose of 
amprenavir.  These results are consistent with those on the metabolism of amprenavir 
during absorptive transport across intestinal tissue from P-gp competent and P-gp 
deficient mice (Figures 3.2 and 3.3).  Thus, unlike in the case of loperamide, P-gp does 
not seem to spare the first-pass metabolism of amprenavir sufficiently to cause an 
increase in FG (Figure 2.5 versus Figure 3.6).  Amprenavir portal concentrations increased 
more than 5-fold in both P-gp competent and P-gp deficient mice when the oral dose 
increased from 0.42 mg/kg to 2.1 mg/kg, suggesting saturation of the intestinal first-pass 
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metabolism rather than saturation of P-gp.  This was also reflected in an increase in FG in 
both strains of mice at the higher dose (Figure 3.6).   
While these results clearly show that P-gp does not spare amprenavir metabolism 
sufficiently to overcome attenuation by P-gp-mediated efflux and increase FG, the 
question remains whether P-gp efflux is not efficient enough (lower AQ than that of 
loperamide) or amprenavir first-pass metabolism is too efficient to be attenuated by P-gp.  
To answer this question, the intestinal absorption of amprenavir was examined without 
the influence of intestinal first-pass metabolism by chemically inhibiting Cyp activity 
with the mechanism-based inhibitor of CYP, ABT (Chapter 2) (Balani et al., 2002; Balani 
et al., 2004).  In the absence or presence of Cyp activity, the FG of amprenavir (0.42 
mg/kg) was ~2-fold lower in P-gp deficient mice compared to that in P-gp competent 
mice (Figure 3.7).  Further, the FG increased by over 10-fold upon inhibition of Cyp 
activity in both strains of mice (Figure 3.7).  These results provide a clear indication that 
intestinal first-pass metabolism is contributing predominantly to attenuating oral 
absorption of intact amprenavir.  Thus, it is reasonable to conclude that the intestinal 
first-pass metabolism is too efficient for P-gp-mediated efflux to spare amprenavir from 
being consumed during its passage across the intestinal epithelium. These results raise an 
interesting possibility that as the expression of Cyp3a decreases and that of P-gp 
increases toward the distal regions of the intestine, P-gp efflux may become more 
effective in sparing the intestinal first-pass metabolism of compounds like amprenavir, 
and contribute to improving their oral bioavailability.  However, it is also possible that 
increased P-gp expression in the distal region may make it a more effective barrier to 
intestinal absorption, and the advantage achieved through increased sparing of the first-
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pass metabolism may be negated.  Clearly, further experimental studies as well as 
modeling of the behavior of compounds toward various permutations of relative 
expressions of Cyp and P-gp and relative efficiencies of these barriers will bring new 
insights into how the enzymatic and efflux barriers work in concert or in conflict with 
each other.   
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3.G. FIGURES 
 
 
 
Figure 3.1.  The chemical structure of amprenavir and its main metabolites (M1-
M5) formed by CYP-mediated metabolism in humans. 
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Figure 3.2.  The metabolism of amprenavir ex vivo in intestinal tissue from P-gp 
competent or deficient mice.  The rate of metabolism of [3H]-amprenavir during 
absorptive transport across intestinal tissue from P-gp competent (solid circle) or P-gp 
deficient (open circle) mice mounted in an Ussing-type diffusion chamber.  The solid and 
dotted lines represent the fit of a Michaelis-Menten model of enzyme kinetics to the rate 
of total metabolite formation versus concentration data profiles.  Each point represents 
the mean ±SD from 3 mice, with four intestinal tissues from each mouse.   Statistical 
significance was assessed using a two-way ANOVA with Bonferroni multiple 
comparison test. 
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Figure 3.3. The extent of metabolism of amprenavir ex vivo in intestinal tissue from 
P-gp competent or P-gp deficient mouse.  The percent of [3H]-amprenavir dose 
metabolized during absorptive transport across intestinal tissue from P-gp competent 
(open bars) or P-gp deficient (closed bars) mice mounted in an Ussing-type diffusion 
chamber over 90 minutes. Values are expressed as the mean +SD for n=3 mice with four 
intestinal tissues from each mouse.   
Statistical significance determined by two-way ANOVA with Bonferroni multiple 
comparisons where * = p < 0.05 for the comparison of P-gp competent and P-gp deficient 
mice, # = p < 0.05 represents the comparison between the 50 and 100 µM concentrations 
of amprenavir in P-gp deficient mouse intestinal tissue and  ### = p < 0.001 represents 
the comparison between the 100 and 200 µM concentrations of amprenavir in P-gp 
competent and P-gp deficient mouse intestinal tissue.   
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Figure 3.4.  The oral absorption of amprenavir measured in portal vein cannulated 
mice.  The plasma concentration time profiles for amprenavir in the portal circulation 
were generated using the serial blood samples that were withdrawn from a portal vein 
cannula that was implanted in P-gp competent (solid circle) or P-gp deficient (open 
circle) mice, over four hours.  Plots in the upper panel show the log portal vein 
amprenavir concentration as a function of time after (A) 0.42 mg/kg and (B) 2.1 mg/kg 
dose, which produce intestinal concentrations of ~100 and 500 µM, respectively.  Plots in 
the lower panel show the AUC0-240 min of the portal concentration versus time profiles 
from P-gp competent and P-gp deficient mice for (C) 0.42 mg/kg and (D) 2.1 mg/kg oral 
doses of amprenavir.  Values are expressed as the mean +SD of n=6 mice.  Analysis of 
significance between the AUC0-240 min of P-gp competent and P-gp deficient mice was 
performed using a two-tailed paired t-test. 
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Figure 3.5. The oral absorption of amprenavir into the systemic circulation of P-gp 
competent or deficient mice.  Plots in the upper panel show the log systemic amprenavir 
plasma concentrations as a function of time in P-gp competent (solid circle) or P-gp 
deficient (open circle) mice.  Systemic blood samples were obtained through a jugular 
vein cannula for 4 hr after a oral dose of (A) 0.42 mg/kg, or (B) 2.1 mg/kg dose of 
amprenavir, which produced intestinal concentrations of 100 µM and 500 µM, 
respectively.  Plots in the lower panel show the AUC0-240 min for the (C) 0.42 mg/kg or (D) 
2.1 mg/kg dose of amprenavir measured in the systemic circulation of P-gp competent 
and P-gp deficient mice.  Values are expressed as the mean +SD of n=6 mice.  Statistical 
analysis of differences in AUC0-240 min of P-gp competent and P-gp deficient was 
performed using a two-tailed paired t-test. 
 
 
 
 128 
 
Figure 3.6. The dose-dependent affect of the interaction of P-gp and Cyp3a on the 
portal bioavailability of amprenavir in P-gp competent or deficient mice. The FG of 
amprenavir in P-gp competent (open bars) or P-gp deficient (closed bars) mice at 0.42 
and 2.1 mg/kg doses of amprenavir.  A 300 µl oral bolus of amprenavir, which is the 
maximum volume that can be orally administered to mice, was selected to produce 
approximate intestinal concentration of 100 and 500 µM for the of 0.42 and 2.1 mg/kg 
doses of amprenavir, respectively.  The FG was calculated (Equation 5-7) from the portal 
vein whole blood concentration versus time data as described in the Experimental Section 
(Hoffman et al., 1995).  The blood concentrations were derived from the measured 
plasma concentrations using Cblood/Cplasma (10 ± 0.29 nM/19 ± 1.1 nM) ratio of 0.51 ± 
0.04 that was experimentally determined at 10 nM blood concentration of amprenavir. 
Values are expressed as the mean +SD of n=6 mice. 
FG = portal bioavailability.  * = p < 0.05 represent the comparison of P-gp competent and 
P-gp deficient mice and # = p < 0.05 represent the comparison of the 0.42 and 2.1 mg/kg 
dose of amprenavir in P-gp competent mice as determined using a two-way ANOVA 
with Bonferroni multiple post hoc test. 
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Figure 3.7. The relative roles of P-gp and Cyp-mediated metabolism in determining 
the portal bioavailability of amprenavir in vivo in mice.  The contribution of intestinal 
first-pass metabolism and efflux by P-gp in mediating the FG of amprenavir was 
compared for P-gp competent (open bar) and P-gp deficient (closed bar) mice in which 
Cyp activity was intact (untreated) (left, +Cyp) or inhibited (ABT treated) (right, -Cyp) 
following a 0.42 mg/kg dose of amprenavir.  Values are expressed as the mean + SD of 
n=6 mice. 
FG = portal bioavailability. Statistical significance was assessed by performing a two-way 
ANOVA with Bonferroni post hoc test, where * = p < 0.05 for the comparison of P-gp 
competent and P-gp deficient mice, and ### = p < 0.001 represents the comparison 
between ±Cyp of P-gp competent or P-gp deficient mice.   
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3.H. TABLE 
Table 3.1. The absorptive permeability and kinetic parameters of metabolism for 
amprenavir in intestinal tissue from P-gp competent or deficient mice.  
 
Vmax Km Papp (-Cyp) (10 µM) 
  P-gp Competent 446 ± 51      103 ± 20.1**      4.3 ± 1.9*** 
  P-gp Deficient 442 ± 52   75.8 ± 13.0 13.8 ± 6.6 
The apparent absorptive permeability (Papp) of [3H]-amprenavir (with Cyp3a inhibited) 
and the kinetic parameters of amprenavir metabolism, during its absorptive transport, 
across intestinal tissue from P-gp competent or P-gp deficient mouse that was mounted in 
an Ussing-type diffusion chamber. The absorptive permeability of amprenavir across P-
gp competent or P-gp deficient mouse intestinal tissue was measured after inactivation of 
Cyp3a by pre-treatment of the intestinal tissue with Cyp3a-specific inhibitor 
troleandomycin (Papp -Cyp). The apparent permeability value across intestinal tissue from 
P-gp deficient mice represents the passive permeability of amprenavir.  Treatment of 
mouse intestinal tissue from P-gp competent or P-gp deficient mice with 100 µM 
troleandomycin completely abolished oxidative metabolism of testosterone (Figure 2.3, 
Chapter 2).  Values are expressed as the mean ±SD of n=3 mice with four intestinal 
tissues from each mouse. 
Vmax = pmol metabolite/min/cm2, Km = µM, and Papp = nm/sec. ** = p < 0.01 and *** = p 
< 0.001 for the comparison of P-gp competent and P-gp deficient mice. The significance 
of between P-gp competent and P-gp deficient groups was determined using a Wilcoxon 
t-test.   
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FROM MICE TO MAN: 
IS THE ORAL BIOAVAILABILITY OF DUAL P-GLYCOPROTEIN (P-gp) AND 
CYTOCHROME P 450A (CYP3A) SUBSTRATES GREATER IN THE 
PRESENCE OF P-gp EFFLUX IN HUMANS? 
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4.A. ABSTRACT 
Loperamide, a µ-opioid receptor agonist that is used as an effective treatment for 
diarrhea, is subject to extensive CYP3A-mediated first-pass metabolism and P-gp-
mediated efflux in the gastrointestinal (GI) tract, and has practically no oral 
bioavailability. Previous studies have shown that the portal bioavailability (FG) of 
loperamide is enhanced in the presence of P-gp, at doses that are sub-saturating for 
CYP3A, by partially protecting it from CYP3A-mediated intestinal first-pass metabolism.  
The goal of this study was to (i) predict how P-gp efflux affects loperamide FG in humans 
by studying the interplay between P-gp efflux and metabolism ex vivo in fresh intestinal 
epithelial tissue from humans (+/- P-gp inhibitor, GF120918) and (ii) correlate the effect 
of P-gp/Cyp3a interactions on loperamide FG from ex vivo studies using mouse intestinal 
tissues from P-gp competent and P-gp deficient mice to in vivo findings in mice (Chapter 
2). Jejunal intestinal segments were collected from human subjects undergoing bariatric 
gastric bypass surgery. The metabolism (during absorptive transport) of loperamide 
across human epithelium was monitored over a 90-minute period.  Findings from these ex 
vivo studies demonstrate that P-gp efflux decreases CYP3A-mediated oxidative 
metabolism of loperamide, in human intestinal epithelia. These human ex vivo findings 
were compared to results from similar mouse ex vivo and in vivo studies.  The ex vivo to 
in vivo relationship was used to predict the effect of the interplay of P-gp and CYP3A on 
the intestinal absorption of loperamide in humans by semi-physiologically based 
pharmacokintic (PBPK) modeling using GastroPlus®. The modeling suggests that, for 
loperamide doses that produce intestinal concentrations that are within the linear range of 
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metabolism, the FG in humans would be greater in the presence of P-gp efflux, than in its 
absence.  
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4.B. INTRODUCTION 
 Prior to an orally administered drug eliciting its effect, the drug must first be 
absorbed across the intestinal epithelium.  However, the intestine also functions in 
protecting the body from potentially harmful xenobiotics that often include drugs.  The 
intestinal epithelium that lines the intestinal cavity provides a physical barrier as well as a 
biochemical barrier to prevent compounds from entering the systemic circulation.  The 
intestinal biochemical barrier comprises apical efflux transporters, such as P-glycoprotein 
(P-gp) and metabolic enzymes, such as Cytochrome P450 3A (CYP3A) (Chapters 1-3). It 
is recognized that P-gp and CYP3A not only affect intestinal absorption individually, but 
they also act additively or synergistically (Chapters 1-3).  The impact of the intestinal 
epithelium in attenuating oral bioavailability in humans by P-gp-mediated AP efflux 
(Augustijns et al., 1993; Schinkel et al., 1995; FDA, 2006; Giacomini et al., 2010) or 
intestinal first-pass metabolism (Benet, 1996; Paine et al., 1996; FDA, 1997) is well 
documented.  Studying the role of intestinal drug efflux and metabolism, or interactions 
of these two barrier mechanisms during the absorption of compounds in vivo in humans is 
challenging due to the practicality and costs associated with performing quantitative 
studies in humans, and the complexity of determining the individual contributions of the 
intestine or liver toward first-pass metabolism and/or oral bioavailability.   
The development of physiologically relevant models of intestinal absorption using 
in vitro cell based systems or ex vivo models of intestinal epithelium from humans or 
animals is important in furthering our understanding of how the intestine mediates or 
attenuates the absorption of drugs.  However, it is essential that tissue- or cell-based 
models of the intestine maintain their natural structural barrier properties, as well as the 
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functional expression of the transporters and metabolizing enzymes that are present in the 
intestine.  One of the most commonly used models to assess human intestinal absorption 
of new drug candidates is human epithelial colorectal adenocarcinoma (Caco-2) cells 
(Artursson and Borchardt, 1997), which are widely used for assessing intestinal 
absorption or possible drug-drug interactions mediated by P-gp and other transporters 
(Proctor, 2010).  Although Caco-2 cells express many of the uptake and efflux 
transporters that are present in the human intestine, a major drawback of Caco-2 cells is 
that they exhibit very low or no endogenous expression of metabolizing enzymes 
(Prueksaritanont et al., 1996), such as intestinal CYP3A. Therefore, methods have been 
developed to artificially introduce the expression of metabolizing enzymes in the Caco-2 
cell line.  This was achieved by transfecting Caco-2 cells with a functionally expressing 
CYP3A4 gene (Cummins et al., 2001), or treating these cells with 1α,25-
dihydroxyvitamin-D3 during cell differentiation, so as to induce CYP3A expression 
(Schmiedlin-Ren et al., 1997).  However, the levels of CYP3A using this method was 
considerably lower than that observed in human small intestinal epithelium (Paine et al., 
2002).  The incorporation of functional CYP3A into Caco-2 cells enables the study of the 
effect of CYP3A alone or in conjunction with P-gp efflux in attenuating intestinal 
absorption of drug candidates.    
The investigation of the interplay of P-gp and CYP3A has primarily been 
conducted using static models of the intestine, such as the Caco-2 cells.  These studies 
have examined the effect of P-gp efflux on the metabolism of dual substrates, such as in 
Caco-2 cells that metabolized cyclosporine (Gan et al., 1996), K77 using CYP3A4 
transfected Caco-2 cells (Cummins et al., 2004), or saquiniavir (Mouly et al., 2004), 
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terfenadine, and loperamide (Knight, 2007) using 1α,25-dihydroxyvitamin-D3 treated 
Caco-2 cells.  However, the role of P-gp in altering CYP3A-mediated metabolism or oral 
bioavailability of shared substrates has not been clearly elucidated.  The use of the 
intestinal epithelia from humans or preclinical animals for Ussing-type diffusion chamber 
studies enables the investigation of the intestinal absorption of drugs in physiologically 
relevant models that express metabolizing enzymes and uptake/efflux transporters.  
Additionally, other studies have shown that in vivo human intestinal absorption of many 
drugs can be successfully predicted from ex vivo studies using the intestinal epithelia 
from humans or preclinical animal species (Lennernas et al., 1992; Lennernas, 2007).   
One of the challenges common to all in vitro or ex vivo models is the difficulty in 
extrapolating the results from static and relatively simple models to a dynamic and 
complex in vivo environment.  Therefore, the approach described here was to implement 
an ex vivo model of intestinal epithelium that closely relates to a corresponding in vivo 
model in terms of species and experimental modality.  This was achieved by using 
intestinal tissues from P-gp competent and P-gp deficient mice to elucidate the effect of 
P-gp efflux on Cyp3a-mediated first-pass metabolism and oral bioavailability.  These 
tissues were mounted in an Ussing-type diffusion chamber to perform transport and 
metabolism studies.  To correlate the results from the ex vivo studies to in vivo findings, 
P-gp competent and P-gp deficient mice were cannulated in their portal veins so as to 
sample the probe compounds absorbed across the intestine prior to their hepatic clearance 
(Chapter 2 and 3).  The use of corresponding ex vivo and in vivo mouse models enables 
detailed mechanistic investigation of the effect of P-gp efflux on first-pass metabolism 
and portal bioavailability of dual P-gp/Cyp3a substrates.  Most importantly, retrospective 
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analysis of the findings from our ex vivo and in vivo mouse models showed that the 
results obtained from ex vivo studies could be correlated to the oral bioavailability 
determined in vivo in mouse (Chapters 2 and 3).  To apply this analysis to humans, the 
interactions of P-gp efflux and CYP3A metabolism during absorptive transport of dual P-
gp/CYP3A substrates were investigated in fresh human intestinal epithelium, so that the 
results and conclusions derived from this ex vivo model can be extrapolated to predict the 
impact of P-gp efflux on first-pass metabolism and oral bioavailability of CYP3A/P-gp 
dual substrates in humans. Semi-PBPK modeling approaches were applied to the ex vivo 
– in vivo findings from mice studies so as to make quantitative predictions of the 
behavior of P-gp/CYP3A interactions under different experimental conditions.  The 
successful use of experimental and semi-PBPK modeling approaches to correlate mouse 
ex vivo and in vivo results enabled the use of a similar approach to translate human ex 
vivo findings on P-gp/CYP3A interactions during absorptive transport of loperamide to 
the predicted in vivo behavior of these interactions in humans.   
4.C. EXPERIMENTAL METHODS 
Materials 
Loperamide, terfenadine, troleandomycin, sodium hydroxide, sodium bicarbonate, 
and Krebs Bicarbonate Ringer (KBR) were purchased from Sigma Aldrich (St. Louis, 
MO, USA).  The metabolites of loperamide (monodemethyl- and didemethyl-loperamide) 
were generously provided by Janssen Pharmaceutica (Beerse, Belgium).  Acetonitrile, 
95% ethanol (EtOH), methanol, ethyl acetate, dimethyl sulfoxide (DMSO) were 
purchased from Fisher Scientific (Pittsburgh, PA, USA).  All other reagents were of 
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analytical grade or higher and triple deionized water was used in all experimental 
procedures. 
Patients 
Jejunal intestinal tissue, which is normally discarded following resection during 
gastric bypass surgery, was collected from 8 adult patients undergoing elective gastric 
bypass surgery at the University of North Carolina Hospitals at Chapel Hill (Chapel Hill, 
NC, USA).  All patients met the recommended criteria for gastric bypass surgery as 
endorsed by the National Institute of Health (NIH) Consensus Development Conference 
Panel (Hubbard and Hall, 1991).  Briefly, all patients were considered morbidly obese 
with a body mass index (BMI) > 40 kg/m2 or with a BMI > 35 kg/m2 with the presence of 
high risk co-morbidities of obesity (i.e. type-2 diabetes, obstructive sleep apnea, 
hypertension, heart disease, stroke or arthritis, etc.), had failed non-surgical attempts for 
weight loss (i.e., physician supervised diet, exercise program, and/or weight loss 
medications), had no presence of uncontrolled psychopathy, and were expected to 
withstand the administration of anesthesia and the surgical gastric bypass operation as 
determined by a multidisciplinary team of physicians with medical, surgical, psychiatric, 
and nutritional expertise.  To preserve patient confidentiality and to obtain approval from 
the Biomedical Institutional Review Board (IRB), the age, gender, health, or other 
personal identifying information was not collected.  The procurement of intestinal tissues 
from gastric bypass surgical patients and all investigational experiments were performed 
in accordance with the approval from the IRB of the Office of Human Research Ethics at 
the University of North Carolina at Chapel Hill and in compliance with federal 
regulations CFR 46.102 (d or f) and 21 CFR 56.102 (c)(e)(l).  
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Transport and Metabolism Studies with Intestinal Tissue 
During the standard operational procedure for a gastric bypass operation a ~10 cm 
intestinal tissue segment from the jejunum is surgically resected during the creation of a 
gastrojejunostomy.   Following surgical resection and excision of the intestinal tissue, the 
intestinal tissue was immediately placed in, and flushed with, 500 ml of oxygenated ice-
cold KBR with 50% complete EDTA-free protease inhibitor (Roche, Basel, Switzerland), 
and transported from the surgical suite to the laboratory for experimentation.  The typical 
time between excision of the intestinal tissue from the patient and transportation to the 
laboratory for experimentation was less than 10 minutes.  Since the harvested intestinal 
tissue from humans consisted of the mucosa (intestinal epithelium) and the exterior 
seromusculature layers, which are not physiologic barriers to in vivo intestinal absorption, 
the tissue was “stripped” of the exterior seromusculature and serosa layers by sharp 
resection.  The intestinal epithelium was separated into six 2 cm segments, mounted 
between two halves of a diffusion chamber insert (aperture area = 0.3 cm2), and held in 
place by eight small pins.  The inserts were placed in ice-cold KBR with 50% complete 
EDTA-free protease inhibitor (Roche, Basel, Switzerland) until they were mounted   
between the diffusion chambers.   The entire procedure was completed in <1 hour from 
the time the tissue was excised from the patient.  The inserts were mounted between two 
side-by-side diffusion chambers (Physiologic Instruments, San Diego, CA, USA).  KBR 
(3 ml) at 37°C was added to the AP and basolateral (BL) chambers and bubbled with 
oxygen/carbon dioxide (95:5) gas to maintain tissue viability (Johnson et al., 2002).  
From each patient, three control intestinal epithelial segments were preincubated for 30 
min at 37°C with 3 ml of KBR buffer containing 0.05% DMSO in the AP and BL 
 
 
 
 143 
compartments, and three P-gp inhibited segments were preincubated with KBR buffer 
containing 5 µM of the P-gp inhibitor elacridar (GF120918) (GlaxoSmithKline, RTP, 
NC, USA) and 0.05% DMSO in the AP and BL compartment.  For CYP3A inhibition 
studies, 100 µM of the CYP3A inhibitor troleandomycin was added to the preincubation 
KBR buffer solutions.  Following equilibration, the transepithelial electrical resistance 
was measured to test the epithelial integrity of the intestinal tissue.  The KBR buffer from 
the BL chamber was removed and replaced with fresh buffer; while the buffer in the AP 
chamber was replaced with 50 or 100 µM loperamide KBR containing 0.1% EtOH and 
0.05% DMSO.  Permeability of loperamide, in the absence of CYP3A activity, was 
measured at 20 µM loperamide in KBR solution containing 0.1% EtOH and 0.05% 
DMSO and 100 µM troleandomycin. All study treatments were performed in the presence 
(inhibited) or absence (control) of GF120918. The intestinal epithelial segments were 
incubated for 90 min at 37°C after which buffer from the AP and BL chambers was 
collected.  The tissues were washed ten times in ice-cold KBR buffer, homogenized for 
30 sec with a sonic dismembrator in 200 µl of 50:50 KBR and 2N NaOH, and vortexed 
with 0.5 ml ethyl acetate for 1 min. The homogenates were centrifuged at 9,000 g at 4°C 
for 10 min, and the supernatants collected.  The homogenized tissues were washed with 
0.5 ml ethyl acetate, vortexed, centrifuged, and the supernatants collected two additional 
times. The supernatants were combined and evaporated under nitrogen gas for 10 min, 
and reconstituted in KBR.  All samples were stored at -20°C until analysis using 
LC/MS/MS. 
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Analytical Procedure 
LC-MS/MS 
Loperamide and its two major metabolites, monodemethyl-loperamide and 
didemethyl-loperamide were quantified in the study samples collected from the receiver 
and donor compartments of the chamber and in the intestinal epithelium.  Experimental 
samples were prepared by the addition of 100 µl of ice-cold acetonitrile, which contained 
20 ng/ml terfenadine internal standard, to 50 µl of sample buffer for precipitation of the 
samples.  The samples were vortexed for 1 min and centrifuged at 9,000 g at 4° C for 10 
min.  Samples were analyzed using LC-MS/MS that consisted of LC10-ADVP 
quaternary pumps (Shimadzu, Kyoto, Japan) that were coupled to a CTC-PAL 
autosampler (LEAP Technologies, Carrboro, NC) and a Sciex API-4000 triple-
quadropole mass spectrometer (Applied Biosystems, Foster City, CA).  The mobile 
phases consisted of 0.1% formic acid in water (Mobile Phase A) and 0.1% formic acid in 
methanol (Mobile Phase B).  The chromatographic separation of the analytes was 
performed with a linear gradient of 5-95% B in A at a flow rate of 0.8 ml/min over four 
min, and an injection volume of 5 µl.  The analytical column was an Aquasil C18, 
50x2.1m, with a 5 µm particle size (Thermo-Scientific, Waltham, MA, USA). The 
samples were ionized using a TuroboIonSpray ion source and the positive ions were 
monitored at the following transitions: 477/266 for loperamide, 463/252 for 
monodemethyl-loperamide, and 449/238 for didemethyl-loperamide.  The terfenadine 
internal standard was monitored at 472/436 transitions.  Calibration standard curves that 
ranged from 0.1-50 ng/ml were linear (R2 > 0.99) throughout the range, and were 
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analyzed at the beginning and end of the sample run.  The data were acquired and 
processed using Analyst 1.4.1 (Applied Biosystems, Foster City, CA, USA). 
Simulations 
 The advanced compartmental absorption and transit (ACAT) model (Figure 4.1) 
(Yu and Amidon, 1999; Agoram et al., 2001) of GastroPlus® was utilized to simulate the 
linear and nonlinear absorption of loperamide in mice and humans.  The ACAT model of 
intestinal absorption is a mechanistic physiologically based model developed to predict in 
vivo drug behavior and absorption.  The ACAT model is comprised of a total of nine 
compartments of the intestine, each of which is divided into four sub-compartments: 
unreleased, undissolved, dissolved, and enterocyte (Figure 4.1). Additionally, simulations 
using the ACAT model of GastroPlus® account for physiological factors that affect 
intestinal absorption such as, intestinal pH dependent solubility of drugs; drug 
formulations; regional absorption in the stomach, small intestine, and colon; intestinal 
metabolism; carrier-mediated transport; exsorption/secretion; pharmacokinetics (Agoram 
et al., 2001).  Additionally, the ACAT model accounts for regional alterations in physical 
and biochemical factors such as, metabolizing enzyme, influx, or efflux transporter 
densities within the intestinal tract (Agoram et al., 2001). 
Simulations were run on a Macbook Pro (Apple Inc., Cupertino, CA, USA) laptop 
computer running OSX Snow Leopard (version 10.6.6) (Apple Inc., Cupertino, CA, 
USA) with boot camp Windows 7 (version 6.1) (Microsoft Corp., Redmond, WA, USA) 
with 2 Gb of RAM and 2.0-GHz Intel dual core processor using GastroPlus® software 
7.0, which was generously provided by Simulations Plus (Lancaster, CA, USA).  The 
simulation for absorption of loperamide in mouse was developed with an ACAT 
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compartmental model using the physiological compartment parameters of the intestinal 
fluid volumes, transit time, intestinal radius, lumen pH, lengths, and the relative 
physiological distributions of P-gp and Cyp3a/CYP3A, which are listed in Table 4.1 for 
the fasted mouse compartmental model and Table 4.2 for the fasted human 
compartmental model.  Protein expression levels of P-gp and CYP3A were represented as 
the regional distribution ratio in the gut relative to that present in the liver, as integrated 
by GastroPlus® based on studies by Paine et al. (1997) for CYP3A and Mouly and Paine 
(2003) for P-gp.  Simulated metabolic elimination was confined to that occurring in the 
intestine.  GastroPlus® simulations of the “dose-dependent oral absorption of loperamide 
versus time” and the “fraction of dose absorbed into the portal circulation” in the absence 
or presence of intestinal P-gp were compared.  Loperamide doses of 0.23 mg/kg and 2.4 
mg/kg doses in mouse and a 0.03 mg/kg clinical loperamide dose (2 mg tablet) and 0.23 
mg/kg dose (8 x 2 mg tablet) in humans were used in these simulations.  The 
biopharmaceutical properties of loperamide used in the simulations are summarized in 
Table 4.3 and were estimated using ADMET Predictor 6.1 (Simulations Plus, Lancaster, 
CA, USA) or referenced from experiments described in this manuscript (Chapter 2), and 
in studies conducted by Knight (2007) and Acharya et al (2006). 
Data Analyses 
The apparent permeability (Papp) of loperamide across the mouse intestinal tissue 
was calculated using Equation 1, 
           
    
€ 
Papp = JCD× A              Equation 1 
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where J represents the mass of drug transported, integrated over time, A is the area of the 
intestinal tissue membrane, and CD is the initial concentration of drug in the donor 
compartment, maintained under sink conditions (Artursson and Karlsson, 1991). 
The efficiency of P-gp in attenuating the passive permeability during intestinal 
absorption can be quantitatively expressed as the absorptive quotient (AQ) (Equation 2). 
   
  
 
       
€ 
AQ = PPD − PAPP , ABPPD   Equation 2 
This parameter can be determined experimentally by measuring (i) apparent permeability 
(AP to BL) in the presence of P-gp mediated efflux (Papp,AB) (ii) passive permeability 
(PPD) in the absence of P-gp efflux (inhibited with GF120918) and by calculating the 
decrease in passive permeability mediated by P-gp in relation to the PPD (Troutman and 
Thakker, 2003a; Troutman and Thakker, 2003b).  Thus, for a compound with an AQ of 
0.9, P-gp efflux attenuates PPD during absorptive transport by 90%. 
Using equation 3, the fraction of dose metabolized (FM) was quantified from the 
amount of total metabolite present in the receiver and donor compartments, and in mouse 
intestinal tissue. 
         
€ 
FM = MApical +MBasolateral +MIntracellularDose
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟ ×100  Equation 3 
M is the total mass of the major loperamide metabolites (mondemethyl-loperamide and 
didemethyl-loperamdie) present in the donor (MApical) and receiver (MBasolateral) 
compartments, and in human intestinal epithelium (MIntracellular) 90 min following the 
addition of the dosing solution to the donor compartment.  Dose is the mass of 
loperamide present in the dose solution in the donor compartment at the initiation of the 
experiment. 
 
 
 
 148 
 The fraction of dose transported (FT) across human intestinal epithelial segments 
(AP to BL) was quantified, using Equation 4,  
  
€ 
FT = ParentBasolateralrDose
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟ ×100  Equation 4 
where Parent Basolateral is the amount of intact parent drug that was present in the receiver 
compartment of the diffusion chamber at 90 min. Dose is the mass of loperamide in the 
dosing solution in the AP chamber at the beginning of the experiment. 
Statistical Analysis 
The overall difference between the experimental groups was determined using a 
two-way analysis of variance (ANOVA) followed by a Bonferroni post-test, using 
GraphPad Prism® statistical software 4.0 Mac (GraphPad Software Inc., La Jolla, CA, 
USA).  All values are expressed as the mean ± standard deviation (SD).  The criterion for 
a significant difference in values was considered as p < 0.05. 
4.D. RESULTS 
Metabolism of Loperamide during Absorptive Transport across Human Intestinal 
Epithelium 
At a 50 µM loperamide concentration the rate of CYP3A-mediated metabolism 
during absorptive transport was 3-fold lower (p < 0.05) in control human intestinal 
epithelium (2.5 ± 2.0 pmol/min/cm2) compared to that observed in intestinal epithelium 
in which P-gp was inhibited by GF120918 (7.8 ± 3.4 pmol/min/cm2)  (Figure 4.2). At a 
100 µM dose, this effect was attenuated, and there was a slight trend towards a decrease 
in the rate of loperamide metabolism in control (2.1 ± 1.2 pmol/min/cm2) versus P-gp 
inhibited (3.7 ± 1.3 pmol/min/cm2) intestinal epithelia (Figure 4.2).   
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The FM of loperamide at a concentration of 50 µM was 3.5-fold lower (p < 0.05) 
in control intestinal epithelium (0.43 ± 0.30 %) versus P-gp inhibited intestinal 
epithelium (1.5 ± 0.77 %) (Figure 4.2B).  There was a slight decrease in the FM observed 
at a 100 µM concentration of loperamide in control intestinal epithelium (0.18 ± 0.09 %) 
compared to the epithelium in which P-gp was inhibited (0.30 ± 0.09 %) (Figure 4.2B).  
In the absence of P-gp, the FM decreased by 5-fold (p < 0.001) at a loperamide 
concentration of 100 µM compared to the FM at a concentration of 50 µM (Figure 4.2B).  
There was a slight reduction in the FM was observed in control human intestinal 
epithelium at 100 µM compared to 50 µM (Figure 4.2B).  
Effect of P-gp on Absorptive Transport of Loperamide Across Intestinal Epithelium 
from Humans   
 The efficiency of P-gp-mediated AP efflux of loperamide in human intestinal 
epithelium was determined by estimating the AQ (Equation 3), which directly measured 
the extent to which P-gp reduces passive permeability (Equation 2) of loperamide (20 
µM) across human intestinal epithelium.  The passive permeability (Equation 2) of 
loperamide (20 µM) was determined in control or P-gp inhibited human intestinal 
epithelium in the presence of the CYP3A inhibitor troleandomycin (100 µM) (Polasek 
and Miners, 2006).  Results show that this permeability was reduced by approximately 
three-fold (i.e., ~69%, AQ = 0.69 ± 0.10) (p < 0.001) in the presence of P-gp (2.5 ± 0.08 
nm/sec) compared to intestinal epithelium where P-gp efflux was inhibited (8.0 ± 0.45 
nm/sec) (Table 4.4).   
The FT of unmetabolized loperamide (Equation 4) during AP to BL transport 
across control or P-gp-inhibited human intestinal epithelium was almost equivalent at 50 
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µM (0.11 ± 0.06 % and 0.14 ± 0.06 %, respectively) and at 100 µM (0.10 ± 0.04 % and 
0.07 ± 0.05 %, respectively) doses (Figure 4.3).  A slight trend towards a decrease in the 
FT in control and P-gp inhibited human intestinal epithelia was observed as loperamide 
concentration increased from 50 µM to a higher concentration of 100 µM (Figure 4.3).   
Pharmacokinetic Modeling of the Interplay of P-gp Efflux and Intestinal First-Pass 
Metabolism by Cyp3a in Modulating the Portal Bioavailability of Loperamide in 
Mouse.    
To develop an in vivo model for investigating the effect of the interplay between 
intestinal P-gp and Cyp3a-mediated first-pass metabolism on the FG of loperamide, the 
effective permeability of loperamide (5.5 nm/sec) and the apparent Vmax (31 
pmol/min/cm2) and Km (22 µM) of Cyp3a-mediated metabolism of loperamide were 
obtained from ex vivo studies using mouse intestinal tissue (Table 4.3).  The estimate of 
the Km (4 µM) for P-gp efflux of loperamide was referenced from studies performed by 
Acharya et al. (2006) using MDR1-Madin-Darby Canine Kidney II (MDR1-MDCKII). 
To obtain good correlations between semi-PBPK simulations (GastroPlus®) and the in 
vivo data, optimization of the in vitro Vmax of P-gp was performed to accurately predict 
the FG data from an oral 0.23 mg/kg dose of loperamide in P-gp competent mice (weight 
35 g) (Chapter 2) in an ACAT compartmental model of intestinal absorption (Figure 4.1) 
that included regional expression of intestinal Cyp3a and P-gp in a fasted mouse (Table 
4.1).  
The effect of the presence or absence of P-gp efflux in modulating oral absorption 
of the dual P-gp/Cyp3a substrate loperamide into the portal circulation of mice was 
investigated using simulations of intestinal absorption of loperamide under the following 
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experimental conditions: (i) an immediate release solution containing 0.23 and 2.4 mg/kg 
doses of loperamide and (ii) intestinal absorption over a 4 hr period (Figure 4.4) in which 
intestinal P-gp efflux was present (solid blue line) or absent (dashed red line).  For the 
0.23 mg/kg dose of loperamide, which was expected to produce intestinal concentrations 
that were slightly greater (but sub-saturating for Cyp3a) than the apparent Km of Cyp3a-
mediated metabolism (Chapter 2), the simulated intestinal absorption of loperamide in the 
presence of P-gp efflux was ~5-fold greater than that derived for mice in which P-gp 
efflux was absent (Figure 4.4A).  Additionally, the predicted FG for the 0.23 mg/kg dose 
of loperamide in mice was ~5-fold greater in the presence of P-gp (3.2 %) than in its 
absence of the efflux transporter (0.69 %) in the simulation model (Table 4.5).  The 
simulated intestinal absorption versus time profiles (Figure 4.4A) and the FG (Table 4.5) 
were consistent with previous results on the portal blood concentrations observed in 
studies using portal vein cannulated mice that were competent or deficient in P-gp 
expression (Figure 4.4A).  For a high dose of loperamide (2.4 mg/kg), which was 
expected to saturate Cyp3a, the simulated intestinal absorption for a 2.4 mg/kg dose of 
loperamide was similar when P-gp was present or absent in the model (Figure 4.4B).  
Additionally, at this dose there was no difference in predicted FG when P-gp was 
included (12.8 %) or excluded (9.5 %) in the model (Table 4.5).  The comparison 
between the doses of the portal Cmax predicted for mice when P-gp was present in the 
simulation model shows that there was a disproportionate ~20-fold increase in the portal 
Cmax as the dose increased to 2.4 mg/kg from 0.23 mg/kg.   However, when P-gp was not 
included in the mouse simulations, there was a ~100 fold increase in the predicted portal 
Cmax between the two doses. 
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Prediction of the Influence of the Interplay between P-gp and CYP3A on the Portal 
Bioavailability of Dual P-gp/CYP3A Substrates in Humans. 
The effect of the presence or absence of P-gp efflux in modulating the portal 
absorption of loperamide in humans was predicted using GastroPlus®.  This was achieved 
by modification of the ACAT compartmental model that was developed to predict the FG 
of loperamide from in vivo mouse studies (described above).  The following model 
parameters were switched to those for a human: a physiologic model of a fasted human 
(weight 70 kg) with intestinal CYP3A and P-gp (Table 4.2), the effective permeability of 
loperamide, and apparent Vmax and Km for CYP3A-mediated metabolism (Table 4.3 and 
4.4).  The effective permeability of loperamide across human jejunum (8.0 nm/sec) was 
obtained from ex vivo studies with fresh human jejunal epithelium as described above 
(Table 4.3 and 4.4). The apparent Vmax (0.8 pmol/min/cm2) and Km (18 µM) of CYP3A-
mediated metabolism of loperamide in humans was estimated from studies by Knight 
(2007), using Caco-2 cells in which CYP3A expression was induced by 1α,25-
dihydroxyvitamin-D3 (it is recognized that the estimates of Vmax and Km obtained from 
Caco-2 cells may be at variance from the actual human intestinal values). 
The predicted FG for a clinical loperamide dose in humans (2 mg tablet, 0.03 
mg/kg), was reduced by ~2-fold when P-gp was present (3.4%) in the model compared to 
that predicted when the P-gp parameter was absent (6.7%) (Table 4.6).  For the 0.23 
mg/kg dose of loperamide, which represented linear conditions in the mouse FG 
simulations, the predicted FG in humans was ~2.5-fold higher when P-gp was present 
(4.0%) than in the absence of P-gp (1.5 %) in the simulation model (Table 4.6).  A 
comparison of the predicted portal Cmax, between the 0.03 mg/kg (0.51 ng/ml) and 0.23 
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mg/kg dose (1.0 ng/ml) in the absence of P-gp in the simulation model, shows that there 
is a ~5-fold under prediction of the portal Cmax at the 0.23 mg/kg dose assuming linear 
increase in portal Cmax with dose.   
The Dependence of the Efficiency of Efflux by P-gp in Shifting the Apparent Km for 
Cyp3a-mediated Metabolism and its Outcome in Altering Portal Bioavailability in 
Mice.   
As shown in Figure 4.6, for drugs that are substrates of Cyp3a-mediated 
metabolism and elicit a low (or no) efficiency for efflux by P-gp, the efflux transporter 
would not alter the Km for Cyp3a-mediated metabolism (ΔKm < 1).  Therefore, as the 
dose increases, the FG would increase proportionately.  As the efficiency for P-gp 
increases, the apparent Km for Cyp3a-mediated metabolism also increases (ΔKm > 1) 
(Chapter 2, Figure 2.1).  The increase in the apparent Km results in the reduction of 
intestinal first-pass metabolism, therefore increasing the net absorption of the drug across 
the intestine, and the FG (Figure 4.6).  However, as the dose is increased to produce 
intestinal concentrations that are greater than the apparent Km for oxidative metabolism, 
Cyp3a would saturate and the effect of P-gp on Cyp3a-mediated metabolism is 
diminished (Figure 4.6).   
4.E. DISCUSSION 
 In the studies presented here, the effect of P-gp efflux on intestinal first-pass 
metabolism of the dual P-gp/CYP3A substrate, loperamide, was investigated in fresh 
human intestinal epithelia harvested from patients undergoing gastric bypass surgery. To 
elucidate the effect of P-gp efflux on CYP3A-mediated metabolism of loperamide, 
CYP3A-mediated metabolism was evaluated in human intestinal epithelium with 
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functional P-gp efflux (untreated control) or where P-gp efflux was inhibited by treatment 
with the P-gp inhibitor GF120918.  These results were compared with findings from 
similar ex vivo (mouse intestinal tissue) studies in P-gp competent and P-gp deficient 
mice.  These investigations provided the data to develop semi-PBPK models of the 
interplay of P-gp and CYP3A during intestinal absorption.  The incorporation of 
experimentally determined pharmacokinetic parameters (apparent permeability, Vmax and 
Km for CYP3A-mediated metabolism), in this semi-PBPK model of oral absorption 
allowed prediction of the potential effect of the interaction of P-gp/CYP3A on human 
oral bioavailability. 
It was shown that when CYP3A was inhibited, P-gp reduced the passive 
permeability of loperamide across human intestinal epithelium by ~70% (AQ = 0.69 ± 
0.10).  This P-gp-mediated reduction in the passive permeability of loperamide confirms 
previous findings in Caco-2 cells (Knight, 2007), which classified loperamide as a drug 
that was subject to P-gp-mediated efflux with high efficiency.  However, this is a lower 
AQ value than that observed in mouse intestinal tissue (AQ = 0.89) (Chapter 2).  The 
loperamide concentrations for the ex vivo studies using human intestinal epithelia were 
selected based on results obtained from similar ex vivo studies conducted in mouse 
intestinal tissue (Chapter 2, Figure 2.1) and from studies by Knight (2007) in Caco-2 
cells, where CYP3A was induced by 1α,25-dihydroxyvitamin-D3  (Knight, 2007).  The 
50 µM concentration of loperamide used in ex vivo human studies was expected to be in 
the linear range for CYP3A-mediated metabolism. A 100 µM concentration was selected 
as it was expected to cause at least partial saturation of CYP3A.  The results showed that 
as was observed in the mouse intestinal tissue (Chapter 2), P-gp efflux reduced the rate 
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(Figure 4.2A) and extent (Figure 4.2B) of oxidative metabolism of loperamide (50 µM) 
in human intestinal epithelium. At a higher loperamide concentration (100 µM), the effect 
of P-gp in reducing metabolism was less pronounced, likely due to partial saturation of 
CYP3A within the intestinal epithelium.  This was confirmed by examination of the FM 
at 50 and 100 µM concentrations of loperamide, which showed that in P-gp inhibited 
human intestinal epithelium, a significant decrease in the FM occurred at the higher 
concentration (Figure 4.2B). Interestingly, the percent of loperamide dose transported 
was approximately equal for the control and the P-gp inhibited tissues at both 50 µM and 
100 µM doses.  Thus, attenuation of loperamide absorptive transport and sparing of the 
metabolism by P-gp appeared to balance each other out in this case.     
  Thus, in general, the effect of P-gp on loperamide metabolism during its 
absorptive transport appears to be similar in mouse and human intestinal tissues.  
Therefore, if a relationship can be developed in mouse between ex vivo and in vivo 
behavior of P-gp with respect to its effect on intestinal first-pass metabolism, then a 
model can be developed that would predict the effect of P-gp on intestinal first-pass 
metabolism of dual substrates in humans (see Figure 4.5) which can be applied to ex vivo 
data.  Therefore, a semi-PBPK model was developed using GastroPlus® based on the 
loperamide data obtained from the mouse ex vivo and in vivo studies.  A successful 
convergence of observed and predicted portal concentrations of loperamide (0.23 mg/kg) 
in P-gp competent and P-gp deficient mice (Figure 4.4) and of values for FG and portal 
Cmax at 0.23 mg/kg dose of loperamide (Table 4.5) provided evidence that the model was 
appropriate.  Furthermore, simulations to predict the effect of the interplay between P-gp 
and Cyp3a on portal concentrations and FG in mice for a high loperamide dose of 2.4 
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mg/kg (that would saturate Cyp3a) showed no difference in the FG whether P-gp was 
present or absent in the model.  This suggests that Cyp3a, and possibly P-gp, was 
predicted to be saturated following a 2.4 mg/kg dose of loperamide in mice. The 
predicted FG at 2.4 mg/kg dose is similar to the experimental values of the FG at a 0.94 
mg/kg oral dose of loperamide in mouse (Chapter 2).   
Using this model and the data obtained from the human intestinal studies on 
loperamide transport and metabolism, the FG and portal Cmax values for humans at 0.03 
mg/kg and 0.23 mg/kg oral dose of loperamide were calculated (Table 4.6).  A 
comparison of the predicted FG and portal Cmax values in humans (Table 4.6) and 
corresponding experimental values in mice (Table 4.5) obtained with 0.23 mg/kg 
loperamide dose suggests that humans will behave similar to mice in that P-gp would 
increase FG of loperamide at this dose.  At a dose equivalent to a single 2 mg tablet of 
loperamide (0.03 mg/kg), the model predicted portal Cmax of 0.24 ng/ml in humans.  
However, in a clinical study performed by Kamali et al. (1992), the observed Cmax in the 
systemic circulation for this dose was also 0.24 ng/ml.  Because the Cmax in the systemic 
circulation is a reflection of both intestinal and hepatic disposition, this comparison 
suggests that the model under-predicts the portal Cmax of loperamide at 0.03 mg/kg dose.  
A similar under-prediction of the portal Cmax (2.5 ng/ml) also occurred at the 0.23 mg/kg 
dose (equivalent to a single oral dose of 16 mg (8 x 2 mg tablets)) when compared with 
the observed systemic Cmax range of 1.09 to 4.1 ng/ml from several clinical studies 
(Kamali et al., 1992; Tayrouz et al., 2001; Mukwaya et al., 2005; Wolf, 2011).  
In conclusion, the studies described in this chapter show that the effect of P-gp to 
spare the intestinal first-pass metabolism and enhance FG of the dual substrate loperamide 
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that was initially observed in mouse (Chapter 2) can be extended to human intestinal 
epithelium. Further, an semi-PBPK model was developed using the ex vivo – in vivo 
relationship with respect to the interaction of P-gp and Cyp3a in mouse that affects the 
intestinal first-pass metabolism and FG of loperamide.  Additional refinement of this 
model will be useful in predicting the effect of P-gp-CYP3A interactions in human 
intestine on oral bioavailability and hepatic/systemic exposure of dual substrates.  In 
addition, the semi-PBPK model can be used to provide valuable insights into the 
intestinal P-gp-Cyp3a (CYP3A) interactions under various conditions that may be 
encountered in the GI tract.  For example, as shown in Figure 4.6, the model predicts that 
the ability of P-gp to enhance FG goes up as P-gp become more effective in increasing the 
apparent Km of the dual substrate toward Cyp3a-mediated metabolism.  Further, the 
simulations show that for compounds whose Km for intestinal metabolism is marginally 
affected by P-gp, the FG increases sharply with increasing doses. In contrast, the increase 
in FG is fairly insensitive to an increase in dose for those compounds where intestinal 
metabolism is attenuated effectively by P-gp.  Thus, the studies described in this chapter 
significantly extends our understanding of the interactions between two important 
biochemical barriers to intestinal drug absorption and their consequence to oral drug 
therapy   
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Figure 4.2:  The ex vivo rate and extent of metabolism of loperamide by CYP3A 
over 90 min during absorptive transport across control or P-gp inhibited human 
intestinal epithelium.  The rate (A) and extent (B) of metabolism of loperamide was 
determined over 90 min during the absorptive transport of loperamide across intestinal 
epithelial segments in the absence (Control, open bars) or presence (P-gp inhibited, 
closed bars) of the P-gp inhibitor, GF120918.  Experiments were performed in side-by-
side diffusion chamber over 90 min. Values are expressed as the mean + SD. Each 
treatment consists of n=4 patients per dose with three intestinal epithelial segments per 
patient.   
* = p < 0.05 for the comparison between control and P-gp inhibited intestinal epithelium, 
## = p < 0.01 for the comparison between the 50 and 100 µM does of loperamide in P-gp 
inhibited intestinal epithelium obtained by  two-way ANOVA with Bonferroni post-test 
analysis. 
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Figure 4.3:  The fraction of dose transported as unchanged parent across control or 
P-gp-inhibited human intestinal epithelium.  The absorptive transport of intact 
loperamide to the receiver compartment measured ex vivo across control (open bars) or P-
gp inhibited (closed bars) human intestinal epithelium is shown. Values are expressed as 
the mean + SD.  Each treatment consists of n=4 patients per dose with three intestinal 
epithelial segments per patient.  Statistical significance was assessed by analysis with a 
two-way ANOVA with Bonferroni post-test. 
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Figure 4.4:  The simulated (GastroPlus®) intestinal absorption of oral loperamide in 
mice. (A) The simulated and observed intestinal absorption of loperamide (0.23 mg/kg 
dose) into the portal circulation of mice when P-gp present (simulated +P-gp = solid blue 
line, Observed = solid black circles) or absent (simulated −P-gp = dashed red line, 
Observed = open gray circles) in the model.  (B) The simulated intestinal absorption of a 
2.4 mg/kg dose of loperamide into the portal circulation of mice where P-gp was present 
(+P-gp, solid blue line) or absent (−P-gp, dashed red line). 
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Figure 4.5:  The relationship between ex vivo and in vivo models of intestinal 
absorption used to study the effect of the interplay of P-gp and CYP3A on the oral 
bioavailability of dual substrates.   
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Figure 4.6:  Simulations examining the effect of changes in efficiency of intestinal P-
gp efflux and dose on mouse portal bioavailability.  This simulation shows the effect 
of P-gp in altering the Km for metabolism in the intestine and FG of compounds that 
have differing efficiency for efflux by P-gp.  These simulations were performed for doses 
which encompassed linear and saturating conditions of intestinal first-pass metabolism. 
 The x-axis represents the effect of P-gp in increasing the metabolic Km for metabolism. 
 This is represented for compounds that are not substrates for P-gp = ΔKm < 1 and for 
compounds that exhibit increasing efficiency for efflux by P-gp = ΔKm > 1.    
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Table 4.3: Key biopharmaceutial and pharmacokinetic properties of loperamide. 
Property Value Reference 
Log D5.0 5.145 Predicted with ADMET Predictor 6.1 
Solubility at pH 8.7 (mg/ml) 0.028 Predicted with ADMET Predictor 6.1  
Passive mouse jejunal 
permeability (nm/sec) 5.5 Chapter 2 
Passive human jejunal 
permeability (nm/sec) 8.0 Table 4.4  
pka  8.737 Predicted with ADMET Predictor 6.1  
Cyp3a Km mouse (µM) 22  Chapter 2 
Cyp3a Vmax mouse 
(pmol/min/cm2) 31 Chapter 2 
CYP3A Km Caco-2 (µM) 18  (Knight, 2007) 
CYP3A Vmax Caco-2 
(pmol/min/cm2) 0.8 (Knight, 2007) 
P-gp Km (µM) 4.0 (Acharya et al., 2006) 
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Table 4.4:  The absorptive transport of loperamide across human jejunal 
epithelium.   
 
Papp (-CYP)  
(20 µM) 
Control    2.5 ± 0.08*** 
P-gp Inhibited 8.0 ± 0.45 
 
The apparent permeability of loperamide measured in the presence (P-gp inhibited) or 
absence (Control) of the P-gp inhibitor GF120918 (5 µM) across human intestinal 
epithelium in which CYP3A metabolic activity was inhibited (Papp (-CYP)) by treatment of 
the intestinal epithelium with troleandomycin (specific CYP3A inhibitor). Values are 
expressed as the mean ±SD of n=3 mice with four intestinal tissues from each mouse. 
Papp = nm/sec. *** = p < 0.001 for the comparison between P-gp control and P-gp 
inhibited intestinal epithelium, as determined using a two-tailed student t-test.   
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Table 4.6:  The simulated portal bioavailability of oral loperamide in humans using 
GastroPlus®.   
 0.03 mg/kg Dose 
CLINICAL DOSE: 2 mg TABLET 
 0.23 mg/kg Dose 
CLINICAL DOSE: 8 x 2 mg TABLETS 
 +P-gp −P-gp  +P-gp −P-gp 
FG (%) 3.4 6.7  4.0 1.5 
Cmax 
(ng/ml) 0.24 0.51  2.5 1.0 
 
The predicted portal bioavailability of loperamide in humans at 4 hr, following a 0.03 
mg/kg clinical dose of loperamide (2 mg tablet) and 0.23 mg/kg dose (8 x 2 mg tablets) in 
humans over 4 hr.  Simulations were performed in the presence (+P-gp) or absence (−P-
gp) of P-gp in the simulated model of absorption using GastroPlus®. 
FG = portal bioavailability of loperamide.  Cmax = Maximum concentration of loperamide 
in the portal circulation.  
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 5.A. PROJECT STRATEGY 
 
The studies undertaken for this dissertation project focused on elucidating the impact of 
the intestinal interaction of P-gp efflux and CYP3A-mediated metabolism on the oral 
bioavailability of drugs that are dual substrates of P-gp and CYP3A.  These studies, for the first 
time, set out to systematically evaluate the in vivo effect of P-gp on intestinal first-pass 
metabolism of the dual P-gp/CYP3A substrates, loperamide and amprenavir, and their 
subsequent bioavailability in the portal circulation (FG) of mice.  The mouse is the most widely 
used preclinical animal model in biomedical research, since this animal species exhibits several 
genetic and physiologic similarities with humans, which are widely documented and understood 
(Fox, 2007).  The mouse was selected as a relevant model for studying intestinal P-gp and 
CYP3A interactions, since orthologs of both these proteins are endogenously expressed in mouse 
as well as human intestine.  Also, the opposing expression gradient of P-gp transporters and 
CYP3A enzymes observed in human intestine (Paine et al., 1997; Tamura et al., 2002; Tamura et 
al., 2003; Iida et al., 2005) is also present in mouse intestine (Perloff et al., 2003; Rayss, 2007) .  
Additionally, within the population of the CF-1 strain of mice that express P-gp, there is a 
naturally occurring subpopulation that is genetically deficient in the functional expression of P-
gp (Mdr1a1-/-) (Umbenhauer et al., 1997; Abbott et al., 2002).  The P-gp deficient mouse model 
enables the evaluation of the impact of P-gp efflux on intestinal first-pass metabolism and FG, 
without the need for P-gp inhibition with chemical inhibitors that are likely to affect other 
transporters/enzymes.  For example, commonly used P-gp chemical inhibitors, such as 
cyclosporine and ketoconazole, inhibit both P-gp and CYP3A, which can confound the 
interpretation of the true effect of P-gp efflux on Cyp3a-mediated metabolism in the proposed 
mouse studies.   
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 The use of a portal vein cannulated mouse model enabled the investigation of the overall 
effect of P-gp and Cyp3a interaction on intestinal absorption of the dual Cyp3a and P-gp 
substrates under non-static and physiologic conditions, without the confounding effects of liver 
metabolism and/or biliary excretion.  However, the caveats to performing studies in this in vivo 
mouse model are the requirements for microsurgical techniques and labor intensive procedures 
that are not amenable to high-throughput, which have led to the under utilization of mouse portal 
cannulation studies on intestinal absorption.  The techniques implemented for these studies have 
proven the model to be technically simple and straightforward, and one that can be used with a 
high level of success.   
A direct comparison of the findings between ex vivo and in vivo mouse studies improved 
our understanding of how P-gp and Cyp3a interactions alter overall intestinal first-pass 
metabolism and oral absorption in vivo.  The correlation between ex vivo and in vivo studies 
allowed development of a semi-physiologically based pharmacokinetic (PBPK) model that was 
used to predict the effect of P-gp and CYP3A interaction on the intestinal absorption of P-
gp/CYP3A dual substrates in humans (Figure 5.1), and to extend our understanding regarding the 
consequences of these interactions for diverse compounds with different biochemical properties.     
For the studies presented in this dissertation, two dual substrates of P-gp and CYP3A, 
loperamide and amprenavir, were selected to elucidate the interaction between the two proteins.  
Using loperamide and amprenavir in ex vivo and in vivo studies, provided an opportunity to 
investigate the effect of P-gp and CYP3A interaction on the oral absorption of two compounds 
that elicit varying affinities for P-gp efflux but are expected to undergo sufficient metabolism 
that would enable the quantification of the substrate and/or metabolites.     
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Based on findings generated from loperamide studies in mouse, a select number of 
studies were performed with amprenavir.  A comparison of the results from corresponding ex 
vivo and in vivo models using these different compounds provided an improved understanding of 
how P-gp efflux alters intestinal first-pass metabolism and oral bioavailability. 
5.B. KEY FINDINGS 
The results from mouse ex vivo and in vivo studies showed that P-gp increases FG of 
loperamide at doses that produced intestinal lumen concentrations near the apparent Km for 
oxidative metabolism by Cyp3a (Chapter 2).  This increase in FG is contrary to the widely held 
belief that P-gp reduces oral bioavailability by attenuating passive permeability and/or enhancing 
intestinal first-pass metabolism of a substrate (Cummins et al., 2002; Cummins et al., 2003; 
Benet et al., 2004; Cummins et al., 2004).  Although unusual, our results are consistent with 
findings from in vivo and mechanistic ex vivo studies in mouse that examined the effect of P-
gp/Cyp3a interactions on intestinal absorption.  These studies revealed that the effect of P-gp on 
sparing loperamide from extensive first-pass metabolism outweighed its effect on attenuating 
absorption of the drug via the efflux mechanism, with the net result of increased oral 
bioavailability of loperamide across the intestinal barrier (Figure 5.2). These are the first 
comprehensive studies performed to understand the dynamic interactions between intestinal P-gp 
and Cyp3a at different doses of loperamide in mice. However, loperamide is a likely 
representative of the extreme effect of the interaction of P-gp and Cyp3a on oral bioavailability.  
This interaction would be considerably different for other dual substrates that exhibit different 
permeabilities or efficiencies for intestinal metabolism or efflux.  Studies using amprenavir 
showed that this drug, which undergoes greater intestinal first-pass metabolism and elicits a 
lower efficiency for P-gp-mediated efflux compared to loperamide, had a ~2-fold lower FG in P-
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gp competent mice compared to mice that lacked P-gp expression.  The results from in vivo and 
ex vivo studies revealed that P-gp has little effect on first-pass metabolism or oral bioavailability 
of amprenavir, regardless of the presence or absence of P-gp.  Cumulatively, the findings from 
mouse in vivo and ex vivo studies with loperamide (Chapter 2) and amprenavir (Chapter 3), 
demonstrated that the effect of P-gp on Cyp3a-mediated intestinal first-pass metabolism and FG 
is dependent on the efficiency of P-gp efflux and the efficiency of metabolism for a given 
substrate.   
For compounds that are extensively metabolized, under linear conditions, there are three 
possible scenarios where alterations in P-gp efflux could alter FG. (i) For compounds that have 
low efficiencies for P-gp efflux (AQ < 0.3), the FG would be solely determined by the extent of 
metabolism. (ii) For a compound that has a high efficiency for P-gp efflux (AQ > 0.7), such as 
loperamide, P-gp would decrease CYP3A-mediated metabolism and subsequently increase FG.  
(iii) For a compound that has a moderate efficiency for P-gp efflux (0.3 < AQ < 0.7), P-gp efflux 
would not play a significant role in its FG depending on whether the metabolisms is highly 
(amprenavir) or moderately efficient.  Of course, a compound may be affected differently 
depending whether it is in the proximal or distal regions of the intestine.  Compounds like 
amprenavir (AQ = 0.69), that elicit a moderate level of efficiency for P-gp in the proximal 
intestine, could behave similarly to loperamide in the distal regions of the intestine, where the 
expression of P-gp increases with a corresponding decrease in CYP3A expression.  In this case, 
the effect of P-gp efflux in attenuating intestinal first-pass metabolism by CYP3A could 
potentially result in an increase in FG.  This concept could be capitalized upon to enhance the 
oral bioavailability of drugs that are normally poorly absorbed in the proximal regions of the 
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intestine.  This could potentially be accomplished by the use of a controlled-release drug 
formulation, targeting the distal intestine to increase the FG of such drugs.    
In addition to the efficiencies of metabolism by CYP3A and efflux by P-gp, the 
concentration of drugs plays an important role on the effect of P-gp on the metabolism and oral 
bioavailability.  The increase in FG will also be dependent on the intestinal concentration 
generated by the specific dose, in relation to the apparent Km for CYP3A metabolism (i.e., linear 
versus non-linear conditions for CYP3A).  In conclusion, the FG would be influenced by the 
efficiencies of P-gp efflux and metabolism for a given substrate, the dose of the substrate, as well 
as other physiological factors such as the different expressions of CYP3A and P-gp in different 
regions of the intestine, that would antagonistically or synergistically determine the FG of the 
dual substrates of P-gp and CYP3A. 
5.C. SIGNIFICANCE 
 Understanding the effect of P-gp efflux and CYP3A-mediated metabolism during 
intestinal absorption of dual P-gp/CYP3A substrates is an important area of research.  To date, 
several contradicting conclusions have been advanced on whether P-gp enhances or attenuates 
the metabolism of dual P-gp/CYP3A substrates during oral absorption.  These conclusions have 
been based on findings of theoretical pharmacokinetic modeling, static models of intestinal 
absorption, such as Caco-2 cells or single pass rat intestinal perfusion studies using single-dose 
concentrations of a very limited number of dual substrates.  Additionally, there have been 
attempts to predict the likely effect of the interaction of P-gp and CYP3A in humans using data 
from in vitro studies that lacked sufficient rationale or sufficient understanding of these 
interactions in humans that could provide the basis for interpretation of the results.   
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The research presented in this dissertation addresses this important gap in our 
understanding of intestinal P-gp and CYP3A interaction and its effect on intestinal first-pass 
metabolism and oral bioavailability of dual substrates. This work, for the first time, methodically 
evaluated the effect of P-gp efflux on first-pass metabolism and FG for two dual P-gp/CYP3A 
substrates that are subject to P-gp efflux with different efficiencies.  Most importantly, the 
influence of drug dose on these interactions provided a greater insight into the dynamic nature of 
the interplay between P-gp and CYP3A interactions. The ex vivo and in vivo approaches in this 
study provide (i) a direct method and proven approach to investigate the interplay of other 
intestinal efflux transporters and metabolizing enzymes, and (ii) perform semi-PBPK modeling 
to predict the effect of these interactions on the oral bioavailability of diverse drugs and different 
doses of drugs in mice and humans.  
These studies also provide knowledge that can be directly utilized for the design of new 
therapeutic compounds that are substrates for apically located efflux transporters or intestinal 
first-pass metabolizing enzymes.  This can potentially be accomplished by further elucidating the 
regional interactions of P-gp and CYP3A interactions in the intestine other than the jejunum, 
where these transporters and enzymes show varying levels of expression.  
In recent years there has been significant interest in targeting the gastrointestinal (GI) 
tract for the treatment of GI motility disorders or Crohn’s disease, where high intestinal exposure 
to the drug and low or no systemic bioavailability would be beneficial.  For such therapeutic 
agents, the general consensus is that susceptibility to concurrent efflux by P-gp and CYP3A-
mediated metabolism within the intestine would result in reduced systemic exposure that could 
reduce toxicity or side effects.  However, the studies presented here show that depending on the 
dose, the absorption of dual P-gp and CYP3A substrates could be significantly enhanced for 
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certain compounds.  Therefore, designing new GI-targeted therapeutics that are not substrates for 
P-gp could potentially improve the therapeutic profile and reduce the possibility of organ-
specific or systemic-related side effects.  These studies can also provide valuable insights and 
point to useful experimental and modeling approaches to design compounds with disease targets 
in the liver.   
5.D. FUTURE STUDIES 
Although comprehensive, these studies have only been conducted using two different P-
gp/CYP3A dual substrates.  Further work is needed to elucidate P-gp and CYP3A interactions 
for other dual substrates with different physiochemical and/or kinetic properties.  Such studies 
could include compounds that are metabolized with different efficiencies, or that elicit a wider 
range of efficiency for efflux by P-gp; for example, low efficiency (i.e., diltiazem), moderate 
efficiency (terfenadine, verapamil) and high efficiency (saquinavir, paclitaxel). This would 
provide a broader understanding of how P-gp and CYP3A interactions will influence FG.  
The interplay of P-gp and CYP3A is the most commonly studied interaction between 
efflux and metabolism within the intestine.  However, such interactions are possible with other 
pairs of efflux transporters and metabolic enzymes. Investigating the interactions between P-gp 
and other isoforms of P450 such as CYP2C9 would be worthwhile; for example CYP2C9, the 
second highest CYP isoform present in the human intestine (Paine et al., 2006), has been 
implicated in interacting with P-gp, and while CYP2D6 may not be expressed highly in the 
intestine, it contributes to the metabolic clearance of large numbers of cationic drugs that are also 
likely to be substrates for P-gp.  Elucidating the interactions between Phase II metabolizing 
enzymes and efflux transporters could also be a future study.  Previous studies using cellular 
systems investigated the interactions of enzymes and transporters, such as glutathione-S-
 
 
 183 
transferases (GSTs) and multidrug resistance associated protein 1/2 (MRP1/2) (Smitherman et 
al., 2004), UDP-glucuronosyltransferases (UGTs) and MRPs / OATs (Chu et al., 2009), 
sulfotransferases (SULTs) and MRP2/3, or carboxylesterases and breast cancer resistance protein 
(BCRP) (Kondo et al., 2005).  Ex vivo and in vivo studies to confirm these in vitro findings, 
using the methods outlined in this dissertation, would significantly improve our understanding on 
the complexity of the interactions between metabolism and efflux.  Furthermore, to obtain an in-
depth understanding of these interactions, additional drugs belonging to a wide range of 
classification should be studied.  Benet et al. propose that BCS Class II and III compounds would 
be susceptible to such interactions within the intestine and liver (Wu and Benet, 2005; Benet, 
2010).  However, recent studies by Darwich et al. (2010) using an advanced dissolution, 
absorption, metabolism (ADAM) simulation model to assess the interaction of efflux and 
metabolism demonstrated that the FG of BCS Class I and II compounds would be influenced by 
P-gp efflux and metabolism (Darwich et al., 2010).  These studies, coupled with the results 
presented in this dissertation, suggest that other variables, such as a compound’s 
physicochemical properties, susceptibility to efflux or metabolism, and dose could potentially 
affect the interaction of P-gp and CYP3A during intestinal absorption. Therefore, using the 
mouse and human models described in this dissertation, it would be beneficial to investigate 
compounds belonging to BCS class I, II, and III, that are susceptible to the interplay of 
metabolism and efflux.  These models and simulations can be further developed and optimized in 
various preclinical species, using a diverse set of compounds that can provide a better 
physiologically accurate approach for semi-PBPK modeling of intestinal absorption. These 
findings could provide the basis for dose adjustments of compounds that have a low oral 
bioavailability due to efflux and/or metabolism, or for the development of new drugs.  
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5.F. FIGURES 
 
Figure 5.1:  The relationship between ex vivo and in vivo models of intestinal absorption 
used to study the effect of the interplay of P-gp and CYP3A on the oral bioavailability of 
dual substrates.   
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Figure 5.2:  Competing effects of intestinal P-gp efflux on portal bioavailability of dual P-
gp and CYP3A substrates. 
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